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ABSTRACT 
The present study investigated the role of free radicals and associated enhanced oxidative 
stress in the pathogenesis of diabetic nephropathy. The study population comprised 40 
diabetic subjects and 20 age- and gender-matched non-diabetic subjects. The diabetic 
subjects were further divided into two groups of 20 subjects, namely Group 1 (disease 
duration <2 years) and Group 2 (disease duration 6-8 years). 
Fasting plasma glucose, MAI, and fructosamine levels, reflections of glycaemic control, 
were elevated in Group 2 compared to results in Group 1 which were in turn higher than 
control group values. Similar findings were observed with total cholesterol, triglycerides, 
LDL cholesterol and HDL cholesterol measurements. 
Lipid peroxidation and antioxidant biochemical markers were also investigated in the 
study population. Urine TBARS were elevated in both Groups 1 and 2, consistent with 
the presence of enhanced lipid peroxidation in the diabetic state. The significant 
correlation between HbAI, levels and TBARS excretion also indicated an association 
between poor glycaemic control and increased lipid peroxidation. Furthermore, 
significant antioxidant depletion, assessed by measurements of vitamin E concentration, 
both erythrocyte and plasma glutathione peroxidase and plasma selenium concentrations 
was observed in Group 2 compared to results from Group 1 and control subjects. 
Renal biomarker (creatinine, sialic acid and cystatin C in serum, and ai and P2- 
microglobulin, AAP, NAG, aGST and 7tGST in urine) studies revealed a significant 
V 
association between free radical formation and both early glomerular and renal tubular 
insult in the diabetic state. Indeed, elevated tGST enzymuria also indicated the presence 
of distal tubular insult in the diabetic state. Considering that hyperglycaemia, enzymuria, 
proteinuria, poor glycaemic control, dyslipidaemia and lipid peroxidation were most 
pronounced in Group 1 suggested that lipid peroxidation associated with oxidative 
damage and renal tubular insult may have accompanied or even preceded the 
onset/presence of microalbuniinuria and renal structural alterations. Finally, NAG, AAP 
and particularly aGST and nGST may be useful predictors of early renal insult in subjects 
with diabetes. 
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CHAPTER ONE 
INTRODUCTION 
1. Introduction 
1.1 Diabetes mellitus 
Diabetes mellitus is a major global life-threatening disease with profound public health 
consequences. Although it has been centuries since diabetes was first recognised, it is still 
poorly understood and generally poorly managed. Consequently, the global prevalence of 
diabetes is predicted to rise from 135 million in 1995 to 300 million by 2025 (Dobson, 
2000). Diabetes mellitus is defined as a metabolic disorder of multiple aetiology 
characterised by chronic hyperglycaemia with disturbances of carbohydrate; lipid and 
protein metabolism resulting from defects in insulin secretion, insulin action or a 
combination of both. It may present with characteristic symptoms such as polydipsia, 
polyuria, polyphagia, weight loss and the long-term effects of diabetes include 
progressive development of microvascular complications, particularly in the eye and 
kidney, and an increased frequency of macrovascular disease such as peripheral vascular 
and coronary heart disease (Bennett, 1989; WHO, 1999). 
1.1.1 Historical review of diabetes mellitus 
Clinical features similar to diabetes were described 3000 years ago by the ancient 
Egyptians. The term "diabetes" was first coined by Araetus of Cappodocia (81-133AD) 
who introduced a clinical description of the disease, observing the increased urine flow, 
thirst hunger and weight loss, features which are instantly recognisable today. The sweet 
taste of urine in polyuric diabetics, which congregated ants was observed during the 5`n 
and 6th century AD by ancient Indians (Susruta and Charuka) and these descriptions even 
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mention two forms of diabetes, one in older (adult onset), obese individuals and another 
in thin and younger subjects and this division predated the modem classification into type 
2 and type 1 diabetes. Later, Thomas Willis rediscovered the sweetness of diabetic urine 
in 1675 (Papaspyros, 1964). 
In 1776, Matthew Dobson in the UK made the crucial observation, confirmed that the 
sweetness in both urine and serum was due to sugar, and suggested that diabetes is a 
generalized disease. Cotunnius (McFarlane et al, 1997), who described the separation of 
a clot in heated diabetic urine, first discovered the presence of proteinuria in a diabetic 
patient in 1764. In 1797, attempts at treatment began on the basis of glycosuria and 
polyuria, John Rollo (McFarlane et al, 1997) performed an extended and meticulous 
metabolic study of a corpulent diabetic, and he demonstrated that the degree of glycosuria 
depended upon the type of food intake. Rollo also observed the smell of acetone on the 
breath of diabetics, presumably those in an advanced stage of type 1 diabetes, and he also 
observed cataracts in diabetics. However, in 1857, an important milestone in the history 
of diabetes was the establishment of the role of the liver in glycogenesis and the concept 
that diabetes was due to excess glucose production, which was discovered by Claude 
Bernard, and he also demonstrated links between the central nervous system dysfunction 
and the diabetic state (Papaspyros, 1964; Ekoe and Zimmet, 2001). In 1869, Paul 
Langerhans was the first to described, pancreatic clusters of cells in teased preparations 
of pancreas which are now known as the "islets of Langerhans" and the role of the 
pancreas in the pathogenesis of diabetes was confirmed by Mering and Minkowski in 
2 
1889. Consequently, this discovery constituted the basis of insulin isolation and its 
clinical use by Banting and Best in 1921. 
Complications of diabetes affecting the eyes, namely diabetic retinopathy, had been 
described before the discovery of insulin but it was a rarity because few diabetics lived 
long enough to develop retinopathy and glomerulosclerosis, which gradually progressed 
to renal failure and death and this condition was named the "Kimmelstiel-Wilson" 
nodules after its American and British co-discovers in 1936. In addition, with longer 
survival of diabetic subjects, complications affecting the peripheral and later the 
autonomic, nervous system and gestational diabetes were described. However, at present, 
diabetes mellitus comprises a heterogeneous group of complex metabolic disorders of 
multiple aetiology and pathogenesis, which lead to a variety of complication and 
hyperglycaemia is the cardinal feature of these conditions and has therefore been used to 
define diabetes (Ekoe and Zimmet, 2001). 
1.1.2 Diagnosis of diabetes mellitus 
As stated before diabetes mellitus is characterised as hyperglycemia and diagnosis is 
based on the presentation of subjects with the classical clinical features as defined earlier. 
However, diagnosis is more difficult in subjects who are asymptomatic and demonstrate 
marginally elevated glucose concentrations. Therefore, measurement of plasma glucose is 
the sole diagnostic criterion and the strategy is indirect as hyperglycemia reflects the 
consequence of the metabolic derangement, not the cause. However, until the underlying 
molecular pathophysiology of the disease is identified, plasma glucose concentrations are 
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likely to remain an essential diagnostic modality and the diagnosis of diabetes is 
established exclusively by the documentation of hyperglycemia, i. e. increased glucose 
concentrations in the plasma. However, widely accepted current (revised) diagnosis 
criteria have been introduced by the World Health Organization (WHO, 1999) and are 
shown in the Table 1.1.2. 
1.1.3 Classification of diabetes mellitus 
The clinical staging reflects that diabetes, regardless of its aetiology, progress through 
several clinical stages during its natural history. Furthermore, individual subjects may 
change from stage to stage in either direction. Subject who have, or who are developing, 
diabetes can be classified by stage according to the clinical characteristics, even in the 
absence of evidence concerning the underling aetiology. The first widely accepted 
classification of diabetes mellitus was published by the WHO Expert Committee in 1980 
and subsequently updated in 1985. However, a recent WHO consultation document 
(1999) proposed a revised classification similar to that of the American Diabetes 
Association classification (ADA, 1997). Consequently, the new WHO classification 
encompassed both clinical stages and aetiological types of diabetes mellitus, mainly type 
1, type 2 and other categories of hyperglycaemia, as suggested by Kuzuya and Matsuda, 
(1997) and are shown in the Table 1.1.3 
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Table: 1.1.2 The new diagnostic criteria for the diagnosis of diabetes mellitus 
(Values for diabetes mellitus and other categories of hyperglycaemia) 
Glucose concentration (mmol /L) 
Whole blood Plasma 
Venous Capillary Venous Capillary 
Diabetes mellitus 
Fasting or z6.1 z6.1 z7.0 z7.0 
2-h post-glucose load 210.0 211.1 211.1 212.2 
or both 
Impaired glucose 
tolerance (IGT) 
Fasting (if measured) and <6.1 and <6.1 and <7.0 and <7.0 and 
2-h post-glucose load X6.7 and <10.0 Z7.8 and <11.1 z7.8 and 11.1 z8.9 and <12.2 
Impaired fasting 
glycaemia (IFG) 
Fasting z5.6 and <6.1 z5.6 and <6.1 z6.1 and <7.0 z6.1 and <7.0 
and (if measured) 2-h <6.7 <7.8 <7.8 <8.9 
post-glucose load 
The glucose load refers to 75 g of anhydrous glucose (or monohydrate equivalent) dissolved in 
250-300 ml of water and consumed over the course of 5 min. For clinical purposes, the diagnosis 
of diabetes should always be confirmed by repeating the test on another day unless there is 
unequivocal hyperglycaemia with acute metabolic decompensation. 
(Report of World Health Organisation 1999) 
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Table: 1.1.3 Clinical and aetiological Classification of Disorder of Glycaemia 
Type 1 diabetes mellitus: (ß-cell destruction, usually leading to absolute insulin 
deficiency). 
Autoimmune diabetes mellitus 
Idiopathic diabetes mellitus 
Type 2 diabetes mellitus: 
Other specific types: 
Impaired Glucose Tolerance 
Gestational diabetes mellitus 
(May range from predominantly insulin resistance with 
relative insulin deficiency to a predominantly secretory 
defect with or without insulin resistance). 
Genetic defects of ß-cell function 
Genetic defects in insulin action 
Disease of the exocrine pancreas 
Endocrineopathies 
Drug-or chemical-induced 
Infections 
Uncommon forms of immune-mediated diabetes 
Other genetic syndromes sometimes associated with 
diabetes 
Adopted from Report of a WHO Consultation Document (1999) 
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Type 1 diabetes mellitus, previously known as insulin dependent diabetes mellitus 
(IDDM) or juvenile-onset diabetes mellitus, results from autoimmune destruction of the 
ß-cells of the pancreas, rendering the pancreas unable to synthesize and secrete insulin. 
Therefore, type 1 diabetics are entirely dependent on endogenous insulin for their 
survival. 
Type 2 diabetes mellitus, previously encompassed non-insulin-dependent diabetes 
mellitus (NIDDM) or adult-onset diabetes, resulting from a combination of insulin 
resistance and inadequate insulin secretion. Type 2 diabetes can be controlled by various 
combinations of dietary modifications, changing lifestyle, increase physical activity and 
certain forms of oral hypoglycaemic agent without depending on exogenous insulin. 
However, some do require some insulin therapy at diagnosis and subsequently oral 
hypoglycaemic agents or dietary modifications. Other types of diabetes are rare as 
indicated in the Table 1.1.3 
1.1.4 Overview of Pathogenesis of diabetes mellitus 
1.1.4.1 Pathogenesis of type 1 diabetes mellitus 
Type 1 diabetes is a chronic disorder resulting from the autoimmune mediated destruction 
of the ß-cells of the pancreas (WHO, 1999). The rate of destruction is quite variable, a 
rapidly progressive form is commonly observed in children and a slow progressive form 
generally occurs in adults, which is referred to as latent autoimmune diabetes in adults 
(LADA). Type 1 diabetes commonly produces subjective and objective signs or 
biochemical changes within a short time duration. The major metabolic derangements are 
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marked hyperglycaemia, excessive ketonaemia, and ketonuria resulting in a life 
threatening metabolic acidosis commonly referred to as diabetic ketoacidosis (DKA), 
observed commonly in type 1 diabetics (Foster and McGarry, 1983). 
Type 1 diabetes can be classified, according to presenting clinical characteristics as well 
as by immune and genetic markers. About 80% of subjects with type 1 diabetes have 
specific HLA phenotypes associated detectable autoantibodies such as specific islet cell 
autoantibodies (ICA) (Botazo et al, 1974), islet cell surface autoantibodies (ICSA) 
(Lernmark, 2001), insulin autoantibodies (IAA) (Palmer, 1983), glutamic acid 
decarboxylase (GAD65) (Karlsen, 1992), and insulinoma associated antigen-2 (IA-2) 
(Payton, 1995) which have all been recognized as dynamic pathogenetic markers of an 
ongoing disease process. 
The process of ß-cell autoimmunity appears to be initiated long before the symptoms of 
hyperglycaemia are present but the clinical onset of disease is not apparent until there is a 
major loss (80% to 90%) of islet ß-cell function. Several studies have also demonstrated a 
direct association between the clinical onset of disease and acute viral infections (Yoon, 
1995; Cahill et al, 1981). In animal cell culture, other studies have demonstrated that 
Coxsackie B virus infection is probably associated with virus replication in the ß-cells 
followed by the formation of GAD65 antibodies (Yoon et al, 1995; Gerling et al, 1991, 
Hou et al, 1993). Apart from Coxsackie B virus, in human studies, different virus species 
studies include congenital rubella (McIntosh and Menser, 1992), cytomegalovirus (Ward 
et al, 1995), retroviruses and Epstein-Barr virus (Krieg et al, 1992) have been implicated 
8 
in the initiation and progression of ß-cell destruction. Although, several viral-mediated 
pathomechanism of ß-cell destruction have been proposed using both different animal 
models of type 1 diabetes and in human studies, the exact mechanisms are not clearly 
defined for most viruses in the pathogenic process. 
Early exposure to cow's milk proteins is also associated with an increased risk of 
childhood diabetes. Molecular mimicry between bovine serum albumin and ICA69, 
another putative ß-cell autoantigen, has been suggested (Pietropaolo et al, 1993). 
Children fed cow's milk formula had higher titers of IgG antibodies to bovine insulin that 
cross reacted with human insulin, and the presence of theses antibodies correlated with 
the presence of human IAA (Vaarala et al, 1998). These findings may explain the high 
incidence of IAA in young children and raise the possibility that sensitization to bovine 
insulin could prime immune system auto aggression towards ß-cells in subjects who are 
genetically predisposed (Vaarala et al, 1998). 
The pathogenetic process is probably the same before and after the clinical diagnosis of 
diabetes and the rate of ß-cell destruction also appears to be influenced by human 
leukocyte antigens (HLA). The HLA DQB1*0302-Al*0301/DQBI*0201-A1*0501 
genotype appears to be associated with accelerated ß-cell destruction and a more rapid 
progression to clinical onset of type 1 diabetes (Graham et al, 1999). HLA molecules are 
important determinants in regulating the immune response in humans; the susceptibility 
to type 1 diabetes is speculated to be conferred by the functional importance of these 
molecules in the restriction of the immune response. Furthermore, the HLA class II 
molecules, the latter which are strongly associated with type 1 diabetes specifically bind 
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short peptides or epitopes. These are recognised by specific T-cell receptors (TCRs) on 
CD4+ T lymphocytes, which is the signal to initiate the development of cytotoxic T 
lymphocytes and B-lymphocytes, which produce antibodies to the antigen. This entire 
process is affected by a number of cytokines, such as interferon gamma (IFN y), tumor 
necrosis factor-alpha (TNF-a) and interleukin-2 (IL-2) (Lernmark, 2001). However, 
recent studies have revealed that these cytokines (IFN y, TNF-a) are associated with an 
increased production of NO due to formation of free radicals and reactive oxygen 
intermediates (Thomas and Kay, 2000), and the elevated concentration of NO leads to 
DNA damage and programmed cell death (apoptosis) by as yet poorly defined 
mechanisms (Mathis et al, 2001). Furthermore, other reactive oxygen species such as 
hydrogen peroxide (Rabinovitch et al, 1992), and peroxynitrite might also be involved in 
ß-cell destruction during the development diabetic states. Over expression of antioxidants 
such as catalase (Lortz et al, 2000), manganese superoxide dismutase and glutathione 
peroxidase have an important influence on cytokine-mediated killing in vitro or on 
diabetes development as demonstrated in animal models (Lortz et al, 2000). 
1.1.4.2. Pathogenesis of type 2 diabetes mellitus 
Type 2 diabetes is a heterogeneous syndrome in which hyperglycaemia resulting both an 
impaired insulin secretory response to glucose and decreased effectiveness in stimulating 
glucose uptake by skeletal muscle and in restraining hepatic glucose production, is 
present (DeFronzo, 1997; WHO, 1999). The primary biochemical events leading to 
chronic hyperglycaemia are still controversial (Ferrannini, 1998) and type 2 diabetes 
probably results from a complex interaction of genetic and environmental factors 
influencing characteristic features relevant to the diabetic phenotype such as insulin 
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action, insulin secretion, ß-cell mass, fat distribution and obesity (Velho and Frogual, 
2001). However, longitudinal studies suggest that abnormalities in both insulin action and 
insulin secretion occur early in the pathogenesis of type 2 diabetes (Ferrannini, 1998). 
Primary defects in pancreatic ß-cells have been recognised in maturity onset diabetes of 
the young (MODY), a rare form of diabetes resulting from gene mutation. MODY is a 
clinically heterogeneous syndrome characterized by non-ketotic diabetes, an autosomal 
dominant mode of inheritance and onset usually before 25 years of age, frequently in 
childhood or adolescence (Bell and Polonsky, 2001). Recently, different types of MODY 
genes have been identified that encode the glycolytic enzyme glucokinase (GCK) and 
transcription factors include hepatocyte nuclear factor (HNF)-4a/MODY1, 
glucokinase/MODY2, HNF- I a/MODY3, insulin promoter factor (IPF)-1/MODY4, HNF- 
1 IMODY5, neueogenic differentiation (NeuroD1)/MODY6 and Islet (Isl)-1/MODY7 
(Bell and Polonsky, 2001; Iwasaki, 2001). The defect in GCK is a stable defect of 
glucose sensing, whereas the HNF-la mutation causes a progressive defect that alters ß- 
cell insulin secretion rather than the sensing of glucose. (Pearson et al, 2001). 
Insulin resistance is a major risk factor for the pathogenesis of type 2 diabetes and the 
insulin resistance syndrome (syndrome X) (Reaven, 1995). Insulin resistance is a 
metabolic state in which a normal concentration of insulin produces a less than normal 
biological response. The clinical manifestations of insulin resistance, glucose intolerance 
and hyperinsulinemia, are the consequence of the inability of insulin to stimulate glucose 
uptake in such target tissues as muscle and adipose tissues. Evidence exists that insulin 
resistance reduces glucose transport activity, the rate-limiting step for glucose uptake 
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(Garvey et al, 1998). Insulin stimulates glucose transport via translocation of GLUT4 
glucose transporter proteins from an intracellular depot to the cell surface. Hence, 
GLUT4 depletion appears to be the major cause of insulin resistance in adipose tissue 
because of the profound degree of GLUT4 loss and its central role in transport 
stimulation (Garvey et al, 1998). Furthermore, recent studies have demonstrated that 
insulin receptor tyrosine kinase activity, together with downstream signalling events for 
example, insulin receptor substrate 1 (IRS-1) phosphorylation, phosphatidylinositol-3 
kinase (PI-3-kinase) activation, are reduced in skeletal muscle (Goodyear et al, 1995). 
Thus, one potential cause of human insulin resistance is a defect in insulin signalling that 
impairs GLUT4 translocation in muscle (Garvey et al, 1998). Although insulin resistance 
involves decreased glucose transport activity in skeletal muscle, its molecular basis again 
remains unclear. 
Obesity is the most common cause of insulin resistance in humans (Cavaghan et al, 
2000). In obese subjects, insulin concentrations typically increase to maintain normal 
glucose tolerance. Basal and total daily 24h rates of insulin secretion are three to four 
times higher in obese insulin resistant subjects than in lean controls (Cavaghan et al, 
2000). There is an inverse relationship between insulin sensitivity and insulin secretion, 
which is indicative of ß-cell compensation for insulin resistance. As insulin resistance 
increases, the early first-phase insulin response must increase proportionately to maintain 
normal glucose tolerance. However, in type 2 diabetes, there is an overall reduction in 
insulin secretion rate as the ß-cell can no longer secrete sufficient insulin to maintain 
normal blood glucose concentrations. (Bell and Polonsky, 2001). 
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The islet amyloid deposition is a pathological feature of the pancreas in type 2 diabetes 
that is associated with reduced ß-cell mass and insulin secretion (Kahn et al, 1999). The 
unique peptide component of islet amyloid is islet amyloid polypeptide (IAPP) or amylin, 
a normal secretory product of the islet ß-cell released with insulin in response to nutrient 
stimuli such as glucose and amino acids (Kahn et al, 1990). The human IAPP (h1APP) 
molecule contains a specific sequence of amino acids rendering it capable of forming 
amyloid fibrils. The association of amyloid deposits and relative hyperproinsulinaemia, 
suggests that fibril formation begins during impaired glucose tolerance after other factors 
cause the initial defects in early insulin secretion and insulin action in type 2 diabetes 
(Porte and Kahn, 2001). 
1.1.5. Biochemical basis of diabetic complications 
All forms of diabetes are typified by hyperglycaemia, a relative or absolute deficiency of 
insulin, and the development of diabetic-specific complications. A diagnosis of diabetes 
immediately increases the risk of developing various diabetic-specific clinical 
complications that are largely irreversible and due to microvascular and macrovascular 
disease. Large prospective clinical studies demonstrated a strong relationship between 
glycaemic control and the development of microvascular complications in both type 1 
and type 2 diabetes (DCCT, 1993; UKPDS, 1998). Furthermore, hyperglycaemia and 
insulin resistance also both play important roles in the pathogenesis of macrovasular 
disease (UKPDS, 1998). As a consequence of its underlying microvascular pathology, 
diabetes is a leading cause of blindness (retinopathy), end stage renal disease 
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(nephropathy) and a variety of debilitating neuropathies. Diabetes is also associated with 
accelerated atherosclerotic macrovascular disease affecting arteries, brain and lower 
extremities, higher risk of myocardial infraction, stroke and limb amputation (Brownlee, 
2001). The `glucose hypothesis' attributed the microvascular and neuropathic 
complications of diabetes to chronic hyperglycaemia and it postulates that 
hyperglycaemia precipitates these complications. Clinical and epidemiological data from 
human studies suggest that the magnitude and duration of hyperglycaemia in diabetes are 
strongly associated with the severity of microvascular complications (Engerman and 
Kern, 1987; Danne et al, 1994) but genetic and environmental factors may also be 
associated with the development and progression of these complications. 
Diabetic retinopathy primarily affects the retinal blood vessels, which may progress 
through different stages of retinopathy including background, preproliferative, 
proliferative, advanced and maculopathy according to the features demonstrated on 
ophthalmoscopy. Cataract is also a common cause of blindness in diabetics due to non- 
enzymatic glycation of lens proteins and the accumulation of sorbitol in the diabetic lens 
as a consequence of increased polyol pathway activity. The clinical manifestations of 
neuropathy in subjects with type 1 and type 2 diabetes can be severe. A peripheral, 
symmetric sensorimotor neuropathy is the most common form of diabetic neuropathy that 
affects the long nerves, whereas other forms include cranial and peripheral motor 
neuropathies and autonomic neuropathy, which is asymptomatic (Nathan, 1993). As a 
consequence of hyperglycaemia, the late complications of diabetes represent in large part, 
microvascular dysfunction (Tooke, 1995) and diabetic-specific complications in the 
retina, glomerulus and vasa nervorum have similar pathophysiological features 
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(Brownlee, 2001). At an early stage in the course of diabetes, intracellular 
hyperglycaemia is associated with abnormalities in blood flow and increased vascular 
permeability (Brownlee, 2001). This reflects decreased activity of vasodilators such as 
nitric oxide, increased activity of vasoconstrictors, for example angiotensin II, and 
endothelin-1, and elaboration of permeability factors such as vascular endothelial growth 
factor (Ebara et al, 2000). An important link between the polio pathway and non- 
enzymatic gyration is supported by the ability of aloes reeducates inhibitors to stimulate 
the action of amino guanidine (a drug used on controlling AGEs formation) and the fact 
that both increased polio pathway activity and non-enzymatic gyration process increase 
the rate of free radical production (Took, 1995). This may ultimately lead to compound 
endothelial dysfunction. Furthermore, micro vascular cell loss occurs, in part because of 
apoptosis, and there is progressive capillary occlusion caused by both extra cellular 
matrix overproduction induced by growth factor including transforming growth factor-ß 
(TGF-ß). In contrast, hyperglycemia may change the function of endothelial and neuronal 
cells resulting in edema, ischemia and hypoxia-induced revascularization in the retina, 
essential matrix expansion and glomerulosclerosis in the kidney and multifocal axonal 
degeneration in peripheral nerves (Brownlee, 2001). 
In diabetic macrovascular disease, it has been postulated that both hyperglycaemia and 
insulin resistance may play a significant role. In diabetic arteries, endothelial dysfunction 
may involve both insulin resistance and hyperglycaema. Furthermore, in diabetic 
dyslipidaemia, hyperglycaemia increases atherogenic cholesterol-enriched apolipoprotein 
B-containing remnant particles by reducing expression of the heparin sulphate 
proteoglycan on hepatocytes (Ebara et al, 2000) and the associations of atherosclerosis 
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and atherosclerosis risk factors with glycaemia have been demonstrated over a wide 
range of glucose tolerance, from normal to diabetic (Brownlee, 2001). 
In contrast, the UK Prospective Diabetes Study (UKPDS, 1998) and the Diabetes Control 
and Complications Trial (DCCT, 1993) Research Group emphasized that diabetic 
complications are common, frequently present by the time of diagnosis, and significantly 
affect the quality of life. Therefore, the preclinical stages of retinopathy, nephropathy and 
neuropathy might also be appropriate targets for screening and diagnosis (Nathan, 1993) 
of diabetic complications. However, it is now well established that intensive therapy to 
improve glycaemic control reduces the risk of microvascular complications in general 
and diabetic nephropathy in particular. (UKPDS 1998, DCCT 1993). 
1.2 Diabetic nephropathy 
The commonest of the systemic disease involving the kidney is diabetes mellitus. Since 
the advent of insulin therapy and improve survival of subjects with diabetes nephropathy 
has proved to be an important consequence of mortality. Diabetic nephropathy plays a 
significant role as one cause of end stage renal failure in the western world. Diabetic 
nephropathy is a clinical syndrome characterized by persistent albuminuria, arterial blood 
pressure elevation, a relentless decline in glomerular filtration rate (GFR), and an 
associated high risk of cardiovascular morbidity and mortality (Parving et al, 2000). This 
major life-threatening complication develops in approximately 35% of subjects with type 
1 diabetes (Rossing et al, 1995). The prevalence in type 2 diabetes is higher than type 1; 
this form of diabetes now contributes to at least 50% (Cooper, 1998) of those with 
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diabetic nephropathy who develops end stage renal disease (ESRD) and require dialysis 
or transplantation for survival. 
1.2.1 Natural history of diabetic nephropathy 
The natural history of diabetic nephropathy has been relatively well defined in type 1 
diabetics. In type 2 diabetics, the process remains unclear with regard to the time of onset 
of disease or the presence of other factors such as hypertension, age or race. However, 
clinical investigators have been able to classify the development of ESRD based on the 
onset and duration of the disease. The classifications of ESRD were introduced by 
Mogensen et al, (1993) and divided into five stages as described below. 
In stage 1, at the onset of the diabetes, there is glomerular hyperfiltration with 
hyperperfusion, renal hypertrophy and glomerular capillary hypertension associated with 
high blood glucose concentrations. At this stage urinary albumin excretion may be 
normal or slightly elevated. Stage II is a silent phase that follows hyperfiltration and is 
associated with subtle morphological changes including thickening of the glomerular 
basement membrane (GBM), glomerular hypertrophy, mesangial expansion, and modest 
expansion of the tubulointerstitium. 
After 7-15 years, with diabetic patients who develop stage III or incipient nephropathy 
this can be detected clinically by the presence of microalbuminuria. Abnormal urinary 
albumin excretion cannot be detected by conventional or dipstick methods (semi- 
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quantitative) but are measurable using sensitive techniques such as quantitative 
immunoassay. Studies in Type 2 diabetes have suggested that in the transition from 
normoalbuminuria to microalbuminuira, there is modest rise in blood pressure 
(systolic/diastolic) of about 3mm/Hg per year. 
Stage IV is characterised by the presence of overt nephropathy, with dipstick-positive 
proteinuria. GFR falls steadily, by about 12ml/min. year, and clinically, measurement of 
plasma creatinine and microalbuminuria are used to monitor renal function and to 
indicate the decline of GFR. Hypertension when present in patients at this stage is usually 
associated with the presence of >500 mg urinary total protein/24 h. However, histological 
glomerular lesions, found in most long-term diabetics with nephropathy, may include 
thickened glomerular capillaries, mesangial expansion, intercapillary nodules of 
glomerulosclerosis of the afferent and efferent arterioles and the presence of glomerular 
microanueurysms. The mesangial cells of one or more of the glomerular segments 
produce excessive amounts of a cellular matrix to form spherical nodules known as 
Kimmelstiel-Wilson nodules. The development of oedema is one of the earliest clinical 
features of renal impairment, often associated with anaemia and a rather non-specific 
decline in general health. 
Stage V is end stage renal failure, with the presence of severe mesangial expansion, 
uraemia, hypertension, and serum creatinine concentration of more than 400 gmol/1. 
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1.2.2 Structural, functional, biochemical and physiological aspects of the kidney 
The kidneys play a major role in the homeostatic mechanisms of the human body and 
reduced renal function strongly correlates with increasing patients morbidity and motility. 
The kidneys form a paired organ system, located in the retroperitoneal space, and 
demonstrate exquisite heterogeneity which consist of three main areas namely the cortex, 
the medulla and the inner medulla or papilla. The kidneys have both sympathetic and 
parasympathetic nervous supply whose function appears to be predominantly associated 
with vasomotor activity. Each kidney receives its blood supply from a single renal artery 
derived from the abdominal aorta, with the venous return along a renal vein that emerges 
into the vena cava. The renal artery divides into posterior and anterior elements, which 
then divide into interlobar, arcuate, interlobular, and ultimately into the afferent 
arterioles, which expand into the highly specialised capillary bed that form the 
glomerulus. These capillaries then rejoin to form the afferent arteriole, which then forms 
the capillary plexuses as well as the elongated vessels such as the vasa recta, which pass 
around the remaining parts of the nephron, the proximal and distal tubules, the loop of 
Henle, and collecting duct, providing oxygen and nutrients and removing ions, 
molecules, and water which are reabsorbed by the nephron. 
Nephron 
The functional unit of the kidney is the nephron and each kidney has been reported to 
contain between I and 1.5 million nephrons. There are at least three types of nephrons, 
which include the superficial, midcortical and juxtamedullary types. Each nephron 
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consists of a glomerulus and Bowman's capsule, which is next to the proximal tubule 
(PT) and the following section is the loop of Henle, which leads into the renal medulla. 
At the junction of the inner and outer medulla, the loop becomes thicker before leading to 
the distal tubule (DT) and collecting tubule (CT). This section of the nephron then 
merges with those of other nephrons to form the renal pelvis and ultimately the ureter. 
Glomerulus 
The glomerulus consists of a turf of blood capillaries, which is in close contact with 
Bowmans's capsule. This close alliance enables the ultrafiltration of plasma through three 
layers of cells which together act as a selective permeable barrier. Glomerular structure 
and permeability are maintained by the glomerular mesangial cells, thereby altering the 
glomerular capillary surface area available for filtration. The glomerular basement 
membrane (GBM) is approximately 300 nm thick in adult humans and consists of three 
distinct electron-dense layers such as the lamina rara interna, the lamina densa, and the 
lamina rara externa. The lamina densa consists of mainly type IV collagen embedded in a 
matrix of glucoprotein and proteoglycans. This forms the main size discriminant barrier 
to protein passage into the tubular lumen. The other two layers of the GBM are rich in 
negatively charged polyanionic glucoprotein such as heparin sulphate proteoglycans 
(HSP). The epithelial cells lining Bowmans's capsule are known as podocytes and have a 
large number of extensions or foot processes that are embedded in the GBM. The foot 
processes from adjacent podocytes are interdigitated to form filtration slits, which are 
covered by highly hydrated anionic mucopolysaccharide that is rich in sialic acid. 
Consequently, the resulting structure is relatively impermeable to most proteins above 60 
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kD, but passage of proteins is also modulated by their charge and shape i. e. charge and 
size selectivity. The final cellular component of the glomerulus are the mesangial cells 
(MC), which are embedded in an extra cellular matrix (ECM) between the capillaries and 
play a critical role in the modulation of glomerular blood flow and filtration by 
contraction and relaxation. MC are of mesenchymal origin and contain contractile 
elements which express receptors to many different hormones and cytokines, including 
angiotensin II, insulin-like growth actor 1 (IGF-1), tumour necrosis factor, inteleukin-1, 
transforming growth factor beta (TGF-ß) and advanced glycation end products (AGES). 
The mesangial matrix, although developmentally and morphologically distinct from the 
GBM, is composed of essentially the same components, i. e. collagen type IV, laminin 
and HSP. 
The proximal tubule (PT 
The proximal tubular region of the nephron consists of the proximal convoluted tubule, 
and a straight segment, also known as the pars recta. Three distinct cell types from the 
epithelial lining of these proximal structures and the Si, S2 and S3 regions are separated 
on the basis of their morphological and functional characteristics. The Si segment, 
composed of S1-type cells, makes up the beginning and middle portion of the convoluted 
proximal tubule and are generally columnar with abundant microvilli on the luminal 
surface, thereby increasing the surface area for reabsorption from tubular fluid by 40 fold. 
A well developed phagolysosomal system, a large endocytotic apparatus of numerous 
apical vacuoles and numerous mitochondria are also present in this segment. The S2 
segment forms the remaining portion of the proximal convoluted tubule and the initial 
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portion of the straight segment. S2 cells have fewer microvilli and mitochondria than Si 
cells and they also contain the majority of the PT lysosomes. Finally, the remaining 
portion of the pars recta is the S3 segment which consists of the end of the straight 
portion and the beginning of the thin descending loop Henle. Cells in this region have 
few microvilli and mitochondria. The Si and S2 segments perform the majority of the 
solute and fluid reabsorption coupled largely to sodium reabsorption. Large basolateral 
membrane (BLM) interdigitations are found within the PT providing a large surface area 
for Na+/K+ transport, which maintains the osmotic gradients necessary for fluid 
reabsorption within the PT. 
Loop of Henle and distal tubule (DT) 
The loop of Henle is divided into the descending and ascending limbs. These limbs form 
a hairpin loop, which either extend deeply into (juxtramedullary) or reach only just into 
the medulla (cortical). The terminal segment of the distal tubule is the convoluted part. 
Each segment of the loop of Henle and the subsequent distal section have different 
permeability properties, allowing the production of concentrated urine, as well as 
controlling intra and extracellular osmolality and pH. Part of the distal tubule is specially 
close to the glomerulus and the afferent and the efferent arterioles. Specialised cells, 
called the macula densa, which are in this area respond to the sodium and chloride 
composition of tubular fluid in order to maintain water and electrolyte homeostasis (i. e. 
tubuloglomerulo feed back). 
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Filtration, reabsorption and secretion 
Glomerular filtration is a passive process dependent on the pressure within the glomerular 
capillary network which in turn depends on the surface area and intrinsic permeability of 
the glomerulus. The hydrostatic and oncotic pressure gradients across the capillary walls 
are determined by both flow and resistance. In the normally functioning kidney, 
molecules of >_ 50 A° are not filtered due to size, shape or charge, whilst molecules <_ 40 
A° are freely permeable. These include glucose, amino acids, urea, Na+ and KK ions. The 
filtrate entering the nephron is isotonic with, and of similar composition to, plasma 
except for the presence of large molecular weight proteins, which remain within the 
plasma. Approximately 60-70% of the filtrate volume (water, sodium, and urea) is 
reabsorbed in the PT whilst some ions and molecules are actively secreted further down 
the nephron to maintain blood ionic concentration and volume. The sodium concentration 
in the PT cell effects levels of energy generation and Na+ ions enter passively down an 
electrical gradient (-70mV) and are then actively transported across the BLM via Na+-K+- 
ATPase and Na+-H+-ATPase activity which allows the reabsorption and secretion of 
other solutes such as Cl", K+, H+ ions, to balance the Na+ ion movement. 
Renal blood flow (RBF) and glomerular filtration rate (GFR) 
According to the myogenic theory, increased tension of the afferent arterioles, brought 
about by an increase in perfusion pressure, causes automatic contraction of the smooth 
muscle fibres in the vessel wall, thereby increasing the resistance to flow and so keeping 
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the flow constant in spite of the increase in perfusion pressure. Tubulo-glomerular 
feedback (TGF) mechanisms are also involved in supporting this process. TGF is a 
mechanism in which changes in DT fluid composition are detected by the macula densa 
and, as a consequence, alter the vascular elements of the glomeruli, thereby affecting 
single nephron GFR, RBF and GFR are also under hormonal and nervous control. An 
intact renin-angiotensin-aldosterone system (RAAS) is required for the normal regulation 
of GFR. 
Measurement of GFR 
GFR is considered to be the most reliable measure of the glomerular functional capacity 
of the kidneys and is often thought of as indicative of the number of functioning 
nephrons. An estimate of the GFR can be made by measuring the urinary excretion of a 
substance which is completely filtered from the blood by the glomeruli and which is not 
secreted, reabsorbed or metabolised by the renal tubules. Experimentally, inulin has been 
found to meet these requirements. However, measurement of creatinine clearance is 
commonly used method for estimation of the GFR in the routine clinical laboratory. 
Clearance =UxV ml/min 
P 
U= urinary creatinine concentration (µmol/1), 
V= urine flow rate [ml/min or (1/24 h)/1.44m2)] 
P= plasma creatinine concentration (gmol/1) 
Furthermore, the GFR can also be estimated using one of several algorithms. The best 
known algorithm is the Cockcroft and Gault formula (Cockcroft & Gault, 1976) as given 
below. 
CrCI (mUmin/1.73 m2) = (140-age in years) x 2.12x weight (kg) xk 
serum creatinine x BSA (m2) 
BSA = body surface area, K=0.85 for women and 1.00 for men 
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1.2.3 Structural and functional changes in diabetic kidney 
Nephromegaly (renal enlargement) was first described in diabetes more than a century 
ago (Ritz et al, 1989) and is an early feature of both experimental and human diabetes. In 
animals, nephromegaly occurs within four days of diabetes onset and most type 1 
diabetics have large kidneys at diagnosis. Consequently, this enlargement is mostly due 
to a combination of tubular hypertrophy and hyperplasia and interstitial expansion, and is 
probably a response to increased glucose and fluid filtration and their active reabsorption. 
Furthermore, glomeruli only account for 1% of total kidney volume, so their contribution 
to whole organ enlargement is significant (Bilous, 2001). 
Glomerular enlargement has been a recognised feature of diabetes, and is present both in 
early and later stages of the disease (DeFronzo, 1995). Early glomerular enlargement in 
experimental diabetes is the result of an increase in capillary filtration surface area caused 
by an increase in capillary length, or number, or both. In experimental diabetes, early 
glomerular enlargement coincides with increased glomerular filtration (Mauer et al, 
1975). This so-called hyperfiltration has been proposed as an important 
pathophysiological factor for diabetic glomerulopathy (Mauer et al, 1984). Glomerular 
enlargement has therefore been considered as a factor predisposing the subject to 
progression of glomerulopathy, perhaps by an increase in capillary wall radius in 
response to raised intraglomerular pressure, thus leading to increased capillary wall 
tension (Bilous, 2001). Furthermore, the end result of diabetic glomerulopathy is a 
globally sclerosed, non-functioning glomerulus. Such glomeruli can appear either as 
relatively acellular, eosinophilic globes, which ultimately hyalinize and become 
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reabsorbed or as collapsed structures with an irregular crenated basement membrane. The 
former appearance is consistent with an internal glomerular obliteration by mesangial 
expansion, the latter more with ischaemia. These interpretations are supported by 
reported positive correlations of percentage of globally sclerosed glomeruli with 
mesangial expansion and afferent arteriolar hyalinosis (WHO, 1985). 
GBM thickening can be demonstrated in most diabetic subjects, irrespective of the 
severity of their nephropathy, although those with heavier proteinuria tend to have thicker 
membranes. It is thus not as specific a sign of renal complication as the diffuse mesangial 
lesion, although those subjects with nephropathy tend to have thicker GBMs than age and 
diabetes duration matched subjects with `normal' renal function (Bilous et al, 2001). 
Most of the increase in matrix is due to type IV collagen accumulation. There is, 
however, a net loss of proteoglycan, which is also dispersed throughout the thicker 
membranes. This loss is probably to result in a loss of negative electrostatic charge and 
thus permit the passage of positively charged proteins such as albumin (Bilous, 2001). 
The Kimmelstiel-Wilson nodule is more specific for diabetic nephropathy but occurs in 
only 20-70% of diabetics who demonstrate the diffuse lesion. Furthermore, there are no 
obvious changes in endothelial or epithelial cells in glomerulopathy, except that there is a 
widening of podocyte foot processes. This development may be a ubiquitous response to 
increased protein passage across the GBM, as its observed in other proteinuric states 
(Bilous, 2001). 
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A tubulo-interstitium compartment is also a major feature of diabetic nephropathy and an 
important predictor of renal dysfunction. Renal enlargement in diabetic animals is due to 
an initial tubular cell hyperplasia and subsequently to cell hypertrophy. These changes 
are associated with alteration in expression of growth factors such as TGF-ß and can be 
prevented by appropriate insulin therapy. Tubular basement membrane (TBM) probably 
has a similar composition and structure to GBM but is almost twice as wide. However, 
the TBM structure has still not been widely studied. Diabetics develop TBM thickening 
about two to three times the value observed in their non-diabetic siblings (Steffes et al, 
1985). Furthermore, macromolecular penetration of the interstitial space may activate 
fibrosis and would be further facilitated by disruption of the TBM. AGES also have been 
demonstrated to increase pore size in bovine TBM, which may also result in increased 
protein permeation (Anderson et al, 1993). 
1.2.4 Clinical and biochemical aspects of diabetic nephropathy 
1.2.4.1 Definition of nephropathy 
Clinical diabetic nephropathy is defined as the development of persistent proteinuria and 
hypertension, and it is preceded by incipient diabetic nephropathy, charaterised by 
persistent microalbuminuria. Once clinical diabetic nephropathy has developed, 
progression is difficult to prevent by improved metabolic control or through the use of 
antihypertensive therapy. (Andersen et al, 1983; Mogensen and Christensen, 1984; 
Okada eta!, 1996). 
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1.2.4.2 Diagnosis of diabetic nephropathy 
The diagnosis of diabetic nephropathy is only definitively made by renal biopsy, but this 
is rarely necessary clinically where the diagnosis is based on both the clinical and 
biochemical abnormalities demonstrated the kidney, such as the presence of proteinuria, 
development of a progressive rise in blood pressure, and a progressive and relentless 
decline in renal function towards end stage renal failure. Elevations of urinary albumin 
excretion are used to define both the diagnosis of diabetic nephropathy and it progression. 
An increase in albumin excretion is taken as the hallmark of diabetic nephropathy 
(Viberti et al, 1982; Mogensen, 1984). 
1.2.4.3 Microalbuminuria 
Clinical significance 
Microalbuminuria is one of the earliest signs of renal insult in diabetes and is currently 
the main focus of attention, as it is also associated with increased risk of morbidity and 
premature death from cardiovascular disease (Haffner et al, 1990). The presence of 
microproteinuria in general, or microalbuminuria in particular, reflects loss of charge 
selectivity and an increase in capillary permeability in the kidneys and other organs. 
Microalbuminuria is a predictor of chronic renal failure (overt nephropathy) in diabetes 
mellitus; its presence here is termed incipient nephropathy. 
Definition 
Microalbuminuria, defined as an increased urinary albumin excretion (UAE) detectable 
only by sensitive immunoassay (Winocour, 1992) expressed either by time or with 
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reference to creatinine concentration), has been used for many years as a predictor of 
incipient nephropathy in diabetics (Viberti et al, 1982; Mogensen, 1984). The `gold 
standard' of microalbuminuria measurement is based on the excretion rate of albumin in 
a timed urine collection, while for more rapid estimations the urinary albumin 
concentration in an early morning mid stream specimen of urine may be used. In order to 
correct for variations in body fluid balance, the latter is normally referenced against the 
urinary creatinine concentration as the albumin: creatinine ratio (ACR) values. 
Table: 1.2.4.3 Classification of albuminuria 
Normalbuminuria Microalbuminuria Macroalbuminuria 
Albumin excretion rate < 30 30-300 > 300 
(mg/24h) 
Albumin excretion rate < 20 20-200 > 200 
(µg/min) 
Albumin concentration < 20 20-200 > 200 
(mgt) 
ACR(mg/g creatinine) <30 30-300 > 300 
ACR < 3.5 3.5-35 > 35 
(mg/mmol creatinine) 
Adopted from Bilous, 2001 
Pro ession 
Microalbuminuria may initially be transient in nature, but may become persistent and 
result in the patient progressing to end stage renal failure if left untreated. Indeed, 
microalbuminuria may progress to ESRD in 7-10 years after onset of diabetes (American 
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Diabetic Association/ADA, 1997). In subjects with type 1 diabetes, about 80% of whom 
develop persistent microalbuminuria if left untreated, develop overt nephropathy within 
10-15 years, accompanied by hypertension. This may eventually lead to end stage renal 
renal failure within a further 10-20 years without appropriate therapeutic intervention 
(ADA, 1997). The higher proportion of individuals with type 2 diabetes who develop 
microalbuminuria and overt nephropathy shortly after the diagnosis of diabetes is 
probably because diabetes has been present for many years before the diagnosis was 
made. However, overall 20-40% of type 2 diabetics with microalbuminuria progress to 
overt nephropathy which ultimately may lead to ESRD (ADA, 2002). 
Pathoph siy ology 
The intimate relationship between low-level albumin excretion and vascular permeability 
makes UAE highly sensitivity to the presence of any inflammatory process, including 
cardiovascular disease (Mogensen, 1976; Haffner et al, 1990). Almost all filtered 
albumin is reabsorbed by the proximal tubule via a high-affinity, low-capacity 
endocytotic mechanism (Hartland and Gosling, 1999). Since tubular mechanisms for 
albumin reabsorption are near saturation, urinary albumin excretion would increase 
following any increase in tubular load. Glomerular permeability to albumin is dependent 
on endothelial charge selectivity as well as size selectivity. The negative charge conferred 
on the glomerular membrane by its constituent glycoproteins plays a role in restricting 
the permeability of anionic proteins. Loss of glomerular charge selectivity has been found 
in both diabetic and non-diabetic subjects with microalbuminuria. However, the 
mechanisms underlying microalbuminuria still remain to be fully elucidated (Hartland 
and Gosling, 1999). 
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Screening 
Annual screening for microalbuminuria will allow the identification of those diabetics 
with either nephropathy or at risk of developing nephropathy. A routine urinalysis should 
be performed at diagnosis in subjects with type 2 diabetes. Conversely, microalbuminuria 
rarely occurs with short duration of type 1 diabetes or before puberty and therefore, 
screening should begin with puberty and after 5 years disease duration. If the urinalysis is 
positive for protein, a quantitative measure is frequently helpful in the development of a 
treatment regime. Screening for microalbuminuria can be performed by three methods: 1) 
measurement of the albumin to creatinine ratio in a random spot urine collection; 2) 24h 
collection with creatinine, allowing the simultaneous measurement of creatinine 
clearance; and 3) timed (e. g. 4h or overnight) collection (ADA, 1997). 
1.2.5 Treatment of diabetic nephropathy 
Effective of glycemic control 
The DCCT, the UKPDS, the Stockholm and Intervention Study have demonstrated 
definitively that intensive diabetes therapy can significantly reduce the risk of the 
development of microalbuminuria and overt nephropathy in subjects with diabetes. 
However, an improvement in renal function, which is already restricted, can be attained 
by limiting maintaining blood glucose concentrations close to reference values (mean 
HbA1c 6.5%) and intensified blood pressure treatment. 
Control of blood pressure and antihypertensive agent 
Both systolic and diastolic hypertension significantly accelerate the progression of 
diabetic nephropathy, and aggressive antihypertensive management is able to greatly 
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decrease the rate of decline of GFR. According to guidelines in the sixth report of the 
Joint National Committee (JNC) on Prevention, Detection, Evaluation, and Treatment of 
High Blood Pressure, blood pressure levels above 135/85 mm Hg in a diabetic is 
abnormal. Treatment should be directed at lowering the systolic level to about 100 to 110 
mm Hg (JNC, 1997). The positive response to antihypertensive treatment coupled with 
the concept that often there is a progressive deterioration of renal function regardless of 
the underlying aetiology gave rise to the idea that haemodynamic factors may be critical 
in furthering the depletion in GFR. In this hypothesis, damage to glomeruli causes 
changes in the microcirculation that result in hyperfiltration occurring in the remaining 
glomuruli with increased intraglomerular pressure and increased sensitivity to 
angiotension II; the single nephron hyperfiltration with intraglomerular hypertension is in 
itself damaging (ADA, 1997). Initially, Angiotensin Converting Enzyme (ACE) 
inhibitors can reduce the degree of microalbuminuria and can reduce the rate of 
progression of diabetic nephropathy to a greater degree in both type 1 and type 2 
diabetics (Mogensen, 1976; DeFronzo, 1995; ADA, 1997). 
Protein Restriction 
Dietary protein restriction has been demonstrated to decrease albuminuria and reduce the 
rate of deterioration glomerular function in various renal diseases. Both animal and 
human studies have demonstrated that restriction of dietary protein intake also reduces 
diabetic intraglomerular pressure and retards the progression of renal disease and diabetic 
nephropathy. The consensus is to prescribe a protein intake of approximately the adult 
recommended dietary allowance (RDA) of 0.8 g kg "1 day "1 (approximately 10% of daily 
calories) in the subjects with overt nephropathy. However, it has been suggested that 
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once the GFR begins to decline, further restriction to 0.6 g kg '1 day 't may prove useful 
in slowing any further decline of GFR. (ADA, 1997). 
Renal replacement therapy(y RRT) 
RRT consists of haemodialysis, continuous ambulatory peritoneal dialysis (CAPD) and 
renal transplantation. Renal transplantation is the treatment of choice for those under 60 
years of age and should be considered when the serum creatinine concentration reaches 
about 500-800 µmol/l (Bilous, 2001). 
1.2.6 Pathogenesis of diabetic nephropathy 
As described previously, diabetic nephropathy is a major cause of renal failure. Several 
factors have been postulated in the pathogenesis of diabetic nephropathy including 
association of genetic factors, haemodynamic factors, vasocoactive factors, growth 
factors, renal structural factors, and hyperlipidaemia. However, it has been confirmed that 
chronic hyperglycaemia plays a significant role, and it is the major culprit in the 
development of diabetic nephropathy. Consequently, the present study focuses on several 
risk factors associated with abnormal glucose metabolism in general and the association 
between free radicals and oxidative stress in the pathogenesis of diabetic nephropathy in 
particular as described in Section 1.3. below. 
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1.3 Free Radicals 
1.3.1 Basic concept of free radicals 
In 1956, Denham Harman, father of the free radical theory postulated that free radicals 
produced during aerobic respiration cause cumulative oxidative damage, resulting in 
aging and death. Free radicals are generally considered harmful byproducts of oxidative 
metabolism (Oberley, 1988), causing molecular damage in living systems. This concept 
has implications in numerous biological phenomena such as cellular aging, mutagenesis, 
inflammation, and other pathologies. Furthermore, it has been suggested that free radicals 
are implicated in the process in part for the development of diabetic microangiopathy and 
macroangiopathy (Barnett, 1991), and excessive free radical production has been reported 
in diabetics with chronic renal failure treated by haemodialysis (Loughrey et al, 1994). 
Consequently, free radical mechanisms have been implicated in the pathogenesis of tissue 
damage in diabetes (Oberley, 1988; Packer, 1993; Wolff; 1993; Halliwell and Gutteridge, 
1998). 
The term "free radical" can defined as any atoms or molecules that contain an unpaired 
electron in its outer obit that can exist independently (Halliwell, 1994; Halliwell and 
Gutteridge, 1998). As a result, they can be highly reactive, although this varies from 
radical to radical, reacting locally to accept or donate electrons to other molecules to 
achieve a more stable state. Ground state 02 (302) has two unpaired electrons each 
located in a different antibonding orbital. An oxidizing agent, such as 02 is effective at 
absorbing electrons from the molecule it oxidizes (Halliwell and Gutteridge, 1998). The 
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collective terms reactive oxygen species (ROS) or active oxygen species have been 
applied for a variety of free radicals and non-radicals intermediates (Halliwell, 1994). 
1.3.2 Pathophysiology of free radicals 
Free radicals are formed in large amounts as an unavoidable by product of many 
biochemical processes and in some instances, deliberately, such as in activated 
neutrophils. In addition, free radicals can be generated in the body in response to 
electromagnetic radiation from the environment and acquired directly as oxidizing 
pollutants such as ozone and nitrogen dioxide (Halliwell, 1994). However, most of the 
free radicals in biological systems are oxygen-derived free radicals. The complete 
reduction of oxygen to H2O requires four steps and the generation of several free radicals 
and hydrogen peroxide (H202), which is in itself, not a free radical. H202 is however, 
considered a reactive oxygen species (ROS) because of its ability to generate highly 
reactive hydroxyl free radicals through interactions that reactive transition metals 
(Gutteridge, 1995; Clarkson and Thompson, 2000). The complete reduction of oxygen 
can be explained in the following equations. 
O2 + e' -º 02~ superoxide radical (1) 
OZ' + H20-º HOZ + OH hydroperoxyl radical (2) 
HOZ + e'+ H -º H202 hydrogen peroxide (3) 
H202 +e -º 'OH + 011- hydroxyl radical (4) 
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Each of these oxygen-derived intermediates are considered highly reactive species 
because their electron configurations allow for the attraction of electrons from other 
molecules, resulting in the formation of other free radicals that are capable of reacting 
with yet another molecule. This chain reaction is thought to contribute to lipid 
peroxidation, DNA damage, and protein degradation during oxidatively stressful events. 
Although all the intermediates are potentially reactive, the intermediates vary in their 
biological importance. The superoxide radical is the leading oxygen-derived free radical 
and, unlike the other oxygen derived intermediates, can lead to the formation of 
additional ROS (Harris, 1992). Furthermore, the protonation of superoxide anion radicals 
results in the formation of perhydroxyl radical (HO2 ), a much more aggressive radical 
than the superoxide radical itself. In addition, superoxide acts as a Bronsted base in 
aqueous solutions to shift the acid-base equilibrium to from a hydroxyl ('OH) radical 
thereby forming hydrogen peroxide in acidic environments. (Halliwell, 1994; Gutteridge, 
1995; Clarkson and Thompson, 2000). Hydrogen peroxide, although not a free radical by 
definition, is a biologically important oxidant because of its ability to generate the 
hydroxyl radical, an extremely potent radical species. Furthermore, because of its non- 
ionized and low charge state, hydrogen peroxide is able to diffuse through hydrophobic 
membranes, as observed with the leakage of hydrogen peroxide from mitochondria. 
Hydroxyl radicals are formed not only by the reduction of hydrogen peroxide but also 
through the interaction between hydrogen peroxide and the reduced forms of metal ions, 
i. e., copper and iron. The ability of the hydroxyl radical to remove or add hydrogen 
molecules to the unsaturated hydrogen bonds of organic lipids makes it potentially one of 
the most reactive oxidants in biological systems (Clarkson and Thompson, 2000). 
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Furthermore, the hydroxyl radical is the most powerful oxidant that can readily attack 
polyunsaturated fatty acids to initiate lipid peroxidation (Gutteridge, 1995). 
Consequently, the most toxic oxygen free radical involved in pathological processes is 
the hydroxyl radical ('OH). In biological systems, 'OH derives from the less toxic 
superoxide anion radical (O2 ') and H2O2 via the Haber-Weiss and Fenton reactions 
(Gutteridge, 1995). 
02' + H202 º 'OH + OH + 02 Haber-Weiss Reaction (5) 
Fe2+ H202 *'OH + OH + Fe 3+ Fenton Reaction (6) 
1.3.3 Antioxidant defence systems 
Antioxidants are defined as any substance that when present at low concentrations, 
compared with those of the oxidative substrate considerably delays or inhibits oxidation 
of the substrate (Halliwell, 1994; Gutteridge, 1995; Halliwell and Gutteridge, 1998). 
Antioxidants can act at many different stages in an oxidative sequence including 
removing oxygen or decreasing local oxygen concentrations, removing catalytic metal 
ions, removing key ROS such as oxygen and hydrogen peroxide, scavenging initiating 
free radicals, breaking the chain of an initiated sequence, and quenching or scavenging 
singlet oxygen species (Gutteridge, 1995; Halliwell and Gutteridge, 1998). Furthermore, 
a variety of antioxidant defense systems operates, including enzymatic and non- 
enzymatic antioxidants (Halliwell, 1994). Enzymatic antioxidants directly involved in the 
detoxification of ROS are super oxide disputes (SOD) and hydroxyperoxidases such as 
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catalase (CAT) and glutathione peroxidase (GSHPx) a selenium-containing enzyme 
glutathione (GSH) (Gutteridge, 1995; Halliwell, 1994). 
Cells have formidable defence mechanisms against oxidative damage of which some may 
not be readily recognisable as antioxidants (Gutteridge, 1995). Enzyme such as SOD 
rapidly promote the dismutation of superoxide into hydrogen peroxide and oxygen at a 
rate considerably faster than it occurs uncatalyzed. Two different superoxide dismutases 
are found in mammalian tissue, namely a Cu/Zn-containing enzyme which is found in the 
cytoplasm of most cells, and a further Mn-containing enzyme present within the 
mitochondrial compartment (Rice-Evans, 1994; Gutteridge, 1995). Both enzymes 
catalase the same reaction as shown below. 
202' + 2H+ -º H202+02 
Hydrogen peroxide, a product of the dismutation reaction, can be destroyed by two 
enzymes, catalase and glutathione peroxidase. Glutathione peroxidase can metabolise 
hydrogen peroxide, generated by SOD, by oxidizing the tripeptide glutathione into its 
oxidized from (GSSG). In addition, catalase transforms hydrogen peroxide into water and 
oxygen (Gutteridge, 1995) as shown below. 
2GSH + H202 -11 GSSG + 2H20 
2H202 -º 2H20 + 02 
Apart from these endogenous antioxidants, an important source of antioxidants is in the 
diet, which contains numerous compounds exhibiting antioxidant activity. The most 
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prominent dietary antioxidants are tocopherols, the fat-soluble vitamin (vitamin E), 
ascorbate water-soluble vitamin (vitamin C) and carotenoids. Furthermore, other 
antioxidants such as albumin and other proteins including ceruloplasmin and transferin 
also protect against oxidative injury by binding the transition metals Fe+2 and Cu+2 
thereby preventing generation of the hydroxyl radical via the Fenton reaction (Gutteridge, 
1995). 
1.3.4 Oxidative stress 
As previously described, oxygen-derived free radicals are constantly formed in the body 
during normal metabolic processes. When free radical formation is greatly increased, or 
protective antioxidant mechanisms compromised, a state of oxidative stress will result. If 
oxidative stress persists, it will eventually lead to molecular damage and tissue injury 
(Symons and Gutteridge, 1998). Consequently, oxidative stress has been defined as a 
disturbance in the balance between the production of free radicals (ROS) and antioxidant 
defenses, which may lead to tissue injury (Halliwell, 1994). Subjects with diabetes may 
be especially prone to oxidative stress, which enhances the development and progression 
of diabetic micro and macrovascular complications (Baynes, 1991; West, 2000). Animal 
and human studies and in vitro experiments all suggest a role of oxidative stress, via an 
increased formation of free radicals in the pathophysiology of diabetic microvascular 
complications (Baynes, 1991; West, 2000) such as nephropathy and retinopathy. 
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1.3.5 Free radical-mediated oxidative tissue damage 
The human body has a multiplicity of different antioxidant defense mechanisms 
(Halliwell and Chirico, 1993). If the defensive processes are overwhelmed, free radicals 
can then become highly destructive to cells and tissues. During oxidative stress, the 
prooxidant-antioxidant balance is tipped in favour of the former, and this may be due to 
exogenous sources of free radicals or other endogenous stresses (Rice-Evans 1994). 
However, oxidative stress can produce major interrelated derangements of cell 
metabolism, including DNA damage, protein damage and peroxidation of lipids 
(Halliwell and Chirico 1993). The relative importance of damage to different molecule as 
targets in producing cell injury or death by improving oxidative stress depends on 
duration, degree of stress underlying mechanism and the nature of the system stressed 
(Halliwell and Chirico, 1993). 
1.3.5.1 Lipid peroxidation 
The free radical oxidation of polyunsaturated fatty acid (PUFA) in biological systems is 
known as lipid peroxidation (Gutteridge, 1995). A PUFA contains two or more double 
bonds, and the presence of an increasing number of double bonds in fatty acids makes it 
more susceptible to oxidative damage by free radicals and peroxidation (Symons and 
Gutteridge, 1998). Both monounsaturated and saturated fatty acids are much less reactive 
and do not usually participate in lipid peroxidation (Abuja and Albertini, 2001). 
The present study focuses on non-enzymatic lipid peroxidation or lipid oxidation 
reactions. In the non-enzymatic lipid peroxidation process, the addition of oxygen yields 
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a lipid peroxyl radical, which is considered a hallmark of peroxidising lipids. Lipid 
peroxidaion consists of mainly three processes, namely initiation, propagation and 
termination (reactions 7-10). 
Initiation: X+ RH ºR+ XH (7) 
Propagation: R+ 02 > R00' (8) 
ROO' + RH º ROOH + R' (9) 
Termination: ROO' + ROO' - 0 [ROOOOR]-º NRP (10) 
Lipid peroxidation can be initiated by any primary free radicals ('OH, 02-') of sufficient 
reactivity to substitute an allylic hydrogen atom from a reactive methylene group of 
PUFA side-chains. In the initiation step, polyunsaturated lipids (RH) may form alkyl 
radicals (R') which react very rapidly with oxygen to form peroxyl radicals (ROO*). In the 
propagation step, a chain reaction with more lipids produces hydroperoxides (ROOH), 
i. e. primary oxidation products. Propagation reactions can repeat themselves many times. 
Thus, an initial event triggering lipid peroxidation can be amplified with the availability 
of oxygen and PUFA side chains (Rice-Evans, 1994). Consequently, the accumulation of 
hydroperoxides and their subsequent decomposition to alkoxyl and peroxyl radicals can 
accelerate the chain reaction with PUFA leading to oxidative damage in cells, membranes 
and lipoproteins (Rice-Evans, 1994). Under such conditions where lipid peroxidation is 
continuously initiated, a termination reaction limits the extent of lipid peroxidation, 
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yielding non-radical products (NRP), and destroying two radicals at the same time (Abuja 
and Albertini 2001). 
In contrast, the potential consequences of the peroxidation of membrane lipids include 
loss of polyunsaturated fatty acids; loss of decreased lipid fluidity, altered membrane 
permeability, effects on membrane-associated enzymes, altered iron transport, release of 
material from subcellular compartments and the generation of cytotoxic metabolites of 
lipid hydroperoxide (Rice-Evans, 1994). Furthermore, cleavage of the carbon bonds 
during lipid peroxidation reactions results in the formation of aldehyde products such as 
cytotoxic alkanals and alkenals, as well as alkanes. The breakdown products of lipid 
peroxidation, for example alkanals such as malondialdehyde (MDA), and hydroxyl 
alkenals such as 4-hydroxynonenal (HNE), have all demonstrated cytotoxic properties 
(Rice-Evans, 1994). 
1.3.5.2 Mechanism of antioxidant actions on lipid peroxidation 
In order to prevent overload of free radicals and peroxides, biological systems possess 
sophisticated antioxidant defensive mechanisms, which operate both in the intra and 
extracellular aqueous phases, and also in membranes (Rice-Evans, 1994). In extracellular 
fluids, numerous antioxidants are present; they can either prevent initiation or intercept 
lipid peroxyl radicals involved in the propagation phase. In human plasma there are 
abundant binding proteins present in order to prevent metal-induced catalysis. In 
addition, cell membranes and lipoproteins contain lipophilic antioxidants, which are able 
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to react with lipid peroxyl radicals, eventually terminating the chain reaction (Abuja and 
Albertini, 2001). 
LOO' + TocOH º LOOH +TocO' 
TocO' + Ascorbate º TocOH + Ascorbate radical' 
TocO' + LH º L' +TocOH 
The tocopherol (Toc) radical (TocO), located in lipid membranes, can be reduced to 
TocOH by ascorbate, located in the aqueous phase. It is probable that physiological 
homeostasis requires a balance presence of antioxidants located in both aqueous and lipid 
phase. There are also synergistic interactions between the tripeptide glutathione (GSH) 
and vitamin E (a- tocopherol), which may involve membrane-bound enzymes. It has been 
demonstrated that under specific experimental conditions in vitro, in the absence of 
water-soluble antioxidants, TocO' can abstract if from an adjacent fatty acid and 
therefore act as a prooxidant. Consequently, removal of lipid hydroperoxides is an 
essential mechanism for preventing such re-formation of free radicals. (Rice-Evans, 
1994; Abuja and Albertini, 2001). 
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1.3.6 The role of free radicals and oxidative stress in the pathogenesis of diabetes 
There is emerging evidence suggesting that subjects with diabetes have concomitant 
increased free radicals production and depletion of cellular antioxidant defense systems. 
It is well established that alloxan and streptozotocin induced diabetic animals become 
hyperglycaemic as the result of destruction of ß-cells of the pancreas by free radicals 
(Oberley, 1988). It is probable that in certain genotypes, glycation and glycoxidation lead 
to an increased susceptibility to oxidative stress than in other genotypes. This would be 
the genotypes in which ß-cell destruction leads to the development of type 2 diabetes 
(West, 2000). Pancreatic ß-cell are especially vulnerable to oxidative stress, probably 
because of their low free radical scavenging enzyme capacity reflected in low SOD, 
catalase and glutathione peroxidase activities. Recent studies have reported a direct link 
between the imbalance of oxidative stress and antioxidants leading to impaired glucose 
uptake. In adiposities, glucose uptake was rapidly decreased when they were incubated 
with glucose oxidise which resulted in a steady production of hydrogen peroxide. The 
reduction of insulin-dependent 2-deoxyglucose uptake was consequently accompanied by 
decreased P13 kinase activity and GLUT4 translocation. These observations support the 
suggestion that free radicals and antioxidant depletion could impair insulin-mediated PI3 
kinase activity, which results in impaired GLUT4 translocation and defective insulin- 
mediated glucose uptake. Increased oxidative stress, in addition to antioxidant depletion, 
leads to decreased glucose uptake were also observed in muscle cells. Furthermore, 
depletion of antioxidants accompanied by decreased glucose uptake has also been 
observed in subjects with type 2 diabetes (Rosen et al, 2001). These observations lead to 
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the hypothesis that the imbalance of free radicals and antioxidants is an important 
pathogenic factor affecting insulin-signalling pathways (Ceriello, 2000; Rosen et al, 
2001). However, clinical and experimental studies have demonstrated that 
supplementation with antioxidants such as vitamin E and a-lipoic acid stimulate glucose 
uptake through activation of the insulin-signalling pathway and provide protective effects 
to diabetic state (Rosen et al, 2001). 
1.3.7 Biochemical pathways of oxidative stress in diabetic complications 
Although the underlying patho-mechanisms remain incompletely understood, it can be 
postulated that oxidative stress due to chronic hyperglycaemia may play a significant role 
in the pathogenesis of diabetic nephropathy, retinopathy and neuropathy. Several 
biochemical pathways have emerged as being predominant potential pathophysiological 
mechanisms of oxidative stress that can be associated with hyperglycaemia (Baynes, 
1991) in diabetes mellitus. Furthermore, diabetes associated oxidative stress is probably a 
result of both an increased production of plasma free radical concentrations and a 
significant reduction in antioxidant defense mechanisms (Mercuri et al, 2000). 
1.3.7.1 Advanced glycation end products (AGEs) pathway. 
Reducing sugars such as glucose react non-enzymatically with amino groups in proteins 
and initiate glycation, the early stage of the Maillard reaction. This process begins with 
the conversion of a reversible Schiff base Amadori adducts. The occurrence of this class 
of non-enzymatic glycosylated adducts in vivo was established after chemical structural 
analysis of the minor haemoglobin species, HbA1, (Bucala and Cerami, 1992). MAI, is 
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formed in the erythrocytes by a non-enzymatic reaction between glucose and 
haemoglobin. The aldehyde group of the glucose and a free amino group of the 
haemoglobin first react to form a Schiffs base (aldimine, unstable form). Subsequently a 
stable ketoamine is formed in a reaction known as Amadori rearrangement (Bucala and 
Cerami, 1992) (Figure 1.3.7.1). The increase in the ambient circulating levels of HbA1, in 
diabetes is due to a shift in the equilibrium between the serum glucose concentration and 
the amount of protein-bound Amadori products. Since haemoglobin has a half-life of 
sixty days and Amadori product formation reaches equilibrium over 28 days, significant 
elevations of HbAIý can be measured during periods of prolonged hyperglycaemia 
(Koenig et al, 1976). Furthermore, in the intermediate stage of the Maillard reaction, the 
Amadori products can then undergo further rearrangenemnt, oxidation, multiple 
dehydration and polymerization resulting in the formation of advanced glycation end 
products (AGEs) (Bucala and Cerami, 1992). AGEs are irreversibly formed, and there 
accumulation has been demonstrated with aging, atherosclerosis, and diabetes, especially 
associated with long-lived proteins such as collagens, lens crystallins, and nerve proteins 
(Bucala and Cerami, 1992; Bucala et al, 1993). It has been suggested that the formation 
of AGEs not only modifies protein properties, but also induces biological damage in vivo 
(Yim et al, 1995). AGEs deposited in the arterial wall, could themselves generate free 
radicals capable of oxidizing vascular wall lipids and accelerate atherogenesis in 
hyperglycaemic diabetics (Yim et al, 1995, Esterbaur et al, 1996). The molecular 
structures of some AGEs have been identified as 1VE-carboxymethyllysine, pentosidines 
and pyrraline. In the presence of molecular oxygen, the formation of these products from 
sugars is catalyzed by transition metal ions via glycoxidation, which oxidizes Amadori 
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products to Ne-carboxymethyllysine, and the autoxidation of glucose, which produces 
superoxide radical anions, hydrogen peroxide and a-ketoaldehydes contribute to the 
generation of free radicals (Hunt et al, 1990). Several cell associated binding proteins for 
AGEs have been identified, including receptor for AGEs (RAGE) (Vlassara, 1996). The 
best characterised AGE receptor is RAGE, which is multiligand member of the 
immunoglobulin superfamily (Schmidt et al, 1996). The RAGE receptor probably acts as 
a scavenger and mediates intracellular signalling. Recently in vitro studies have 
demonstrated that AGE-RAGE binding on macrophages leads to free radical mediated 
oxidative stress and activation of the transcription factor NF-KB (Schmidt et al, 1994; 
Schmidt et al, 1996). 
Jib- NH2 + O=CH 
H-t --Oll 
HO - C- H 
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Figure 1.3.7.1: The glycation reaction of proteins in haemglobin as an example 
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1.3.7.2 Polyol pathway 
Hyperglycaemia associated with increased glucose metabolism can lead to the 
accumulation of sorbitol (Greene et al, 1988). Intracellular formation of sorbitol from 
glucose catalysed by aldose reductase (AR) is the first enzyme in the polyol pathway. In a 
hyperglycaemic situation, increased intracellular glucose results in its enzymatic 
conversion to the polyalcohol sorbitol, with concomitant decreases in NADPH. In the 
polyol pathway, sorbitol is then oxidized to fructose by the enzyme sorbitol 
dehydrogenase, with a stoichiometric reduction of NAD+ (Greene et al, 1988). Organ 
dysfunction in diabetes caused by the increased flux of glucose through the polyol 
pathway has been linked to the hyperglycaemia-induced increase in the NADH/NAD+ 
ratio, which is associated with the de novo synthesis of diacylglycerol (DAG) and the 
downstream stimulation of protein kinase C (PKC) activity. Disordered cellular 
metabolism or depletion of myo-inositol uptake, increased osmotic pressure and 
diminished Na fK+-ATPase activity may also be contributory factors, for example the 
reduced glomerular hyperfiltration observed in an animal model of type 1 diabetes 
(Goldfarb et al, 1991). Furthermore, recently it has been suggested that oxidation of 
sorbitol by NAD+ increases the cytosolic NADH/NAD+ ratio, thereby inhibiting activity 
of the enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and subsequent 
increased concentrations of triose phosphates. Elevation of triose phosphate 
concentrations could increase formation of AGEs, and DAG thus activating PKC 
(Brownlee, 2001). The activation of PKC, through which hyperglycaemia stimulates 
extracelluar matrix (ECM) production, is presumably due to increased de novo synthesis 
of DAG. The increase in the NADH/NAD+ ratio that results from the increased activity 
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Figure 1.3.7.2 Glucose and AGEs formation pathways incorporating the polyol pathway. 
CML=N-c-(carboxymethyl) lysine. 
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of the polyol pathway favouring this process. Increased de novo synthesis of DAG 
activates PKC both in cultured vascular, retinal and glomeruli cells in diabetic animals 
(Koya and King, 1998). However, increased de novo synthesis of DAG (Koya and King, 
1998) and the effect of hyperglycaemia on PKC activation probably reflects increased 
dyhydroxyacetone phosphate concentrations, resulting from inhibition of GADPH by free 
radicals. Hyperglycaemia may also activate PKC isoforms (PKC-a and PKC-ß) indirectly 
through both ligation of AGE receptors and increased activity of the polyol pathway, 
presumably by increasing production of free radicals (Brownlee, 2001) thereby 
enhancing oxidative stress. 
1.3.8 Biochemical markers of free radical mediated oxidative stress 
In the present study, appropriate biochemical markers were used in order to evaluate free 
radical by products and antioxidants in cohorts of both type 1 and type 2 diabetics as 
described below. 
Thiobarbituric acid reactive substances (TBARS) 
In vivo measurement of reactive free radicals is difficult because of their reactivity, short 
half-life, low concentration and complexity of products formed (Baynes and Thorpe, 
1996). Consequently, measurements of thiobarbituric reactive substances are suggested to 
reflecting free radical generation and peroxidative damage. TBARS mainly consists of 
malondialdehyde (MDA), recognised end products of polyunsaturated fatty acids 
peroxidation. However, they are also formed during oxidative stress including DNA, 
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protein, or carbohydrates. In clinical and experimental studies, TBARS measurements 
have been used for evaluate lipid peroxide both in plasma (Kuyvenhoven and Winders, 
1999) and urine (Kosugi et al, 1993). 
Increased TBARS concentrations in urine were observed in poorly control type 1 and 
type 2 diabetic subjects when compared to control subjects (Sato et al, 1979). Several 
studies have reported an increased susceptibility to lipid peroxidation in subjects with 
diabetes mellitus and diabetic nephropathy as measured by TBARS assay (Gallou et al, 
1993; Rabini et al, 1994). 
Total Antioxidant Status 
The antioxidant defense mechanisms provide protection from reactive free radical 
products, which cause peroxidation of lipids and destruction of biological molecules in 
the cell. Several methods (Whitehead et al, 1992; Miller et al, 1993) have been developed 
to determine the total antioxidant capacity of human serum or plasma because of the 
difficulty of measuring each individuals antioxidant components in the serum or plasma 
(Cao and Prior, 1998). Recently, the 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic 
acid (Trolox) equivalent antioxidant capacity (TEAC) assay introduced by Miller et al, 
(1993) has been introduced. The assay based on the inhibition by antioxidants of the 
absorbance of the radical cation of 2,2'-azinobis (3-ethylbenzothiazoline-6-sulfonate) 
(ABTS) as described in Chapter 2. 
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Several studies have noted a decrease in total antioxidant status in the plasma of subjects 
with diabetes (Sundaram et al, 1996; Leonhardt et al, 1996; Srinivasan et al, 1997). 
Recently, Valublji et al, (2001) demonstrated reduced total antioxidant status in type 1 
diabetes compared with non-diabetic control subjects. The reduction in total antioxidant 
status in diabetics has been associated with poor glycaemic control and duration of 
diabetes. 
Vitamin E (a-tocopherol) 
Vitamin E includes eight, naturally occurring compounds in two classes such as 
tocopherols and tocotrenols, and in each class there are a, ß, y and S. The tocopherols are 
more active than tocotrenols, which have three double bonds in the side chain. a- 
tocopherol is biologically the most active and widespread. One of the most characterised 
features of a-tocopherol is its ability to prevent the initiation and propagation of lipid 
peroxidartion by scavenging the free radicals contributing to the process by preventing 
oxidative damage to cell membrane thereby preserving structure and functional integrity 
of membranes and organelles. (Warren et al, 1992). 
Several studies, particularly clinical prospective studies have demonstrated decreased 
plasma vitamin E concentrations in subjects with diabetes compared with value from 
non-diabetic control subjects (Salone et al, 1995). Furthermore, vitamin E concentrations 
were directly associated with LDL concentrations subjects with type 2 diabetes (Reaven 
et al, 1995). 
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Glutathione neroxidase 
In normal biochemical processes, superoxide is detoxified rapidly by the enzyme 
superoxide dismutase (SOD), leading to the formation of hydrogen peroxide, which is 
subsequently converted to water in the cytosolic compartment of the cells, through the 
action of the selenonenzyme glutathione peroxidase (GSH-Px) using glutathione as an 
essential cofactor. Glutathione peroxidases (EC 1.11.1.9) constitute a family of enzymes 
which are capable of reducing a variety of organic hydroperoxides and lipid 
hydroperoxides to the corresponding hydroxyl compounds, utilizing glutathione, and/or 
other reducing equivalents, thus protecting cells from free radical mediated oxidative 
damage. Furthermore, two types of glutathione peroxidases have been identified in the 
blood, namely classical cellular glutathione peroxidase in red blood cells and 
extracellular glutathione peroxidase in plasma (Brigelius-Flohe, 1999). 
Several studies, including both human (Aaseth and Stoa-Birketvedt, 2000; Varvarovska 
et al, 2003) and experimental (Mukherjee et al, 1998) have reported significant depletion 
of glutathione peroxidase in diabetics associated with enhanced lipid peroxidation as a 
result of decreased scavenging of free radicals. In addition, a recent study reports a 
dramatic decrease in glutathione peroxidase activity, which occurred early in the course 
of chronic renal failure and associated with diabetic renal parenchymal destruction 
(Bonnefont-Rousselt et a1,1997) 
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Selenium 
Selenium has been demonstrated to be essential for effective intermediate metabolism. Its 
biochemistry, toxicology and nutritional importance have been recently reviewed 
(Whanger, 1998). The antioxidant ability of selenium resides in the active side chain of 
the seleno-enzyme glutathione peroxidase. The importance of selenium as an essential 
trace element is probably due to its presence in this enzyme. Furthermore, selenium is 
generally present as either part of the metallenzyme, glutathione peroxidase, or as 
selenoprotein P which function remain as yet unclear (Sheehan and Halls, 1999). 
Several studies have reported a decreased selenium concentrations in subjects with type 1 
and type 2 diabetes. In ketotic type 1 diabetic subjects, plasma selenium concentrations 
tended to be decreased in comparison with standard values and were not corrected by 
insulin treatment that normalised blood glucose concentrations (Faure et al, 1993). 
Furthermore, the effects of selenium on diabetic complications, an association between 
plasma selenium concentrations and high index of micro and macroangiopathy was 
observed in subjects with both type 1 and type 2 diabetes (Douillet et al, 1999). 
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1.3.9 Aims and objectives of the present study 
Evidence has accumulated indicating that hyperglycaemia associated with generation of 
free radicals and subsequent enhanced oxidative stress may play an important role in the 
pathogenesis of diabetic nephropathy. These processes are believed to reflect 
biochemical/pathophysiological changes in the diabetic kidney, resulting in both 
glomerular and tubular insult that may ultimately lead to the development of early 
diabetic nephropathy. However, the exact pathogenic processes, and the time needed to 
develop renal dysfunction involved in the development of diabetic nephropathy have not 
yet been clearly defined. Consequently, the overall aim of the present studies was to 
investigate the role of free radicals in the pathogenesis of diabetic nephropathy. Specific 
aims were as follows. 
1. To investigate the role of hyperglycaemia and poor glycaemic control in promoting 
lipid peroxidation and subsequent oxidative stress in a cohort of diabetic subjects. 
2. To establish any associations between estimates of lipid peroxidation, associated 
oxidative stress and early renal insult in the diabetic state. 
3. To investigate any temporal relationship between disease duration, length of exposure 
to hyperglycaemia and altered carbohydrate and lipid metabolism in the diabetic state. 
4. To investigate the role of antioxidant defence mechanisms with disease duration and 
any associations with renal insult and dysfunction in the diabetic state. 
5. To investigate the use of sensitive renal biomarkers in the early recognition of 
diabetic renal insult and dysfunction, and any associations with lipid peroxidation, 
associated antioxidant defence mechanisms and glycaemic control. 
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CHAPTER TWO 
MATERIALS AND METHODS 
2. Materials and methods 
2.1 Clinical investigation protocol 
One of the main aims of the present studies was to investigate if the generation of free 
radicals and lipid peroxides, associated dyslipidaemia and renal insult was temporally 
related to the presence of hyperglycaemia. Consequently, length of disease duration 
rather than the type of diabetes present, was a major consideration in selecting study 
populations. However, this was recognised as being a significant limitation of the present 
study due to the heterogeneous nature of the type 2 diabetic state. 
2.1.1 Study design 
The subjects were patients undergoing routine clinical review in the out patients clinic at 
York Diabetes & Endocrine Centre, York District Hospital, York National Health 
Services Trust and diagnosed as type 1 or type 2 diabetics according to the WHO (1985) 
criteria. All patients volunteered and appropriate clinical information (age, gender, 
duration of disease, type of diabetes and current medication) was obtained from the 
diabetes assessment package. Both inclusion and exclusion criteria were adopted as 
follows 
1. All volunteers should be aged 18 and 68 years. 
2. Diabetic subjects with evidence of renal disease charaterised by frank proteinuria, 
hypertension with or without antihypertensive treatments, dyslipidaemia or 
cardiovascular disease, evidence of renal insufficiency, chronic urinary tract 
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infections, renal stones and renal tumors and any antioxidant supplementations were 
excluded from the study. 
3. Informed consent would be obtained from all patients for the acquisition of human 
biological specimens, both blood and urine. 
4. Age and gender-matched control subjects studied for comparative reasons were 
healthy individuals. 
Sixty diabetic subjects were recruited and separated into two groups (both 20 subjects) 
according to duration of disease i. e. Duration of diabetes was defined as the time between 
diagnosis and initial visit for the present study. The two groups studied, in addition to a 
healthy non-diabetic control group were 1. Recently diagnosed diabetics (disease 
duration up to 2 years) and 2. Established diabetics (6-8 years disease duration). The 
study was reviewed and approved by both the De Montfort University Research Ethics 
Committee and York Heath Services Research Ethics Committee, and conducted under 
the guidance and supervision of Dr. Paul Jennings, Consultant Physician in diabetes and 
endocrinology, York Diabetes & Endocrine Center, York District Hospital, and Professor 
Paul Whiting, Professor of Biomedical Science at De Montfort University. The clinical 
characterization of these patients is given in Table 2.1.1 
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Table: 2.1.1 Clinical characteristics of the study groups 
Control Group/ Group 1/GP 1 Group 2/GP 2 
Cont GP (Recently diagnosed (Established 
diabetics) diabetics) 
n 20 20 20 
Duration -- _S 
2 years 6-8 years 
Age (years; mean±SD) 41±17 40±18 40±18 
Type 1/ Type 2 -- 9/11 9/11 
Male/Female 10/10 10/10 10/10 
Insulin therapy -- 9 9 
Metformin 5 5 
Glibenclamide -- 2 2 
Metformin and -- 4 4 
glibenclamide 
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2.1.2 Specimen collection, transportation and storage 
Appropriate sample acquisition, storage, and handling are essential, but frequently 
neglected, steps that precede biochemical investigations. However, it is crucial that all 
specimens to be used for experimental investigation have been collected from the 
appropriate patients using standardized protocols and placed in the appropriately labeled 
specimen collection tubes, and the stored in a manner that maintained specimen integrity. 
In this study, fasting venous blood samples (10-12 hours) were obtained from selected 
diabetic subjects by a research nurse in the out patients clinic at York Diabetes & 
Endocrine Centre. Blood samples were collected in clean polypropylene tubes, labeled 
and immediately transferred to the Chemical Pathology/Clinical Chemistry laboratory for 
biochemical investigations. Although in most cases urine is an easier specimen to obtain 
than blood, collection requirements must also be strictly adhered. Furthermore, all urine 
specimens must be appropriately stored to minimise the risk of growth. In this study, 
morning mid stream urine specimens were collected in clean polypropylene tubes from 
previously selected diabetes subjects in the hospital. Urine specimens were labeled and 
immediately transferred to the Chemical Pathology/Clinical Chemistry laboratory for 
biochemical investigations. All specimens (blood and urine) were alequoted into 2m1 and 
storage at -20 °C unless otherwise stated. All frozen specimens were thawed completely 
and mixed well before the appropriate analysis was performed. 
Various laws and regulations apply to the shipment and or transportation of biological 
specimens. It is very important factor that appropriate temperature must be maintained 
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during the transportation of the clinical specimens. Commercially available Styrofoam 
containers with dry ice were used for the transportation of all specimens (blood and 
urine) from York District Hospital to De Montfort University for biochemical analysis. 
2.2 Metabolic biochemical markers investigation 
2.2.1 Glucose analysis 
Serum glucose concentrations were measured using the glucose oxidase method 
(enzymatic colorimetric) described by Tinder, (1969). Glucose is oxidized to gluconate 
by atmospheric oxygen in the presence of glucose oxidase (GOD). The indicator 4- 
aminophenazone and phenol are oxidize by the hydrogen peroxide forms in the presence 
of peroxidase (POD). The intensity of the colour produced is proportional to the glucose 
concentration in the sample. Finally, colour intensity was measured at 546 nm on a 
Hitachi 911 fully automated clinical chemistry analyser manufactured by Boehringer 
Mannheim /Roche Diagnostics Germany. The glucose reagent kit was supplied by the 
Boehringer Mannheim /Roche Diagnostics Germany. Results were expressed as mmol/l. 
The test principle of the glucose oxidase method is given below. 
GOD 
Glucose + 02 + H2O º gluconate + H202 
POD 
H202 + 4-aminophenazone + phenol 4-(p-benzoquinone-mono-imino)-phenazone 
4H20 
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2.2.2 Fructosamine analysis 
Serum fasting fructosamine concentration was measured according to the colorimetric 
assay method described by Kruse-Jarres et al, (1989). Fructosamine (ketoamines) from 
the sample is present in an alkaline medium (reagent solution at pH 10.3) in the enol 
form, which reduces nitrotetrazolium-blue (NBT) to a formazan compound. The rate of 
formation of formazan is directly proportional to the concentration of fructosamine 
presence in the sample. The rate of reaction was measured photometrically at 546 nm on 
a Hitachi 911 fully automated clinical chemistry analyser (Boehringer Mannheim /Roche 
Diagnostics Germany). The fructosamine reagent kit was supplied by the Boehringer 
Mannheim /Roche Diagnostics Germany. Results were expressed as mmol/l. 
2.2.3 Glycosylated haemglobin (HbA1, ) analysis 
The HbA1, assay was based on the turbidimetric inhibition immunoassay (TINIA) as 
introduced by Karl, (1993). A commercially available reagent kit (Tina-quant HbAIc, 
Boehringer Mannheim /Roche Diagnostics Germany) was used to determine HbAlc % in 
the whole blood samples. The HbAI, kit was contained the following reagents. 
Reagent 1 (Rl): 2-morpholinoethane sulfonic acid (MES) buffer, tris (hydroxymethyl)- 
aminomethane [TRIS] buffer and MAI, antibody (ovine serum). 
Reagent 2 (R2): MES buffer, TRIS buffer and HbAic polyhapten. 
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In brief, RI was added to the blood samples to be measured. HbAjc in the sample reacts 
with the anti- HbAjc antibody to form soluble antigen-antibody complexes. Since the 
specific HbAjc antibody site was present only once on the HbAI. molecule, complex 
formation does not take place. After the addition of R2 which contained buffers and 
polyhapten the reaction was initiated. The polyhaptens react with excess anti- HbAjc 
antibodies to form an insoluble antibody-polyhapten complex which was measured 
turbidimerically at 340 nm on a Hitachi 911 fully automated clinical chemistry analyzer 
(Boehringer Mannheim /Roche Diagnostics Germany). Results were expressed as 
percentage of HbA1 jtotal Hb. The HbA1, assay principle is given below 
Excess anti- HbAI, antibody + Polyhaptens º Antibody/polyhapten complex 
Antibody/polyhapten complex º Turbidimetric measurement at 340 nm 
2.2.4 Total cholesterol analysis 
Serum cholesterol concentrations were measured by the method of Siedel et al, (1983). 
Cholesterol esters were first hydrolyzed into cholesterol and fatty acids in the presence of 
cholesterol esterase. Free cholesterol was then oxidized into cholestenone by atmospheric 
oxygen in the presence of cholesterol oxisase, the reaction also producing hydrogen 
peroxide. The latter compound then oxidised an incorporated indicator namely, 3,3,5,5'- 
tetramethylbenzidine (TMB), in the presence of peroxidase to produce a blue coloured 
complex. The concentration of complex was finally determined by a microprocessor- 
controlled reflectance photometer at 642 nm. The microprocessor-controlled reflectance 
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spectrophotometer ("REFLOTRON" semi automated dry chemistry analyzer, 
manufactured by Boehringer Mannheim /Roche Diagnostics Germany) and dry chemistry 
reagent carrier test strips (REFLOTRON test strips produced by Boehringer Mannheim 
/Roche Diagnostics Germany) were used for the determination of all lipid parameters 
such as total cholesterol, triglycerides and HDL in this study. Results were expressed as 
mmol/l. The reaction principle is given below. 
Cholesterol esterase 
cholesterol esters 10 cholesterol + ROOH 
Cholesterol oxidase 
cholesterol + 02 10 cholestenone + H202 
Peroxidase (POD) 
TMB + H202 TMB-complex + H2O 
CH3 CH3 CH3 CH3 
H202 + H2N (ý HN2 Per- 
oxidase+ 
H2NN 
G). ýý 
HN2 +2H 20 
CH3 CH3 CH3 CH3 
Tetramethylbenzidine blue dye 
(The indicator reaction) 
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2.2.5 Triglycerides analysis 
Serum triglycerides were measured according to the method described by Nagele et al, 
(1984). The triglycerides were first hydrolysed into glycerol and free fatty acids by 
lipase. The glycerol was then phosphorylated into L-a-glycerol phosphate by 
glycerokinase (GK) and adenosine triphosphate (ATP) in presence of Mg 2+ions. The 
glycerol phosphate was then oxidised by atmospheric oxygen into hydroxyacetone 
phosphate and hydrogen peroxide in the presence of L-a-glycerol phosphate oxidase 
(GPO). Finally, the blue colour of the oxidised indicator, which becomes deeper coloured 
with time, is determined using a "REFLOTRON" dry chemistry analyzer at 642 nm. 
Results were expressed as mmol/l. The reaction principle is given below. 
Lipase 
triglycerides + 3H20 glycerol + 3RCOOH 
GK 
glycerol + ATP 
GPO 
L-a-glycerol phosphate + 02 -º 
L-a-glycerol phosphate + ADP 
hydroxyacetone phosphate + H202 
POD 
Indicator (colourless) + H202 0 indicator (blue) 
N 
ýHo OCHS 
0_ /ý'''ý Hp2+ (CHýýN_ Cý 
I 
OH 
oxdase 
(CH3)IIN-(( )}-CC 
N 
NC 
O +2H20 
IC-1k 
*- 
CH3 H OCH2 CH3 OCH3 
Diarylimidazole dorivative blue-green dye 
(The indicator reaction) 
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2.2.6 High density lipoprotein (HDL) cholesterol analysis 
Serum HDL concentrations were measured by the method of Siedel et al, (1983). The 
enzyme cholesterol esterase catalyses the cleavage of cholesterol esters into cholesterol 
and the corresponding fatty acid. In the presence of oxygen, free cholesterol is oxidized 
by means of cholesterol oxidase to produce chlestenone and hydrogen peroxide. The 
hydrogen peroxide forms converts the reduced form of the indicator 4-(4- 
dimethylaminophenyl)-5-methyl-2-(4-hydroxy-3,5-dimethoxyphenyl)-imidazole dihydro- 
chloride into blue (oxidized) from, provided peroxidase (POD) is present. The 
concentration of blue dye is proportional to the concentration of HDL in the sample and 
was determined by "REFLOTRON" dry chemistry analyzer at 642 nm. Results were 
expressed as mmol/l. The reaction principle is given below. 
Cholesterol esterase 
cholesterol esters 10 cholesterol + ROOH 
Cholesterol oxidase 
cholesterol + 02 10 cholestenone + H202 
POD 
H202 + indicator (colourless) blue-green dye + H2O 
OCH3 OCH3 
^ N+ N H202 + (CHF ), N-(( , C. C OH 
a 
Per- (CHF )z N( 
'C 
O+2HO ý/ýJJ C-N C-N z 
CH3 H OCHS CHF OCH3 
Diarylimidazole derivative blue-green dye 
(The indicator reaction) 
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2.2.7 Low density lipoprotein (LDL) cholesterol estimation 
The Friedewald Equation 
In the most widely used indirect method, total cholesterol, triglycerides and HDL 
cholesterol are measured and LDL cholesterol is calculated from the primary 
measurements using the empirical equation of Friedewald et al, (1972). In this study LDL 
concentration of the samples were estimated by the Friedewald equation as given below. 
Results were expressed as mmol/l. 
[LDL cholesterol] = [Total cholesterol] - [HDL cholesterol] - [Triglycerides] (mmol/1) 
2.2 
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2.3. Lipid peroxidation and plasma antioxidant investigations 
2.3.1 Urinary Thiobarbituric Acid Reactive Substances (TBARS) analysis 
The most widely used method for the detection of lipid peroxidation is the TBA reaction 
with malondialdehyde (MDA) resulting in the formation of a MDA-TBA complex. This 
complex could be separated from other TBA-reactive compounds by both 
chromatography and spectrofluorimetry. Urine TBARS were analysed using a 
fluorimetric technique introduced by Yagi, (1976) and subsequently modified by 
Wasowiez et al, (1993). 
. Reagents were prepared using double distilled deionised water in order to prevent iron 
contamination, which may cause an arteactual increase in the final fluorescent product. 
The TBA reagent was prepared by mixing thiobarbituric acid 0.67% (w/v) with an equal 
volume of glacial acetic acid. A stock solution of MDA (0.5 nmol/ml) was prepared by 
hydrolysing tetramethoxypropane (103 µl; MW 164.2,0.997 g/ml) with water to a final 
volume of 250 ml and then dissolving 50 µ1 of this solution in another 250 ml of water. 
Standards (0 to 0.5 nmol/ml) were prepared by placing the appropriate quantity of stock 
solution in a glass tube and adding water to a final volume of 1 ml. Previously aliquoted 
and stored (at -70°C) urine specimens were brought up to room temperature, 
reconstituted and 100 µl pipetted into a separate glass tubes and water (0.9 ml) added. 
TBA reagent (lml) was then added to both standards and specimens and they were placed 
in a water bath and heated for 1 hour at 95-100 °C After the samples cooled, 5 ml of 
butanol was added to each tube and after mixing, the tubes centrifuged at 1500 r. p. m. for 
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10 minutes. Finally, the butanol layer was read using a fluorimeter (Perkin-Elmer LS-5, 
UK) with excitation at 515 nm and emission at 546 nm and a standard curve was 
constructed as shown in Figure 2.3.1. The concentration of the unknown was then 
calculated. All standards and specimens were analysed in triplicate and all chemicals for 
this assay were obtained from Sigma-Aldrich Ltd, UK. 
2.3.2 a-tocopherol (vitamin E) analysis 
a-Tocopherol was measured by the method of Macaulay, (1999) using a reverse phase 
high performance liquid chromatography (HPLC) system (Shimadzu Class-VP, 
Shimadzu Corporation, Japan). 
An internal standard was added to the plasma samples, which were then extracted and 
loaded onto the column. Both a-tocopherol and the internal standard, a-tocopherol 
acetate, have polar attraction and specificity for the column and are therefore retained on 
the column before being eluted and detected. The retention times for a-tocopherol and a- 
tocopherol acetate were determined by observing the times for peaks eluting after loading 
pure standards. A standard a-tocopherol solution was prepared by dissolving 20mg of a- 
tocopherol (Sigma-Aldrich, UK) in 100m1 of HPLC grade ethanol (Fisher Chemical, UK) 
(Standard Solution 1). Solution 1 was then further diluted 1 in 20 with ethanol to forms 
solution 2. Maximum absorption of standard solution 2 was observed and confirmed at 
292 nm by using a scanning spectrophotometer (UNICAM UV I) without any detectable 
contamination. 
68 
40 
°Q 30 
U 
O 
20 
P4 10 
0 
[Malondialdehyde] ng/ml 
Figure 2.3.1 Typical standard curve for TBARS assay. Results are expressed as mean 
± SEM for triplicate determinations. 
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The concentration of standard solution 1 (3.44mmol/1) was determined using the Beer- 
Lambert law. 146µl of standard solution 1 was made up to 10ml with pooled serum. Both 
spiked and non-spiked serum samples were aliquoted and frozen at -20 °C. For each run, 
a sample of spiked and non-spiked pooled serum was measured. The internal standard 
was prepared by dissolving approximately 14g of a-tocopherol acetate (Sigma-Aldrich, 
UK) in 50m1 of ethanol. This solution was scanned and a single peak obtained indicating 
again no significant contamination. 
Plasma samples (100µ1) (spiked pool/non-spiked pool) were pipetted into a 1.5m1 
polypropylene tube and l00µ1 of a-tocopherol acetate internal standard was added. After 
vortex mixing for 20 seconds, 400µl of hexane (HPLC grade, Fisher Chemicals, UK) was 
added and, after further vortexing for 60 seconds, the tubes were centrifuged and the 
hexane layer separated. The sample were then dried under a stream of nitrogen, 
reconstituted with 50gl methanol (HPLC grade, Fisher Chemicals) and analysed. 
A stainless steel column (C18: 5µi, 150 mm x 4,6 mm/Phenomenex UK) was used with 
the HPLC system and HPLC grade methanol was used as a mobile phase. The mobile 
phase was pumped through the column at 1.5m1 per minute and the injection volume was 
20µl. The retention time for a-tocopherol was 3.5 minutes and that for a-tocopherol 
acetate 4.4 minutes, determined from the analysis of standard solutions. Standards and 
samples were analysed and the areas under the respective peaks obtained. All standards 
and specimens were analysed in triplicate. A typical standard curve is given in Figure: 
2.3.2 and the concentration of a-tocopherol in samples was calculated as detailed given 
below. 
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Concentration = Absorbance 
Extinction coefficient x Path length 
Extinction coefficient for a-tocopherol 
Pathlength = 
Mean absorbance of standard solution = 
(from the Beer-Lambert Law) 
= 75.8 for a 1% solution 
(i. e. 1g in 100m1 in a1 cm lightpath) 
l cm 
0.561 
a-tocopherol in standard solution 1= 20 x 0.561 = 0.148g = 3.44mmol/l 
(MW 430.7) 75.8 x1 100ml 
146µ1 made up to 10ml with pooled serum = 50 µmol/1 
Area a-tocopherol in spiked pool 
= Rs 
Area internal standard in spiked pool 
Area a-tocopherol in patient sample 
= Rp 
Area internal standard in patient sample 
Area a-tocopherol in unspiked pool 
= RU 
Area internal standard in unspiked pool 
The concentration of the internal standard is the same in all three samples 
The difference between the spiked and unspiked pool (Rs- RU) = 50 µmol/l 
Therefore lµmol/1= Rs- Ru/50 and the patients sample concentration can be calculated. 
Concentration of a-tocopherol in the patient sample = Rp x (Rs- Ru)/50 
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Figure 2.3.2 Typical standard curve for the a-tocopherol (vitamin E) assay. Results are 
expressed as mean ± SEM for triplicate determinations. 
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2.3.3. Total antioxidant status analysis 
The total antioxidant status assay method described by Miller et al, (1993) was used in 
the present studies. Plasma total antioxidant status was measured using a commercial 
reagent kit (Randox Laboratory, UK). The assay principle is that metmyoglobin reacts 
with hydrogen peroxide to form the radical species, ferrylmyoglobin. A chromogen 
solution such as 2,2'-azino-di-(3-ethylbenzthiazoline sulphonate) (ABTS®) is incubated 
with the ferrylmyoglobin to produce the radical cation species ABTS+. This has a 
relatively stable blue green colour, which was measured at 600 nm using a Hitachi 911 
fully automated clinical chemistry analyzer. Antioxidants in the sample cause 
suppression of this colour production to a degree that was proportional to their 
concentration in the sample. Results were expressed as mmol/l. The reaction principle is 
given below. 
HX-Fe "I (Metmyoglobin) + H202 X-(Fei'-O)(Ferrylmyoglobin) + H2O 
ABTS® + 'X-(Fen'-O) ABTS® ++ HX-Felu 
2.3.4. Glutathione peroxidase (GSHPx) (EC. 1.11.19) analysis 
Glutathione peroxidase was measured by the method of Paglia and Valentine, (1967). In 
brief, glutathione peroxidase catalyses the oxidation of glutathione (GSH) by cumene 
hydroperoxide. In the presence of glutathione reductase (GR) and NADPH, oxidized 
glutathione (GSSG) is immediately converted to the reduced form with a concomitant 
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oxidation of NADPH to NADP+. The decrease in absorbance at 340 run was measured 
using a Hitachi 911 fully automated clinical chemistry analyzer. A commercial reagent 
kit (Randox Laboratory, UK) was used for the determination of glutathione peroxidase in 
this study. The reaction principle is given below. 
GSHPx 
2GSH + ROOH º ROH + GSSG + H2O 
GR 
GSSG + NADPH + H+ º NADP+ + 2GSH 
2.3.5 Selenium analysis 
Selenium concentrations in plasma were determined by a Varian model SpectrAA-880 
Zeeman graphite furnace atomic absorption spectrometer (GFAAS, Varian, UK) with 
software SpecrAA-880 following the method of Knowles and Brodie, (1988). In brief, 
plasma samples were diluted 1/10 by using a sample diluent. The sample diluent was 
prepared by dissolving 0.56g of ascorbic acid (BDH, UK) 0.88 ml of TritonX-100 (BDH, 
UK), 1 ml of Antifoam B (Sigma-Aldrich, UK) and 0.1 ml of hydrochloric acid (Sigma- 
Aldrich, UK), made up to 1.0 L with deionized water. Then 20 µ1 of plasma sample was 
injected into the graphite furnace with a modifier solution (500 mg palladium, 0.05 % 
Triton X-100 and 0.1% Antifoam B). By using the auto sampler facility of the GFAAS 
the calibration curve was prepared from the stock solution of selemium (1 mg/L) by 
mixing the appropriate volume. The hallow cathode lamp from selenium was operate at 
20 mA and absorbance was measured at 196 nm. The analysis was performed in triplicate 
and results are expressed as gmol/l. 
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2.4. Renal biochemical markers investigation 
2.4.1 Serum and urine creatinine analysis 
Serum and urine creatinine concentrations were measured by the method of Heinegard 
and Tiderstrom, (1973) a reaction first described by Jaffe in 1886. Creatinine in an 
alkaline solution reacts with picric acid to form a coloured (orange-red) complex. The 
amount of the complex formed is directly proportional to the creatinine concentration in 
the sample. A commercial reagent kit obtained from Boehringer Mannheim/Roche 
Diagnostics, Germany and measured at 546 nm using a Hitachi 911 fully automated 
clinical chemistry analyzer (Boehringer Mannheim/Roche Diagnostics, Germany). 
Results were express as µmol/1 for both serum and urine. 
2.4.2 Microalbuminuria analysis 
As previously described, the occurrence of microalbuminuria is an early feature of 
diabetic nephropathy and can be regarded as the first marker of impaired glomerular 
function in subjects with either type 1 and type 2 diabetes mellitus. Albuminuria analysis 
can be performed according to two methods including semi quantitative and quantitative. 
However, in the present study quantitative assay was performed as detailed below. 
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uantitative analysis 
Quantitative albumin determination was based on an immunoturbidimeric assay 
(Multicentre study 1991) as initially introduced by Hofmann and Guder, (1989). A ready- 
made reagent kit (Tina-quant® Albumin) obtained from Boehringer Mannheim/Roche 
Diagnostics, Germany use in the present study. It contained two reagents (reagent 1 and 
reagent 2) as described below. 
Reagent 1/R 1(buffer): TRIS buffer, 50mmol/1. pH 8.0, EDTA 3.7 g/1 
Reagent 2/R 2: Polyclonal anti-human albumin antibodies (sheep); TRIS buffer 
100mmol/1, pH 7.2 
Initially, reagent R1 (100 µl) was mixed with the urine specimen (20 µl) and then 
subsequently. The addition of reagent R2 (150 µl) (anti-albumin antibodies) initiated the 
reaction. Anti-albumin antibodies react with the antigen in the urine specimen to form 
antigen-antibody complexes which, following agglutination, were measured 
turbidimetrically at 340 nm using a Hitachi 911 fully automated clinical chemistry 
analyzer. Results were expressed as mg/l. 
2.4.3 Serum sialic acid analysis 
Serum sialic acid concentrations were measured by the method of Zoppi, (1985). The 
glycosidically bound sialic acid is hydrolysed by neuraminidase to release free N- 
acetylneuraminic acid (AcNeu) (reaction 1). In the presence of AcNeu-aldolase, AcNeu 
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is cleaved into N-acetylmannosamine and pyruvate (reaction 2). The pyruvate formed is 
oxidized in the presence of MgC12, flavine adenine dinucleotide (FAD) and thiamin 
pyrophosphate (TPP) by pyruate oxidase to formed acetyl phosphate, CO2 and H202 
(reaction 3). The amount of H202 formed, which is equivalent to the free N- 
acetylneuraminic acid present, is converted by peroxidase (POD) in the presence of 4- 
aminoantipyrine (4-AAP) and N-ethyl-N-2-hydroxyethyl-3-toluidine (EHMT) to form a 
red coloured product (reaction 4), which absorbance was measured at 550 nm using a 
Hitachi 911 fully automated clinical chemistry analyzer. Results were expressed as 
mmol/1. 
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neuraminidase 
AcNeu (bound typr) 10 AcNeu + aglycon (reaction 1) 
AcNeu-aldolase 
AcNeu N-acetylmannosamine + pyruvate (reaction 2) 
pyrvate oxidase 
Pyruvate + 02 P; acetyl phosphate + CO2 +H202 (reaction 3) 
POD 
2H202 + 4-aminoantipyrine + EHMT Red dye (reaction 4) 
2.4.4 Serum Cystatin C analysis 
The cyctatin C assay was based on the method of the turbidimetric immunoassay 
introduced by Kyhse-Andersen et al (1994). A commercial reagent kit (DAKO Cystatin 
C PET) was obtained from DakoCytomation Ltd, UK. It was contained polystyrene 
particles of uniform size, chemically coupled with a rabbit antibody against human 
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Cystatin C. A reaction between these immunoparticales and Cystatin C in a patient 
specimen results in the formation of agglutinates and a concomitant changes in the 
absorbance measured at 340 nm. Again, a Hitachi 911 fully automated clinical chemistry 
analyzer was used for the analysis. Results were expressed as mg/L. 
2.4.5. Urine N-acetyl-ß-D-glucosaminidase assay/fl-NAG (EC. 3.2.1.30) 
ß-NAG activity in urine was measured by the method of Whiting, (1979) which was 
adapted from the method of Dance et al, (1969). The assay was based on the cleavage by 
ß-NAG of the novel substrate 4-methylumbelliferyl-2-acetamido-2-deoxy-ß-D- 
glucopyranoside, a non-fluorescent compound to release 4-methylumbelliferone (4-MU). 
4-MU fluoresces at a pH greater than 10, and consequently the reaction was terminated 
by the addition of an alkaline glycine buffer, pH 10.4. The final absorbency of 4-MU is 
obtained spectrophotometrically (UNICAM 8625 UV/VIS, UK) at a wavelength of 360 
nm. The following buffer solutions were used in the assay as detailed below. 
I. Trisodium citrate (TSC) buffer (assay buffer): trisodium citrate, 20 mM, pH 4.3 (with 
concentrated HC1). 
ii. Glycine buffer (stop solution): glycine, 0.5M adjusted pH 10.4 (with 5M NaOH). 
iii. Standard 4MU solution: 3mg of 4-methylumbelliferone (4-MU) in lml ethanol 
made up to 100ml with TSC buffer. 
iv. Substrate: 40mg of 4-methylumbelliferyl-2-acetamido-2-deoxy-p-D-glucopyranoside 
was dissolved in 50ml of TSC buffer. 
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The following procedure was adopted in order to determined NAG activity in the diabetic 
and control urine specimens. A standard curve was constructed (Figure 2.4.5), specimens 
were analysed in triplicate and results were expressed as units/mmol urinary creatinine. 
All chemicals were used in this analysis were obtained from Sigma-Aldrich, UK. 
Sample (Test) Blank 
0.1ml urine 0.1 ml urine 
0.65m1 TSC buffer 0.65m1 TSC buffer 
2m1 glycine buffer 
Incubate for 10 minutes at 37°C 
0.25m1 substrate 0.25m1 substrate 
Incubate for 30 minutes at 37°C 
2m1 glycine buffer 
Read optical density at 360 nm 
Calculation: ECorrected = ETest - EBlank 
The amount of 4-MU released was determined from the standers curve. The activity was 
expressed as nmol/ml/hr = µmol/Uhr = unit of enzyme activity 
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Figure 2.4.5 Typical standard curve for 4-methyl umbelliferone. Results are expressed 
as mean ± SEM for triplicate determinations. 
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2.4.6 Urine alanine amino peptidase (AAP) analysis (a-aminoacyl-peptide hydrolase, 
EC 3.4.11.2) 
Urine alanine amino peptidase activity was measured by the method of Jung and Scholz, 
(1980). The enzyme activity was determined in the presence of the model substrate L- 
alanine-4-nitroanilide hydrochloride which is hydrolysed by AAP to release the coloured 
compound 4-nitro aniline which absorbs maximally at 405 nm as measured by a 
UNICAM UV I (UK) double-beam spectrophotometer. The reaction principle as given 
below. 
L-alanine-4-nitroanilide hydrochloride b, 4-nitroaniline + L-alanine 
Urine samples were prepared by using PD-10 Sephadex G-25M columns. Previously 
aliquoted and centrifuged urine 2ml was added to the column and the eluent drained and 
discarded. Collection of the filtered urine was obtained following the addition of 4m1 of 
NaCI to the column. Then two solutions (solution 1 and solution 2) were prepared in 
order to determine AAP activity in urine. Solution 1 contained 59 mmol of tris adjusted 
to pH 7.8 with HCl and solution 2 contained 26 mmol of alanine-4-nitroanilide 
hydrochloride dissolved in solution 1 (250 ml). Then 1 ml of solution 1 was mixed with 
0.2 ml of urine, and allowed to equilibrate at 37°C for 15 minutes. 
The assay was initiated by the addition of 0.1 ml of solution 2 and the enzyme activity 
was determined kinetically by measuring the increase in optical density over a five 
minute period at 405 nm. 
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Calculation: 
K= (TV/SV) x 106 x (1/E) 
K= calibration factor 
TV = final reagent volume with include sample volume 
SV = sample volume 
E= molar extinction coefficient factor of 4-nitroaniline = 9620 
K= (1.3/0.2) x 106 x (1/9620) = 675.7 
Optical density (OD) xK= IU 
AAP activity was expressed as IU/mmol urinary creatinine 
2.4.7. Urine al-microglobulin analysis 
Urine al-microglobulin concentration was measured using the method described by 
Kurrle-Weittenhiller and Engel, (1992), and based on an immunoturbidmetric assay. A 
commercially available ready-made reagent kit (Tina-quant® al-microglobulin, 
Boehringer Mannheim/Roche Diagnostics, Germany) was used. The kit contained two 
reagents (R 1 and R 2). RI mainly consisted of 35 mmol of acetate buffer at pH 5.3, 
while R2 contained a polyclonal anti-human al-microglobulin antibody (sheep) and 50 
mmol of acetate buffer at pH 5.3. Initially, reagent R1 (100 µl) added to the urine 
specimen (20 µl) mixed and then reagent R2 (150 µl) was added start the reaction. al- 
Microglobulin antibodies react with antigen in the urine specimen to form an 
antigen/antibody complex which, after agglutination, was detected tuibidimetrically using 
a Hitachi 911 fully automated clinical chemistry analyzer. 
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2.4.8. Urine ß2-microglobulin analysis 
02-microglobulin in urine was measured by the method of Junge et al, (1996). The 
method was based on a immunoturbidmetric assay. A commercial reagent kit was 
obtained from Roche Diagnostics Germany (Tina-quant) ß2-microglobulin, Boehringer 
Mannheim/Roche Diagnostics, Germany) and it contained the following reagents. 
Reagent 1 (Rl): TRIS/HCI buffer 23 g/1, pH 8.7; NaC119 g/1, EDTA 2 g/1 
Reagent 2 (R2): latex particles coated with polyclonal anti-human ß2-microglobulin 
antibody (rabbit) 0.5 g/l 
In brief, reagent R1 (100 µl) was mixed with the urine specimen (20 µl) and then addition 
of reagent R2 (150 µl) initiated the reaction. ß2-microglobulin antibodies react with 
antigen in the urine specimen to form an antigen/antibody complex which, after 
agglutination, was detected tuibidimetrically using a Hitachi 911 fully automated clinical 
chemistry analyzer. 
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2.4.9 Urine alpha glutathione-S-transferase (aGST) and pi glutathione-S-transferase 
(nGST) analysis 
The determination of both aGST and 7tGST was based on a quantitative enzyme 
immunoassay. The analytical procedure was similar for both parameters and based on the 
sequential addition of urine sample, enzyme-conjugate and substrate to Microassay (96- 
well) plates pre-coated with anti- aGST-IgG/ 7rGST-IgG antibodies. The resultant colour 
intensity was proportional to the activity of GST present in the urine sample. 
The aGST and iGST activity in urine was measured using the method described by 
Hassett and Doyle, (1995) and Maning, (1995) respectively. Commercial reagent kits 
(Biotrin International Ltd, Dublin, Ireland) were used and the following components were 
included in the reagent kit. 
i. Antibody coated Microassay plate: 96-well plates (12x8 strips) pre-coated with IgG 
directed against aGST or itGST. 
ii. Calibrators (stock solution). aGST 4 mg/l: Purified aGST in stabilizing buffer (200 
µl), Thiomersal and sodium azide and 5 mg/1 or: Purified iGST in 50% (v/v) glycerol 
(200 µl). 
iii. Sample diluent: Protein containing solution (50 ml) and sodium azide. 
Positive control: Protein containing solution with added stabilisers (4.5 ml) 
Thiomersal and sodium azide. 
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iv. Conjugate solutions: Anti- aGST IgG or Anti- 7LGST IgG conjugated to horseradish 
peroxidase (1400 µl). 
A. Wash solution: Phosphate buffered saline (PBST 55 ml). 
vii. Substrate: Stabilised liquid tetra methyl benzene (TMB) solution (11 ml). 
viii. Stop solution: 1N sulphuric acid (11 ml). 
ix. Urine stabilizing buffer (10 ml) which contains Thiomersal and sodium azide. 
In brief, immediately prior to the analysis, urine samples were diluted (1/2 dilution) by 
addition of 200 pl sample to 200 µl sample diluent. Then 100 µ1 of diluted urine, 
previously prepared calibrators and positive control were placed in the Microasay plate 
(100 jVwel1). The assay plate was covered and incubated at room temperature (20-25°C) 
for 60 minutes with uniform shaking (LUCKHAM, UK Titer-plate shaker was used with 
speed 2-3). 
After exactly 60 minutes, the cover was removed and 250 gl of wash solution added to 
each well and washed 4 times. When this procedure was completed, the plate was firmly 
tapped against a paper towel to ensure complete removal of wash solution from the wells. 
Then after addition of 100 µl of conjugate solution to each well the assay plate was again 
covered and incubated at room temperature (20-25°C) for 30 minutes with uniform 
shaking as described above. 
After the exactly 30 minutes, the assay plate was again washed as described earlier. Then 
substrate 100 µl was added to the each well and the assay plate was again incubated at 
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room temperature for 15 minutes. Finally, after the exactly 15 minutes, 100 µl of stop 
solution were added on to each well and immediately readings were taken at 450 nm by 
using a micro-titer plate reader (Labsystems MS, UK). A typical calibration curve was 
constructed for both aGST and tGST (Figure 2.4.9 and 2.4.10) and urine GST activity 
was expressed as U/mmol urinary creatinine. 
2.5 Statistical analysis 
Statistical analyses were performed using the GarphadPad Prism Software (1999) Inc, 
San Diego, Canada. 
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Figure 2.4.9 Typical standard curve for the aGST assay. Results are expressed as mean 
± SEM for duplicate determinations. 
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Figure 2.4.10 Typical standard curve for the 7tGST assay. Results are expressed as mean 
± SEM for duplicate determinations. 
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CHAPTER THREE 
AN INVESTIGATION OF HYPERGLYCAEMIA 
AND LIPID METABOLISM IN A DIABETIC POPULATION 
3. Introduction 
The studies presented in this chapter investigate possible associations between altered 
metabolic parameters such as glucose, HbAtc, fructosamine and lipoproteins in a cohort 
of both recently diagnosed (group 1) and established (group 2) diabetic subjects. 
Abnormal glucose metabolism has been shown to be a risk factor for mortality, even in 
non-diabetic individuals (Feener and King, 1997). As a consequence, a pathological 
elevation of blood glucose concentration is the cardinal feature of diabetes mellitus. It is 
well established that hyperglycaemia is associated with altered protein and lipid 
metabolism resulting in an increased risk of development and progression of both micro 
and macrovascular complications in diabetes. Furthermore, at the cellular level, the major 
factors that contribute to and initiate the progression of diabetic microvascular disease are 
chronic or persistent hyperglycaemia, dyslipidaemia, insulin resistance, various 
cytokines, vasoactive hormones and free radical mediated oxidative stress (Feener and 
King, 1997; Baynes and Thorpe, 1999; West, 2000). However, the relative contribution 
of these factors to the development and progression of diabetic microvascular 
complications such as diabetic nephropathy, retinopathy and neuropathy depends on the 
specific vascular tissue affected and on the particular stage of the disease (Baynes, 1991; 
Giugliano et al, 1996; Feener and King, 1997; Baynes and Thorpe, 1999; West, 2000). 
Consequently, several theories have emerged to describe the adverse effects of 
hyperglycaemia on diabetic specific complications and these include glucose 
autoxidation, non-enzymatic glycation of both extracellular and intercellular proteins, 
metabolism of glucose and fructose via the polyol pathway and altered lipid metabolism 
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associated with the generation of free radicals thereby enhancing oxidative stress that 
may ultimately leading to the progression and the development of so-called diabetic 
specific complications (Baynes, 1991; Brownlee, 1995; Schwartz, 1992; DCCT, 1993; 
UKPDS, 1998). 
3.1 Materials and methods 
The study groups, materials and methods are as described in Chapter 2, Sections 2.2.1 to 
2.2.7. 
3.2 Results 
3.2.1 Fasting plasma glucose concentrations (Figure 3.2.1) 
Fasting plasma glucose concentrations (mmol/1) were significantly increased in both 
recently diagnosed diabetic group (GP 1) and established diabetic group (GP2) compared 
with non-diabetic control group values (Cont GP) (Cont GP vs GPI vs GP2, P<0.001). 
Higher plasma glucose concentrations were observed in the established diabetic group 
(GP2) compared with both the recently diagnosed diabetic group (GPI) and control group 
subjects (both P <0.001). Fasting glucose concentrations in the control group were within 
the laboratory reference intervals (4.2-6.1 mmol/1). 
3.2.2 Glycated haemoglobin (HbA1J levels (Figure 3.2.2) 
HbAI, (%) values were significantly increased in both the established diabetic (GP2) and 
recently diagnosed diabetic (GPI) groups compared with control group (Cont GP) values 
(Cont GP vs GP1, P<0.001, Cont GP vs GP2, P<0.001). HbAtc values were 
significantly higher in the established diabetic group than those observed in the recently 
diagnosed diabetic group values (GPlvs GP2, P<0.001). In the control group, MAI, 
levels were within the laboratory reference range (4.4 %-5.7 %). 
90 
12.5 
10.0 
7.5 
bA 
cr) 5.0 
2.5 
0.0 
*** 
*** *** 
Subjects 
EJ Cont GF' 
O GP1 
=GP2 
Figure 3.2.1 Fasting plasma glucose concentrations (mmol/1) in control group (Cont GP), 
recently diagnosed diabetic group or group I (GP 1) and established diabetic 
group or group 2 (GP2) subjects. Results (mean ± SIN) were compared 
using a one-way analysis of variance test (1-way ANOVA) followed by 
Bontcrroni's multiple comparison test. (*, P<0.05, ** P<0.01, *** P 
0.001). 
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Figure 3.2.2 HbA1, (%) levels in control group (Cont GP), GPI and GP2 subjects. 
*ýý 
Results (mean + SEM) were compared using a one-way analysis of 
variance test (1-way ANOVA) followed by Bonlcrroni's multiple 
comparison test. (***, P<0.001). 
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3.2.3 Fructosamine concentrations (Figure 3.2.3) 
Fasting fructosamine concentrations (mmol/1) were also significantly increased in both 
the recently diagnosed diabetic (GP1) and established diabetic (GP2) groups compared 
with control group (Cont GP) results (GP1 vs Cont GP, P<0.001, GP2 vs Cont GP, P< 
0.001). Although fructosamine concentrations were increased in both diabetic groups, 
higher values were noted in the established diabetic group compared to the recently 
diagnosed diabetic group values (GP2 vs GP1, P<0.001). Control group fructosamine 
concentrations remained within the laboratory reference intervals (1.87-2.87 mmoUl). 
Mean fasting fructosamine concentrations (mmol/1) were increased 3-fold and 1.5-fold 
respectively in the established diabetic and recently diagnosed diabetic groups compared 
with control group results. 
3.2.4 Association between plasma glucose concentrations, MAI, and fructosamine 
levels in both diabetic groups (Figure 3.2.4) 
In the established diabetic group (GP2), mean fasting blood glucose concentrations, 
MAI, and fructosamine values were significantly increased compared to recently 
diagnosed diabetic group (GP1) values (glucose: GP2 vs GP1, P<0.001, fructosamine: 
GP2 vs GP1, P<0.001, HbAi,: GP2 vs GPI, P<0.001). There was however, no 
significant correlation noted between the above parameters in these two groups. 
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Figure 3.2.3 Fasting fructosamine (mmol/1) levels in control group (Cont GP), GP1 and 
*** 
*** *** 
GP2 subjects. Results (mean f SEM) were compared using a one-way 
analysis of variance test (1-way ANOVA) followed by Bonfen-oni's 
multiple comparison test. (***, P<0.001). 
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Figure 3.2.4 Fasting glucose concentrations, HbA1, levels and frutosamine 
concentrations in the recently diagnosed diabetic group (GPI) and 
established diabetic group subjects (GP2). Results are expressed as the 
mean: (SEM). Numerical values are given above the error bars. 
95 
GPl GP? 
3.2.5 Plasma total cholesterol concentrations (Figure 3.2.5) 
Increased fasting plasma total cholesterol concentrations (mmol/1) were observed in the 
established diabetic group (GP2) compared to those observed in both recently diagnosed 
diabetic group (GPI) and control group (Cont GP) subjects (GP2 vs GPI, P<0.001, GP2 
vs Cont GP, P<0.001). In the recently diagnosed diabetic group fasting plasma total 
cholesterol values were not significantly different compared to control group values, and 
within the laboratory reference range (<5.2 mmol/1). The mean fasting plasma total 
cholesterol concentrations in the established diabetic group were 2-fold increased 
compared to both recently diagnosed diabetic group and control group values. 
3.2.6 Plasma triglycerides concentrations (Figure 3.2.6) 
Fasting plasma triglycerides concentrations (mmol/1) were significantly increased in the 
established diabetic group (GP2) compared to those observed in recently diagnosed 
diabetic group (GPI) and control group (Cont GP) subjects (GP2 vs GPI, P 0.001, 
GP2 vs Cont GP, P<0.001). Recently diagnosed diabetic group and control group 
plasma triglycerides were similar and within the reference range (<2.3 mnmol/I). The 
mean fasting plasma triglycerides concentrations were increased 2-fold in the established 
diabetic group compared to both recently diagnosed diabetic group and control group 
values. 
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3.2.7 Plasma HDL cholesterol concentrations (Figure 3.2.7) 
Plasma HDL cholesterol concentrations (mmol/1) were significantly decreased in the 
established diabetic group (GP2) compared with both recently diagnosed diabetic group 
(GP1) and control group (Cont GP) values. (GP2 vs GP1, P<0.001, GP2 vs Cont GP, P 
< 0.001). In the recently diagnosed diabetic group plasma HDL cholesterol values were 
similar to control group values and within the laboratory reference range (>0.9 mmol/l). 
The mean plasma HDL cholesterol concentration values were reduced 3-fold in the 
established diabetic group compared to both recently diagnosed diabetic group and 
control group values. 
3.2.8 Plasma LDL cholesterol concentrations (Figure 3.2.8) 
Increased plasma LDL cholesterol concentrations (mmol/1) were also noted in the 
established diabetic group (GP2) compared with both recently diagnosed diabetic group 
(GP1) and control group (Cont GP) values (GP2 vs GP1, P<0.00 1, GP2 vs Cont GP, P< 
0.01). Plasma LDL cholesterol concentrations in the recently diagnosed diabetic group 
were similar to control group values and within the laboratory reference intervals (2.6-3.9 
mmol/1). The mean plasma LDL cholesterol concentration values were around 3-fold 
increased in the established diabetic group compared to both recently diagnosed diabetic 
group and control group values. 
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3.2.9 Relation of plasma total cholesterol triglycerides, HDL and LDL 
concentrations in both diabetic groups (Figure 3.2.9) 
In the established diabetic group (GP2), the mean concentrations of plasma total 
cholesterol triglycerides, HDL and LDL were significantly increased compared to those 
in the recently diagnosed diabetic group (GP1) (cholesterol: GP2 vs GP1, P<0.001, 
triglycerides: GP2 vs GP1, P < 0.001, HDL: GP2 vs GP1, P<0.001, LDL: GP2 vs GP1, P 
< 0.001). However, significant correlations were not observed with these parameters in 
these two groups. 
3.2.10 LDL: HDL ratio (Figure 3.2.10) 
LDL: HDL ratio were significantly increased in the established diabetic group (GP2) 
compared to both recently diagnosed diabetic group (GP1) (GP2 vs GP1, P<0.001) and 
control group (Cont GP) (GP2 vs Cont GP, P<0.01) values. In the recently diagnosed 
diabetic group LDL: HDL ratio was similar when compared to control group values. 
3.2.11 (LDL+TG): HDL ratio (Figure 3.2.11) 
(LDL+TG): HDL ratio were also significantly increased in the established diabetic group 
(GP2) compared to both recently diagnosed diabetic group (GP1) (GP2 vs GP1, P< 
0.001) and control group (Cont GP) (GP2 vs Cont GP, P<0.01) values. In the recently 
diagnosed diabetic group (LDL+TG): HDL ratio was similar when compared to control 
group values. 
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Figure 3.2.5 Fasting plasma total cholesterol concentrations (nunol/l) in control group 
(Cont GP), GPI and GP2 subjects. Results (mean f SEM) were compared 
using a one-way analysis of variance test (1-way ANOVA) followed by 
Bonferroni's multiple comparison test. (***, P<0.001, NS: not 
significant). 
99 
Cont GP GP 1 GP 2 
4 
3 
C) Q -0 2 
C) U 
0 
NS *** 
Subjects 
Cont GP 
=GP 1 
=GP 2 
Figure 3.2.6 Fasting plasma triglycerides concentrations (mnlol/l) in control group 
(Coat GP), GPI and GP2 subjects. Results (mean f SEM) were compared 
using a one-way analysis of variance test (1-way ANOVA) followed by 
Bonferroni's multiple comparison test. (***, P<0.001, NS: not 
significant). 
100 
Cont GP GP 1 GP 2 
2.0 
1.5 
O 
1.0 
Ö 
0.5 
0.0 
Subjects 
0 Corns GP 
=GP I 
=GP2 
Figure 3.2.7 Fasting plasma HDL concentrations (mmol/I) in control group (Cont GP), 
GPI and GP2 subjects. Results (mean ± SEM) were compared using a 
one-way analysis of variance test (1-way ANOVA) Collowed by 
Bonferroni's multiple comparison test. (***, P<0.001, NS: not 
significant). 
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Figure 3.2.8 Plasma LDL concentrations (mmol/t) control group (Cont GP), GPI and 
GP2 subjects. Results (mean f SEM) were compared using a one-way 
analysis of variance test (1-way ANOVA) followed by Bonferroni's 
multiple comparison test. (***, P<0.001, NS: not significant). 
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Figure 3.2.9. Plasma total cholesterol (T: CHO), triglycerides (TG), LDL and HDL 
concentrations in the recently diagnosed diabetic group (GPI) and 
established diabetic group (GP2). Results are expressed as the mean :+ 
(SEM). Numerical values are given above the error bars. 
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Figure 3.2.10 LDL: HDL ratio in control group (Cont GP), GP1 and GP2 subjects. 
Results (mean ± SEM) were compared using a one-way analysis of 
variance test (1-way ANOVA) fbilowed by Bonferroni's multiple 
comparison test. (***, P<0.001, NS: not significant). 
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Figure 3.2.11 (LDL+TG): HDL ratio in control group (Copt GP), GPI and GP2 subjects. 
Results (mean f SEM) were compared using a one-way analysis of' 
variance test (l-way ANOVA) followed by Bonferroni's multiple 
comparison test. (***, P<0.001, NS: not significant). 
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3.3 Discussion 
The results of the studies presented here reveal significantly altered carbohydrate and 
lipid metabolism in both the recently diagnosed and established diabetic subjects. 
Furthermore, increased fasting plasma glucose concentrations, fructosamine and glycated 
haemoglobin (HbAI, ) levels were observed in both diabetic groups compared with non 
diabetic control groups. However, and not surprisingly, higher fasting plasma glucose 
concentrations, fructosamine and HbA1c levels were noted in the established diabetic 
group compared to recently diagnosed group subjects. As previously described (Chapter 
2), duration of the diabetes was less than two years in recently diagnosed group and 6-8 
years in the established diabetic group subjects suggesting that the severity of 
hyperglycaemia is related to the duration of disease (DCCT, 1993). However, correlation 
analysis failed to reveal any significant association between these parameters. 
Distribution of fasting plasma glucose concentration within the general population 
provides valuable information for comparison with those subjects with diabetes. Many 
studies have demonstrated that increased fructosamine and HbAIc levels in both type 1 
and type 2 uncontrolled diabetes directly correlate with fasting plasma glucose 
concentrations (DCCT, 1993; DCCT 1995; Goldstein et al, 1995; UKPDS, 1998; ADA, 
2002). Nevertheless, in the preset study a significant direct correlation between fasting 
glucose concentrations and HbAIc levels was not observed. This of course may be due to 
the relatively small sample populations (Goldstein et al, 1995) when compared to the 
large scale clinical prospective studies. The formation of HbAic occurs over the average 
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life span of erythrocytes (approximately 120 days) and depends on the timed average 
glucose concentration over this period and measurement of both glycated haemoglobin 
and proteins in subjects with diabetes is an established procedure for evaluating long- 
term glycaemic control (Goldstein et al, 1995; ADA, 2002). Consequently, the results of 
the present study are consistent with these observations and confirm that prolonged 
exposure to abnormal glucose concentration (i. e. persistent hyperglycaemia resulting in 
poor glycaemic control) is associated with abnormal elevation of glycated proteins and 
albumin. Furthermore, many prospective clinical studies have demonstrated that 
intensified glycaeniic control was associated with a reduced risk for the development and 
progression of diabetic specific microvascular complications such as nephropathy, 
retinopathy and neuropathy. (DCCT, 1993; Ohkubo et al, 1995; Stratton et al, 2000). 
Recently, the United Kingdom prospective diabetes study (UKPDS, 1998) group 
demonstrated that maintaining blood glucose concentrations as close to normal as 
possible prevented and retarded the development of diabetic nephropathy. 
Hyperglycaemia appears to damage tissue by acute but reversible changes in metabolism. 
In the setting of hyperglycaemia, no-enzymatic glycation results from the interaction of 
aldoses, such as glucose, with free amino groups on polypeptides or lipids. Formation of 
early glycation end products, such as Schiff bases and Amadori products, the best known 
of which is haemoglobin At,, is reversible. Further molecular rearrangements, often 
involving oxidation, eventually result in the formation of AGEs"(Brownlee, 1995). The 
rate of formation of AGEs exceeds that predicted by first order kinetics and this implies 
that, over time, even modest hyperglycaemia can result in a significant accumulation of 
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AGEs on long-lived macromolecules. This is well established for certain long-lived 
proteins such as those of the ocular lens. For example, the progressive post-translational 
modification on lens crystallins by glucose-derived AGEs explains the premature 
lenticular browning and cumulative cross-linking occurring during the course of diabetes 
(Brownlee, 1984). Immunohistochemical studies of kidney from normal and diabetic 
animals have suggested that GBM, mesangium, podocytes, and renal tubular cells 
accumulate high concentrations of AGEs that may ultimately be associated with diabetic 
nephropathy (Vlassara, 1995). Recent studies have demonstrated that AGEs appears to 
stimulate the generation of free radicals, thereby enhancing oxidative stress in the 
diabetic state (Yan et al, 1994; Schmidt et al, 1996; Vlassara, 1996). 
A complications linkage between hyperglycaemia, hyperlipidaemia, and atherosclerosis 
in the pathogenesis of diabetic complications is highly probable. Several studies have 
suggested that hyperglycaemia itself, and closely associated risk factors including insulin 
resistance, obesity, hypertension and lipid abnormalities are important predisposing 
factors. Diabetic subjects with altered lipid metabolism are at high risk of vascular 
disease, particularly those with symptoms of diabetic nephropathy (Friedman, 1999). 
Diabetic dyslipidaemia is often called atherogenic dyslipidaemia and is characterised by 
lipoprotein abnormalities including elevated total cholesterol, triglycerides and LDL, and 
low HDL concentrations. Increased total cholesterol, triglycerides and LDL, and 
decreased HDL concentrations were noted in the established diabetic group compared to 
both recently diagnosed diabetic group and control group subjects (Figure 3.2.6,3.2.7, 
3.2.8,3.2.9) in the present study. In addition, increased LDL: HDL and (LDL+TG): HDL 
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ratios (Figure 3.2.10,3.2.11) were observed in the established diabetic group when 
compared to recently diagnosed diabetic group. Although increased fasting glucose 
concentrations, fructosamine and HbAIc levels were associated with increased total 
cholesterol, triglycerides and LDL, and decreased HDL concentrations in established 
diabetic group subjects, no significant correlations could be demonstrated. 
The degree of glycaemic control is an important determinant of serum lipoprotein 
concentrations in diabetes mellitus (Taskinen 1987). Consequently, serum cholesterol and 
triglyceride HDL and LDL concentrations provide a first impression in diabetic subjects 
of altered lipid metabolism, and provide valuable information for further diagnostic 
interpretation, therapy, and monitoring for hyperlipidaemia in diabetes (Chait and 
Haffner, 2001). The results of the present study are consistent with these observations 
and confirmed that poor metabolic control associated with altered lipid metabolism was 
present in the established diabetic group subjects. Furthermore, in diabetes, moderate 
hypertriglyceridaemia associated with a reduced concentration of HDL cholesterol is a 
common observations (Betteridge, 1994), again results similar to those observed in the 
present study. The Framingham study revealed that the prevalence of 
hypertriglyceridaemia in subjects with type 2 diabetes was significantly increased 
compared with non-diabetic control subjects values and significantly correlated with poor 
glycaemic control (Miettinen et al, 1998). Despite adequate glycaemic control, mild 
hypertriglyceridaemia and decreased HDL concentrations often persist in subjects with 
type 2 diabetes. Diabetic hypertriglyceridaemia is based on enhanced hepatic very low- 
density lipoprotein (VLDL) secretion and diminished VLDL and chylomicron clearance 
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(Koschinsky and Gries, 1992). As a consequence of their cholesterol content, an increase 
in triglyceride rich lipoproteins leads to an elevation in total serum cholesterol 
concentration (Betteridge, 1997). When glycaemic control is poor, total serum cholesterol 
concentrations in diabetes can be significantly enhanced due to the additional 
accumulation of LDL (Taskinen et al, 1996) as observed in the established diabetic group 
in the present study. Moreover, diabetic subjects with good or reasonable glycaemic 
control still tend to demonstrate increased LDL cholesterol concentrations. Nevertheless, 
LDL catabolism is impaired in subjects with moderately severe diabetes, resulting in an 
increased proportion of triglycerides. The increase in the concentration of small, dense 
LDL in serum, their glycation and oxidative modification (Brownlee et al, 1984) 
contributes to the increase of total serum LDL in poorly controlled diabetic subjects. The 
size and density of LDL is considerably influenced by changes in triglycerides content. 
Under conditions of poor glycaemic control, LDL in type 2 diabetic subjects is 
charaterised by an elevated proportion of triglycerides, mostly at the expense of 
cholesterol (Kramer-Guth et al, 1996; Kramer-Guth et al, 1997). Alterations in the lipid 
composition or size of LDL particles have consequences for their binding to lipoprotein 
receptors. Triglyceride-rich and small dense LDL demonstrate a reduced cellular uptake 
via the LDL receptor, leading to accumulation of LDL in the vascular system which is 
associated with the development of diabetic complications (Kramer-Guth et al, 1996). 
Dyslipidaemic changes are evident in diabetic subjects and are characterised by increased 
concentrations of LDL, which significantly predispose these subjects to atherosclerosis, 
with a subsequent increased risk of coronary heart and kidney diseases. (Bucala et al, 
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1993). Advanced glycation of the lipid component of LDL occurs concomitantly with 
LDL oxidation in vivo (Bucala et al, 1993). During glycation, fatty acid residues can be 
oxidized independently of transition metals resulting in the generation of free radicals 
(Bucala et al, 1993; Bucala et al, 1994). Furthermore, it has been suggested that lipid- 
advanced glycation and oxidation increase during the persistent hyperglycaemia of 
diabetes, further support the concept that AGE oxidation plays an important and probably 
primary role in initiating lipid oxidation in vivo and thereby enhance free radical 
formation (Bucala et al, 1992; Bucala et al, 1993). 
In contrast, the observation in the present study is consistent with evidence from other 
studies that suggests the persistent hyperglycaemia can exert pathological effects in 
diabetes. As a consequence of increased formation of non-enzymatic glycation of protein 
and altered lipids metabolism, this may result in an increase of free radical production 
thereby enhancing oxidative stress that may eventually lead to progression and the 
development of diabetic specific complications. Evidence suggests that in subjects with 
diabetes increased free radical production associated with increased lipid peroxidarion 
and depletion of antioxidant mechanisms results in enhanced oxidative stress that 
eventually lead to enhanced development/progression of diabetic nephropathy. However, 
the next chapter addresses the association between lipid peroxidation and antioxidants in 
both recently diagnosed diabetic and established diabetic subjects. 
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CHAPTER FOUR 
AN INVESTIGATION OF LIPID PEROXIDATION AND 
ANTIOXIDANT BIOCHEMICAL MARKERS 
IN A DIABETIC POPULATION 
4. Introduction 
Free radical mediated events in biochemical processes play a significant 
pathophysiological role in disease process, implicated in a number of disorders including 
diabetes and its complications (Oberley, 1988; Baynes, 1991; Packer, 1993; Baynes, 
1996; West, 2000). The intracellular or extracellular conditions that result in either the 
chemical or the metabolic generation of reactive species is known as oxidative stress. 
Generally, metabolic activity, in conjunction with the structural organisation of the cell, 
is able to control or prevent the adverse effects of oxidative stress. The susceptibility of a 
given organ or organ system to oxidative stress is a function of the overall balance 
between the factors that exert oxidative stress and those that exhibit antioxidant 
capability. Oxidative damage can, therefore, be described as a consequence of excessive 
oxidative stress via formation of free radicals or insufficient antioxidant potential. 
Consequently, oxidative stress is defined as a disturbance in the balance between the 
production of free radicals and antioxidant defences, which may eventually lead to tissue 
injury (Halliwell, 1994; Betteridge, 2000). Increased oxidative stress may result from the 
overproduction of precursors of reactive oxygen radical and/or a decreased efficiency of 
inhibitory and scavenger systems. Oxidative stress then may be amplified and propagated 
by an autocatalytic cycle of metabolic stress, tissue damage, and cell death, leading to a 
simultaneous increase in free radical production and compromised inhibitory and 
scavenger mechanisms, which further exacerbate the severity of the oxidative stress 
(Baynes, 1991; Baynes and Thrope, 1999). The potential contribution of increased 
oxidative stress to the development and progression of diabetic complication in general, 
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and diabetic nephropathy in particular, may be associated with a number of biochemical 
pathways. It is now well recognised that hyperglycaemia is the major pathophysiological 
contributor to the development of diabetic complications. Increased generation of 
reactive oxygen metabolites, such as superoxide anions and hydrogen peroxide, has been 
demonstrated to occur in diabetes in response to hyperglycaemia (Baynes and Thrope, 
1999). 
Baynes, (1991) suggested that oxidative stress might be a common pathway linking 
diverse mechanisms for the pathogenesis of diabetic complications. Mechanisms that 
contribute to increased oxidative stress in diabetes may include not only increased non- 
enzymatic glycosylation and autoxidative glycosylation, but also metabolic stress 
resulting from changes in energy metabolism, alteration in sorbitol pathway activity, 
changes in inflammatory mediators, the status of antioxidant defence systems, and 
localized tissue damage resulting from hypoxia and ischaemic-reperfusion injury. 
However, in diabetes, oxidative stress is mainly caused by both an increased production 
of plasma free radicals associated with an increased lipid peroxidation and a sharp 
reduction in antioxidant defences (Jain et al, 1989; Griesmacher, 1994; Giugliano et al, 
1996). Consequently, the main aims of the present study is to evaluate the association 
between lipid peroxidation and antioxidant activities in recently diagnosed and 
established diabetic subjects. 
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4.1 Materials and methods 
Investigated study groups, materials and methods are as described in Chapter 2 Sections 
2.3.1 to 2.3.5 
4.2 Results 
4.2.1 Lipid peroxidation and antioxidant markers in diabetes mellitus 
An initiate of lipid preoxidation was assessed by using the TBARS (MDA) assay as 
described in Section 2.3.1 and antioxidants such as total antioxidant status (Section 
2.3.3), a-tochopherol (vitamin E) (Section 2.3.2), glutathione peroxidase (Section 2.3.4) 
and selenium (Section 2.3.5) were analysed by the standard methods as described in 
Chapter 2. 
4.2.2 Urinary Thiobarbituric Acid Reactive Substances (TBARS) (Figure 4.2.2) 
Increased urinary TBARS levels (µmol/mmol creatinine) were observed in both diabetic 
groups [recently diagnosed diabetic group (GP1) and established diabetic group (GP2)] 
compared with the nondiabetic control group (Cont GP) subjects (Cont GP vs GP1 vs GP 
2, P<0.001). The mean TBARS levels were increased 3-fold and 2-fold respectively in 
the established diabetic and recently diagnosed diabetic groups compared with control 
group (Cont GP). 
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4.2.3 Association between TBARS and HbA1, levels in the established diabetic 
group (Figure 4.2.3) 
In the established diabetic group (GP2) a significant correlation between urinary TBARS 
(pmoll) and HbAI, (%) was observed (n = 20, y=3.6802x-2.1447, r2 = 0.894, P< 
0.0001). 
4.2.4 Plasma total antioxidant status (Figure 4.2.4) 
Plasma total antioxidant status (mmoUl) was significantly decreased in the established 
diabetic group (GP2) compared to recently diagnosed diabetic (GP2 vs GP1, p <0.001) 
and control groups (GP2 vs Cont GP, p <0.001) values. However, in the recently 
diagnosed diabetic and control groups plasma total antioxidant status levels were not 
significantly different, and remained within the stated reference range. The mean plasma 
total antioxidant status levels were 3-fold increased in the established diabetic group 
compared to control group values. 
4.2.5 Plasma a-tochopherol (vitamin E) concentration (Figure 4.2.5) 
Plasma vitamin E concentration (µmoUl) were also significantly decreased in the 
established diabetic group (GP2) subjects compared with values from both recently 
diagnosed diabetic group (GP1) and non-diabetic (Cont GP) (Cont GP vs GP1 vs GP2, P 
<0.001) group subjects. In the recently diagnosed diabetic group and control group 
plasma vitamin E concentrations were almost similar and within the stated laboratory 
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reference range. However, mean concentrations of plasma vitamin E in the established 
diabetic group were 4-fold and recently diagnosed diabetic group were 3-fold decreased 
compared with the control group values. 
4.2.6 Association between plasma vitamin E concentration and HbAi, levels in 
established diabetic group (Figure 4.2.6) 
Decreased plasma vitamin E concentration (µmol/1) was correlated with increased HbAIc 
(%) in the established diabetic group (GP2) as observed in the present study (n = 20, r2 = 
0.3678, y=0.8292x - 18.441, P <0.001). 
4.2.7 Association between plasma vitamin E concentration and urinary TBARS 
levels in established diabetic group (Figure 4.2.7) 
Plasma vitamin E concentrations (µmol/l) were inversely and significantly correlated 
with increased urinary TBARS levels (µmoUl) in the established diabetic group subjects 
(n = 20, r2 = 0.5024, y=0.3266x - 6.8581, P <0.0001). 
4.2.8 Erythrocyte glutathione peroxidase (E-GSH-Px) levels (Figure 4.2.8) 
Decreased erythrocyte glutathione peroxidase levels (U/g Hb) were observed in both the 
established diabetic group (GP2) and recently diagnosed diabetic group (GP1) compared 
with control group (Cont GP) values (Cont GP vs GP1 vs GP2 P <0.001). In the 
established diabetic group, erythrocyte glutathione peroxidase levels were significantly 
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decreased when compared to both recently diagnosed diabetic and control groups 
(P<0.001). Both recently diagnosed diabetic group and control group erythrocyte 
glutathione peroxidase levels remained within the standard reference range. The mean 
erythrocyte glutathione peroxidase levels in the established diabetic group were 3-fold 
and 2.5-fold decreased compared with the control group and recently diagnosed diabetic 
group respectively. 
4.2.9 Plasma glutathione peroxidase (P-GSH-Px) activity (Figure 4.2.9) 
Plasma glutathione activity (U/1) was also decreased in both established diabetic group 
(GP2) and recently diagnosed diabetic group (GP I) compared to control group (Cont GP) 
values (Cont GP vs GP1 vs GP2 P <0.001). Although recently diagnosed diabetic group 
plasma glutathione activities demonstrated a decreased trend, both recently diagnosed 
diabetic and control groups plasma glutathione values remained within the stated 
reference range. The mean plasma glutathione peroxidase activities in the established 
diabetic group were 3-fold and 2.5-fold decreased compared with the control group and 
recently diagnosed diabetic group, respectively. 
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Figure: 4.2.3 Correlation between urinary TBARS (µmol/mmol creatinine) and HbAlc 
(%) levels in the established diabetic group subjects (n = 20, r2 = 0.894, 
y=3.68.2x - 2.1447, P <0.0001). 
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(Cont GP), GPI and GP2 subjects. Results (mean I SEM) vvcrc rumharcd 
using a one-way analysis of variance test (1-way ANOVA) l llowed by the 
Bonferroni's multiple comparison test. (***, P<0.001). 
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Figure: 4.2.6 Correlation between plasma vitamin E concentration (µmol/1) and fbAlc 
(%) levels in the established diabetic group (GP2) subjects (n = 20, 
r2 = 0.3678, y= -0.8292x + 18.441, P <0.001). 
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Figure 4.2.7 Correlation between plasma vitamin E concentration (µmol/1) and urinary 
TBARS (µmol/mmol creatinine) levels in the established diabetic group 
(GP2) subjects. n= 20, r2 = 0.896, y= -0.3266x - 6.8581, P <0.0001. 
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4.2.10 Plasma selenium concentration (Figure 4.2.10) 
Plasma selenium concentrations (µmol/1) were significantly decreased in the established 
diabetic group (GP2) compared to both GPI (GP2 vs GP1, p <0.001) and non-diabetic 
control group (GP2 vs Cont GP, p <0.001) values. In the recently diagnosed diabetic 
group, plasma selenium concentrations were not significantly different from values in the 
non-diabtic control group, and were within the laboratory reference range. Mean plasma 
selenium concentrations in the established diabetic group were reduced by 4-fold 
compared to non-diabetic control values. 
4.2.11 Association between plasma selenium concentration and plasma glutathione 
peroxidase activity in established diabetic group (Figure 4.2.11) 
Correlation analysis revealed a significant association between reduced plasma selenium 
concentration (mol/1) and plasma glutathione peroxidase (P-GSH-Px) activity (U/1) in the 
established diabetic group values (n = 20, r2 = 0.633, y= 98.908x - 2801.1, 
P <0.0001). 
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Figure 4.2.10 Plasma selenium concentrations (µmol/I) in control group (font GP), 611 
and GP2 subjects. Results (mean ± SIN) were compared using a one-way 
analysis of variance test (1-way ANOVA) followed by the Bonlcrroni's 
multiple comparison test. (***, P<0.001, NS: not signilicant). 
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Figure 4.2.11 Correlation between plasma selenium concentration (µmol/l) and plasma 
glutathione peroxidase (P-GSH-Px) activity (U/1) in the established 
diabetic group (GP2) subjects (n = 20, r2 = 0.633, y= -78.908x - 2801.1, P 
<0.0001). 
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4.3 Discussion 
Several studies have demonstrated enhanced lipid peroxidaion in both human diabetics 
and experimental diabetic animal models. (Armstrong and Al-Awadi, 1991; Armstrong et 
al, 1992; Hartnett et al, 2000). The studies of Akkus et al, (1996) and Santini et al, 
(1997) have demonstrated increased lipid peroxidation in both type 1 and type 2 diabetes 
when compared with non-diabetic age and sex matched control subjects using a TBARS- 
MDA assay. In the present study, significant elevation of TBARS levels was observed in 
both recently diagnosed diabetic and established diabetic group subjects compared to 
non-diabetic control group subjects (Figure 4.2.2). Increased TBARS levels associated 
with increased fasting glucose concentrations, fructosamine and glycated haemoglobin 
levels were noted in both diabetic group subjects. Increased glycated haemoglobin levels 
(HbAic) were also significantly correlated with increased TBARS levels in the 
established diabetic group subjects. Furthermore, Sato et al, (1979) demonstrated that 
increased fasting plasma glucose concentrations were directly associated with increased 
TBARS concentrations in both type 1 and type 2 diabetics compared to control values. In 
addition, Griesmacher et al, (1994) observed that both type and type 2 diabetic subjects 
with good metabolic control (HbA1, <6.5%) demonstrated significantly lower urine 
TBARS concentrations than those with poor metabolic control, but all groups 
demonstrated TBARS values higher than non-diabetic control subjects. The results of the 
present studies are consistent with the findings of the above and other studies that 
enhanced lipid peroxidation is present in subjects with diabetes as measured by the 
TBARS assay (Rabini et al, 1994; Akkus et al, 1996). Increased glycated protein and 
increased TBARS levels in the established diabetic group suggesting that poor metabolic 
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control and persistent hyperglycaemia is associated with increased lipid peroxidation 
(Rabini et al, 1994; Griesmacher et al, 1994; Jain, 2000). Furthermore, the accumulation 
of glycosylation products (i. e., HbAic) may have a predictive value for the presence of an 
enhanced rate of lipid peroxidation in subjects with poor glycaemic control. (Jain, 2000). 
Consequently, the above observations are consistence with the suggestion that glycation 
products can be associated with the generation of free radicals, and subsequently 
enhanced lipid peroxidation (Halliwell and Gutteridge, 1998). 
Clinical and experimental diabetic studies have also demonstrated a relationship between 
increased lipid peroxidation and hyperlipidaemia (Nishigaki et al, 1981; Griesmacher et 
al, 1994; Mooradian, 1991; Esterbauer et al, 1992; Nacitarhan et al, 1995; ). The present 
study also revealed a close association between increased TBARS excretion and 
dislipidaemia, as shown by elevation of cholesterol, triglycerides and LDL concentrations 
in the established diabetic group. However, this association was not statistically 
significant in the present study. Furthermore, controversial results have been reported 
regarding the association between cholesterol, triglycerides and LDL with circulating 
TBARS levels. Nacitarhan et al, (1995) demonstrated higher concentrations of TBARS in 
hyperlipidaemic diabetics (cholesterol > 6mmol/1 and triglycerides concentration > 
2mmol/1) compared to nonlipidaemic diabetics and a significant correlation between 
TBARS and lipid concentration was also noted. Conversely, Griesmacher et al, (1994) 
did not observe any such correlation between TBARS and lipid concentrations. 
Consequently, these observations suggest that the concentration of TBARS does not 
depend only the availability of substrate for lipid peroxidation (Mooradian, 1991). This 
131 
would suggest that an increase in the total amount of circulating lipids plays an additional 
role in the enhanced lipid peroxidation observed in diabetes (Griesmacher et al, 1994). In 
subjects with moderately severe diabetes, LDL catabolism is impaired resulting in an 
increased proportion of triglycerides. Furthermore, the increase in the concentration of 
small, dense LDL in serum, their glycation and oxidative modification (Brownlee et al, 
1984) contribute to the increase in total serum LDL observed in poorly controlled 
diabetic subjects. In vitro studies have also demonstrated that the incubation of lipids 
with glycated proteins resulted in an elevation of lipid peroxidation (Lyons, 1992). 
Moreover, it has been suggested that lipid-advanced glycosylation and oxidation 
increased during the persistent hyperglycaemia associated with diabetes, supports the 
concept that AGE oxidation plays an important role in initiating lipid peroxidation in vivo 
(Bucala et al, 1993). 
An inverse association was observed between total antioxidant status and plasma glucose 
concentration, HbA1c, in the established diabetic group subjects. Similarly, the studies of 
Johnston and Miller, (1998) and Vantyghem et al, (2000) have also noted that lipid 
peroxidation was increased and total antioxidant status significantly decreased in poorly 
controlled diabetes. The reduction in total antioxidant status in diabetics has been 
significantly associated with increasing HbAtc levels and also with the duration of 
diabetes (Valublji et al, 2001). These observations are further supported by the evidence 
that increased HbAIc can influence the generation of superoxide radicals, that may 
ultimately lead to increased lipid peroxidation (Griesmacher et al, 1994; Eriksson et al, 
1996; Jain et al, 1999). Although significantly increased TBARS and decreased total 
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antioxidant capacity were observed in the established diabetic group in the present study, 
a significant correlation between these two parameters was not observed. However, a 
positive correlation between total antioxidant status and TBARS in other studies 
(Asayama et al, 1993; Sundaram et al, 1996) suggests that extracellular antioxidants were 
unable to provide an effective protection against lipid peroxidation in subjects with 
inadequate glycaemic control. Consequently, the results presented here are consistent 
with other similar studies that suggest persistent hyperglycaemia, poor metabolic control 
and increased non-enzymatic glycation can be associated with increased lipid 
peroxidation via enhanced free radical production, resulting from impaired antioxidants 
status (Sundaram et al, 1996; Maxwell, 1997; Sirinivasan et al, 1997) in established 
diabetic subjects. 
Vitamin E concentrations were significantly decreased only in the established diabetic 
group compared to both recently diagnosed diabetic and control group values (Figure 
4.2.5). Furthermore, a significant apparent correlation between vitamin E concentration, 
HbAi, and TBARS levels were also observed in the established diabetic group subjects 
(Figure 4.2.6,4.2.7). In addition, in a study by Girelli et al, (1992) an inverse association 
between decreased vitamin E and increased total cholesterol, triglycerides and LDL 
concentrations was noted in the established diabetic group. However, no correlation was 
observed between TBARS and LDL concentrations in this group. Conversely, Reavan et 
al, (1995) demonstrated a significant correlation between vitamin E and LDL 
concentrations in subjects with diabetes. Decreased vitamin E was associated with a 
decreased susceptibility of LDL to oxidation in comparison with placebo 
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supplementation of 600 IU vitamin E/day for 4 weeks to type 2 diabetic which reduced 
the observed elevated levels of TBARS. There is also sufficient evidence for vitamin E 
deficiency in the diet of diabetic subjects which subsequently results in decreased plasma 
vitamin E concentrations compared with values observed in non-diabetic controls 
(Salonen et al, 1995). Consequently, consistence with these observations, the results of 
present study suggest that persistent hyperglycaemia, increased glycated protein and poor 
metabolic control can precipitate influenced increase lipid peroxidation in diabetic 
subjects with inadequate vitamin E levels that may ultimately lead to enhanced oxidative 
stress (Jain, 1989; Leonhardt, 1996; Santini, 1997). 
Several studies, including both human (Aaseth and Stoa-Birketvedt, 2000; Varvarovska 
et al, 2003) and experimental (Mukherjee et al, 1998), have demonstrated a significant 
depletion of glutathione peroxidase in the diabetic state. In the present study, both 
erythrocyte and plasma glutathione peroxidase levels were significantly decreased in the 
established diabetic group compared to both recently diagnosed diabetic and non-diabetic 
control groups values, (Figure 4.2.8). However, no significant correlation was observed 
between erythrocyte and plasma glutathione peroxidase levels in studies by Bennefont- 
Rousselot et al, (1997). In present studies the established diabetic group demonstrated, 
increased fasting glucose concentration, HbAtc, total cholesterol, tryglycerides, LDL, 
TBARS, decreased total antioxidant status and vitamin E levels associated with a 
decrease in both erythrocytes and plasma glutathione peroxidase levels. However, 
correlation analysis did not reveal any significant associations between these parameters 
and glutathione peroxidase levels. However, Jain and McVie, (1994) and Jain et al, 
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(2000) both demonstrated a significant correlation between increased HbA1,, MDA and 
decreased glutathione peroxidase levels suggesting an important association between 
poor metabolic control and oxidative stress in subjects with diabetes. Conversely, several 
other studies have reported increased cellular glutathione peroxidase activity in subjects 
with diabetes and its complications, in both human and experimental animal models 
(Kakkar et al, 1997; Ceriello et al, 2000). This evidence may have important 
consequences with regard to glucose-induced oxidative insult to the cell. Hydrogen 
peroxide, produced during the lipid peroxidation process, is converted to water in 
peroxisomes by the antioxidant enzyme catalase (CAT) and in the cytoplasm by 
glutathione peroxidase. These antioxidant enzymes protect the cell from oxidative stress 
but the threshold of protection dramatically depends on the total antioxidant capability. 
Consequently, increased glutathione peroxidase activity may suggest a compensatory 
response by the defence mechanisms in response to increased oxidative stress (Ceriello et 
al, 2000). However, the results of the present investigation are consistent with previous 
studies on depletion of cellular glutathione levels in diabetic states as reflected by 
reduced glutathione peroxidase activity in poorly controlled diabetes (Aaseth and Stoa- 
Birketvedit, 2000). Furthermore, vitamin E supplementation has been demonstrated to 
increase cellular gluthione concentration, decrease HbA1c, MDA concentrations and may 
reduced the incidence of vascular disease in diabetics (Jain et al 2000). Several 
mechanisms contribute to glutathione deprivation in subjects with diabetes and its 
complications and the abundance of glucose involving activation of the polyol pathway 
has been suggested as enhanced oxidative stress is observed in the diabetic state (Rosen 
et al, 2001). 
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The antioxidant ability of selenium resides in the active side chain of the seleno-enzyme 
glutathione peroxidase and the importance of selenium as an essential trace element is 
probably due to its presence in this enzyme. Significantly decreased plasma selenium 
concentrations were noted in the established diabetic group subjects. The results from 
recently diagnosed diabetic and control groups were within reference intervals. As 
previously described, increased fasting glucose concentration, HbA1ý, total cholesterol, 
triglycerides, LDL, TBARS and decreased total antioxidant status, vitamin E and 
erythrocyte glutathione peroxidase levels were all associated with decreased selenium 
concentration in the established diabetic group. However, correlation analysis did not 
reveal any significant associations between these parameters and selenium 
concentrations. The above observation is consistent with other studies suggesting that the 
deficiency of selenium would tend to increase oxidative stress in subjects with persistent 
hyperglycaemia (Schlienger et al, 1988; Meydani et al, 1988; Bennefont-Rousselot et al, 
(1997). Furthermore, a correlation between both low selenium concentration and plasma 
glutathione peroxidase activity (Bennefont-Rousselot et al, 1997) was observed in the 
established diabetic group subjects. Plasma glutathione peroxidase originates from both 
the cells of the proximal tubular epithelium, and the parietal cells of Bowman's capsule 
in the kidney (Mony and Larras-Regard, 2000). Consequently, the kidney play a major 
role in selenium and plasma gluthione peroxidase metabolism (Mony and Larras-Regard, 
2000). The effects of selenium on diabetic complications, an association between low 
plasma selenium concentration and a high index of micro and macroangiopathy has 
previously been observed in subjects with diabetes. Furthermore, dietary supplementation 
improved glycaemic control normalised the renal lipid peroxide levels of the kidney and 
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normalised hyperfiltration (Douillet et al, 1999). This reduced oxidative stress would also 
be involved in the reduction of renal lesions since oxidative stress has been implicated in 
the development of diabetic nephropathy (Douillet et al, 1999). 
In contrast, in the recently diagnosed diabetic group, the presence of increased TBARS 
and stable antioxidants such as total antioxidant status, vitamin E, both erythrocytes and 
plasma glutathione peroxidase and selenium levels suggests that the presence of recent 
onset hyperglycaemia may contribute to increased lipid peroxidation via free radical 
production as an ealy event in the pathogenesis of diabetic nephropathy. However, while 
at this stage the antioxidant defence mechanisms are still sufficient to counteract their 
activity and balance (Asayama et al, 1993), in the established diabetic group subjects, 
defence mechanisms are overwhelmed because of the increased severity of oxidative 
stress. Furthermore, consistent with this observation made in the present study and 
supported by other studies persistent hyperglycaemia is the major potential determinant 
of increased free radical production by stimulating several biochemical pathways, 
producing enhanced oxidative damage in subjects with diabetes mellitus. Consequently, 
the association between oxidative stress, progression and the development of diabetic 
kidney dysfunction has been evaluated in order to further establish the free radical 
mediated oxidative stress plays in pathogenesis of diabetic nephropathy. 
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CHAPTER FIVE 
AN INVESTIGATION OF GLOMERULAR AND TUBULAR 
FUNCTION IN A DIABETIC POPULATION 
5. Introduction 
It is well established that the free radical mediated oxidative stress associated with 
persistent hyperglycaemia plays an important role in the development of diabetic 
nephropathy. Furthermore, it has been demonstrated that oxidative stress is increased in 
the diabetic kidney, presumably before onset of any clinical signs of nephropathy. High 
glucose concentrations have been shown to increase oxidative stress in target ells in vitro, 
and oxidative stress has a relevant effect on target cells in both in vivo and in vitro (Fukui 
et al, 1992; Ha and Kim, 1999). The early changes in diabetic nephropathy are 
characterised by increased kidney size, glomerular volume and kidney function and later 
on by the development of mesangial proliferation, accumulation of extracellular matrix 
and increased urinary albumin excretion (UAE). (Flyvbjerg et al, 2000). However, in the 
initial stages of diabetic nephropathy, clinical signs and symptoms may be vague or even 
absent for sometime. 
In its early appearance, the first morphological alterations observed in the kidney are 
hypertrophy of both the glomerular and tubular elements; subsequently, a thinning of 
glomerular and tubular basement membranes is evident, with enhanced glomerular 
permeability to albumin also being observed (Christiansen et al, 1981). This leads to a 
progressive accumulation of extracellular matrix components in both the glomerular 
mesangium and in tubulointerstitial structures (Parving et al, 2000). Clinical and 
experimental studies have suggested that oxidative injury may alter the structure and 
biochemical functions of the diabetic kidney due to the effect of free radicals on both 
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glomerular and tubular structures and their function. However, the early recognition of 
renal insult remains controversial. Serum creatinine, the standard marker of glomerular 
function, is at best insensitive and represents a relatively late manifestation of diabetic 
nephropathy. The aims of this study was refer to investigate the use of other proteins, 
namely specific proteins, enzymes and serum components including cyctatin C and sialic 
acid, in the early recognition of kidney insult in a diabetic population. A second 
subsidiary aim was to relate any changes in these parameters indicating early renal insult 
to the antioxidant status present in the diabetic state as discussed in the previous chapter. 
5.1 Materials and methods 
The study groups (Section 2.1.1), materials and methods (Section 2.4.1 to 2.4.9) are as 
described in Chapter 2. 
5.2 Results 
5.2.1 Serum creatinine concentration 
Serum creatinine concentrations were similar in the recently diagnosed diabetic group, 
established diabetic group and control group subjects at 96.0±6.0,97.1±6.7 and 98.6±5.8 
pmol/1 (Mean±SEM) respectively. All patients results were within the laborotary 
reference intervals (Men: < 115 pmol/1, Women : <97. tmol/l). 
139 
5.2.2 Albumin: creatinine ratio (microalbuminuria) (Figure 5.2.2) 
In the established diabetic group (GP2) the albumin: creatinine concentration (mg/mmol 
creatinine) was significantly increased compared to values observed from both the 
recently diagnosed diabetic group (GP2 vs GP1, P <0.001) and control group (GP2 vs 
Cont GP, P <0.001) respectively. In the recently diagnosed diabetic group (GPI), the 
albumin: creatinine concentration (mg/mmol creatinine) was similar to that observed in 
the control group and both groups remained within the laboratory reference intervals 
(<3.5 mg/mmol creatinine). The mean albumin: creatinine concentration (mg/mmol 
creatinine) was 3-fold increased in the established diabetic group compared with both the 
recently diagnosed diabetic and control groups. 
5.2.3 Association between albumin: creatinine ratio and glycated heamoglobin 
(HbAi, ) (Figure 5.2.3) 
A significant correlation between albumin: creatinine ratio and glycated haemoglobin 
(HbA1c ) values was observed in the established diabetic group (GP2). r2= 0.42, 
y=1.3313x-3.0152, P <0.001. 
140 
5.2.4 Serum sialic acid concentration (Figure 5.2.4) 
Serum sialic acid concentration (mmol/1) was significantly increased in the established 
diabetic group (GP2) compared to results observed from both the recently diagnosed 
diabetic group (GP1) and control group (GP2 vs GP1, P <0.001, GP2 vs Cont GP, P 
<0.001) subjects. Serum sialic acid concentrations were similar in the control and 
recently diagnosed diabetic group and were within the laboratory reference interval (1.5- 
2.2 mmol/1). Furthermore, mean concentrations of sialic acid (mmol/1) in the established 
diabetic group were increased 1.5-fold compared with both results from the recently 
diagnosed diabetic and control groups. 
5.2.5 Serum cystatin C concentration (Figure 5.2.5) 
In the established diabetic group (GP2), significantly increased cystatin C concentration 
(mg/1) were observed compared to results from both the acute hyperglycaemic (GP2 vs 
GP1, P <0.001) and control groups (GP2 vs Cont GP, P <0.001). Although the acute 
hyperglycaemic group (GP1) demonstrated a decreased trend in cystatin C concentration 
compared to the control group (Cont GP) values, results were similar and within the 
stated reference range (0.7-1.2 mg/1). Mean serum cystatin C concentration (mg/1) in the 
established diabetic group were increased 1.5-fold comapared to those observed in the 
recently diagnosed diabetic group. 
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Figure 5.2.2 Alburnin: creatinine ratio (mg/mmol creatinine) in control group (Coat 
GP), GPI and GP2 subjects. Results (Mean ± SF. M) were compared using 
a one-way analysis of variance test (1-way ANOVA) lollowed by the 
E3onterrionie's multiple comparison test. (*** 1' -- 0.001 ). 
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Figure 5.2.3 Correlation between microalbuminuria (albumin: creatinine mg/mmol 
creatinine) and glycated haemoglobin (HbA1, %) in the chronic 
hyperglycaemic group (GP2) subjects (n = 20, r2 = 0.42, y=1.3313x- 
3.0152, P <0.001). 
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Figure 5.2.4 Serum sialic acid concentrations (mmol/1) in control (font GP), (; P1 and 
GP2 subjects. Results (Mean + SEM) were compared using a one-way 
analysis of variance test (1-way ANOVA) followed by the 13onicrrionie's 
multiple comparison test. (***, P<0.001, NS: not significant). 
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Figure 5.2.5 Serum cystatin C concentrations (mg/1) in control (Cons GP), OPI and 
GP2 subjects. Results (Mean f SEM) were compared using a one-way 
analysis of variance test (1-way ANOVA) followed by the Bonl'errionie's 
multiple comparison test. (***, P<0.001, NS: not significant). 
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5.2.6 Urinary al-microglobumin (Figure 5.2.6) 
Increased urinary al-microglobumin (g/mol creatinine) was observed in the established 
diabetic group (GP2) compared with values obtained from the both recently diagnosed 
diabetic group (GP2 vs GP1, p <0.001) and control group (GP2 vs Cont GP, p <0.001) 
subjects. In the recently diagnosed diabetic group, al-microglobumin values were similar 
to those of control group subjects, and within the stated reference range (<1.58 g/mol 
creatinine). However, a 2-fold elevation al-microglobumin values were observed in the 
established diabetic group compared to both the control and recently diagnosed diabetic 
group values. 
5.2.7 Urinary ß2-microglobumin (Figure 5.2.7) 
Urinary (3-2-microglobumin (µg/mmol creatinine) was also only significantly increased in 
the established diabetic group (GP2) compared with results from the recently diagnosed 
diabetic group (GP2 vs GPI, p <0.001) and control group (GP2 vs Cont GP, p <0.001) 
subjects. ß2-microglobumin levels were similar in both the control and recently 
diagnosed diabetic groups and within the stated reference range (0.8-2.2 µg/mmol 
creatinine). A 1.5-fold elevation in ß2-microglobumin levels were observed in the 
established diabetic group when compared to values obtained from both the recently 
diagnosed diabetic group and control group subjects. 
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Figure 5.2.6 Urine al-microglobulin (g/mol creatinine) in control (font GP), GPI and 
NS *** 
GP2 subjects. Results (Mean + SEM) were compared using a one-way 
analysis of variance test (]-way ANOVA) followed by the 13onlcrrionie's 
multiple comparison test. (***, P<0.001, NS: not significant). 
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Figure 5.2.7 Urine (32-microglobulin (µg/mmol creatinine) in control (font GP), (P1 
and GP2 subjects. Results (Mean + SEM) were comppared using a one-way 
analysis of variance test (1-way ANOVA) performed by the 
Bonferrionie's multiple comparison test. (***, 1' < 0.001, NS: not 
significant). 
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5.2.8 Urine alanine amino peptidase (AAP) activity (Figure 5.2.8) 
Urinary AAP activity (U/mmol creatinine) was increased in both the established diabetic 
group (GP2) and recently diagnosed diabetic group (GP1) compared with control group 
(GP2 vs GP1 vs Cont GP, P <0.001) values. Highest AAP activities were observed in the 
established diabetic group compared with both recently diagnosed diabetic and control 
group values. The mean urinary AAP activities were increased 5-fold in the established 
diabetic group (GP2) and 3-fold in recently diagnosed diabetic group when compared 
with control group values. 
5.2.9 Urine N-acetyl-ß-D-glucosaminidase (ß-NAG) activity (Figure 5.2.9) 
Urinary ß-NAG activity (U/mmol creatinine) was increased in both the established 
diabetic group (GP2) and recently diagnosed diabetic group (GP I) compared with control 
group (GP2 vs GP1 vs Cont GP P <0.001) values. The higher elevation of ß-NAG 
activity was observed in the established diabetic group compared with both recently 
diagnosed diabetic group and control group. Control group, ß-NAG activities were within 
the laboratory reference interval (<35 U/mmol creatininne). The mean urinary n-NAG 
activities were increased 5-fold in the established diabetic group and 3-fold in the 
recently diagnosed diabetic group when compared with control group values. 
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Figure 5.2.9 Urinary (3-NAG activities (U/mmol crcatininc) in control (('ont (1I1), (il'I 
and GP2 subjects. Results (Mean _t SF, M) were compared using a one-way 
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multiple comparison test. (***, I' < 0.001, NS: not significant). 
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5.2.10 Urinary alpha-glutathione-S-transferase (a-GST) activity (Figure 5.2.10) 
Urine a-GST activity (U/mmol creatinine) was significantly elevated in both the 
established diabetib group (GP2) and recently diagnosed diabetic group (GP I) compared 
to control group (GP2 vs Cont GP, P <0.001, GPlvs Cont GP, P <0.001) values. Similar 
elevations in activity were observed in both the recently diagnosed diabetic and 
established diabetic groups. 
5.2.11 Urinary pi-glutathione-S-transferase (7r-GST) activity (Figure 5.2.11) 
Similar, significant increased urine it-GST activity (U/mmol creatinine) was observed in 
both diabetic groups compared with control group (both, P <0.001) values. A 7-fold in 
increase urine 7r-GST activities were noted in both diabetic groups compared to control 
group values. 
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Figure 5.2.10 Urine a-GST level (U/mmol creatinine) in control (Coat GP), 6111 and 
GP2 subjects. Results (Mean + SI: M) were compared using a one-vw"ay 
analysis of variance test (1-way ANOVA) li0llowed by the 13onlcrrionie's 
multiple comparison test. (***, P°0.001, NS: not signilicant). 
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5.3 Discussion 
The overall aim of the present study was to investigate the behavior of selected serum 
and urine biomarkers reflecting insult to the renal architecture. In particular, the early 
recognition of renal insult in a diabetic population can lead to improved management and 
potentially either a showing in the rate of disease progression or reduction in disease 
severity. The markers chosen, however in previous investigations have been shown to be 
sensitive, and in many cases they are site-specific indicators of early renal insult that 
preceded reductions in GFR or increases in serum creatinine concentration. Enzymuria 
has been quantitated in many studies on either drug-induced nephrotoxicity in both 
clinical and experimental diabetes and in both medical and surgical studies (Whiting et 
al, 1980, Whiting et al, 1983a; Whiting et al, 1983b; UKPDS, 1993; Weitgasser et al, 
1999). ß-NAG and AAP enzymuria have previously been increased and shown to be 
sensitive indicators of renal proximal tubular insult in several disease processes (for a 
review see Whiting and Price 2001). Furthermore, they can be considered as site-specific 
markers with NAG being a lysosomal hydrolase and AAP being located in mitiochondria 
of the brush border. In addition, measurement of the small molecular weight proteins, al- 
microglobulin, 02-microglobulin, allows the transport of small protein by the proximal 
tubule to assessed. 
Glutathione-S-tranferase (GST) activity, both a and n isoenzymes has recently been 
proposed as markers of proximal and distal tubular integrity respectively (Sundbcrg, 
1994; Fujita, 2001; Maxwell and Gordon, 2002). In addition, while serum crcatinine 
concentrations are a standard and commonly used estimate of GFR, cystatin C, a new 
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sensitive biochemical marker, has also been demonstrated recently to offer advantages in 
the evaluation of glomerular function, particularly in diabetes mellitus. The results of the 
present study clearly demonstrate altered renal glomerular and tubular integrity and 
function that predated alterations in serum creatinine concentration that remained within 
the reference range in all three experiment groups. 
Initially, the association between microalbuminuria, serum creatinine, sialic acid and 
cystatin C concentrations in diabetic states was investigated. Increased albumin: creatinine 
ratio, sialic acid and cystatin C concentrations were observed in the established diabetic 
group compared to those from the recently diagnosed diabetic group and control group 
subjects (Figure 5.2.2,5.2.4,5.2.5). Consequently, this observation confirmed that the 
established diabetic group is `microalbuminuric' whereas the recently diagnosed diabetic 
group is `normoalbuminuric'. However, serum creatinine concentrations in both groups 
were within the standard reference for the laboratory (Section 5.2.1) suggesting that 
increased serum creatinine concentration is a late manifestation of diabetic nephropathy, 
GFR is only reduced when 50% of the nephrons cease to function and is at best an 
insensitive measure of glomerular function (Whiting and Price, 2001). 
The established diabetic group, demonstrated increased fasting blood glucose 
concentration, fructosamine and glycated haemoglobin (HbA1J levels (as described in 
the Chapter 3) that were associated with an increased albumin: creatininc ratio. (increased 
fibAic levels directly correlated with microalbuminuria levels in the established diabetic 
group subjects as shown in Figure 5.2.3). Consequently, results of the present study are 
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consistent with previous studies (DCCT, 1993; UKPDS, 1998; ADA, 2000) that 
demonstrated persistent hyperglycaemia and poor metabolic control significantly 
increased the risk for the development of microalbuminuria. 
Furthermore, protein glycation was associated with the changes in glomerular 
permeability that may be a determining feature in the loss of negative charge from the 
GBM; leading to less repulsion of anionic proteins, and consequent altered glomerular 
permeability in subjects with diabetes (Ward, 1995). Sialic acid are found in the GBM 
glycoproteins associated with heparin sulfate proteoglycacns, which contribute to the 
negative charge/size selectivity of the GBM. Increased serum sialic acid concentrations 
have been observed previously to be associated with diabetic retinopathy and 
nephropathy (Sillanaukee et al, 1999). Consequently, increased microalbuminuria 
(albumin: creatinine ratio) and serum sialic acid content may be explained, at least in part, 
by the loss of the glomerular polyanion, associated decrease in negative charge and 
biochemical alterations to the glomerular capillary wall (Yokoyama et al, 1996) in 
subjects with persistent hyperglycaemia. However, the mechanism of increased serum 
sialic acid in subjects with diabetes and diabetic nephropathy still remain unclear 
(Sillanaukee et al, 1999). 
The GFR still provides the best overall estimation of renal function and serum cystatin C, 
a protease inhibitor, has been suggested as a new sensitive biochemical marker of GFR 
(Newman et al, 1995; Stabuc et al, 2000). Consequently, the observation of normal 
serum creatinine concentration but increased microalbuminuria, sialic acid and cystatin C 
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concentrations in the established diabetic group further suggested that the former analyte 
i. e. serum creatinine is of limited value in the early detection of renal insult because of it 
poor sensitivity to early nephron dysfunction (Perrone et al, 1992; Newman et al, 1995). 
Consequently, the present study supports the notion that cystatin C is a useful and 
sensitive biochemical maker for the overall estimation of renal function (Stabue et al, 
2000) in established diabetic subjects. 
Kidney disease can be differentiated by the estimation of selected proteins in urine. 
Consequently, estimation of renal tubular function and integrity may provide an early 
indication of renal insult and potentially identify those at risk of developing pre-clinical 
kidney dysfunction (Whiting and Price, 2001). A lesion of the renal tubular apparatus is 
characterized by a reduced reabsorption of low molecular weight proteins, such as al- 
microglobulin and/or ß2-microalglobulin, which are completely filtered at the glomerular 
and 99% reabsorbed by the proximal tubules. Significant elevation of both urinary at- 
microglobulin (Figure5.2.6) and ß2-microalglobulin (Figure5.2.7) concentrations were 
observed in the microalbuminuric group subjects compared to both normoalbuminuric 
and control group subjects suggesting renal tubular insult reduced protein absorbtive 
capacity. The urinary concentration of proteins will depend on the filtered load i. e. 
glomerular permeability, and on the proximal tubular reabsorptive process utilizing 
clatharin coated pits in the brush border of proximal tubular cells (Newman and Price, 
1999). Consequently, the al-microglobulin and ß2-microalglobulin appear in 
significantly higher amounts in urine as a result of decreased tubular reabsorption 
capacity and therefore will provide evidence for the so-called tubular protcinuria and loss 
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of function in the proximal tubular (Jung and Jung, 1994; Newman and Price, 1999). 
Furthermore, insult of the tubular epithelial cells will result not only functional and 
biochemical changes but also ultimately in structural changes with increased cellular 
function and cell lysis resulting in the release of brush border enzymes such as AAP 
(Jung et al, 1988; Jung, 1994). The increased AAP activity observed in both 
microalbuminuric group and normoalbuminuric group compared to control group 
subjects (Figure5.2.8) suggests that AAP is an indicator of early tubular changes even 
when the glomerular filtration and renal plasma flow are still within the `normal' limits or 
marginally deteriorated although without histological changes (Jung, 1994; Holdt- 
Lehmann et al, 2000). 
Evidence suggests that urinary enzyme excretion is increased in the earliest stage of 
diabetic nephropathy (Jung et al, 1988; Whiting et al 1979; Price, 1979). ß-NAG a 
lysosomal proximal tubular cell enzyme increase was found to be associated with early 
diabetic nephropathy and poor long-term glycaemic control (Watts et al, 1988). In the 
present study, ß-NAG enzyme activities were elevated in both microalbuminuric group 
and normoalbuminuric subjects compared to control group subjects, with the highest 
activity been observed in the established diabetic group (microalbuminuric) subjects 
(Figure 5.2.9). Elevated NAG activities were directly associated with MAI, levels in 
both diabetic groups. Furthermore, the proximal tubules are the most metabolically active 
renal segment and potentially vulnerable to damage and evidence suggests that elevated 
p-NAG activity may be consequences of hyperglycaemia and increased polyol pthway 
activity associated with proximal tubular insult resulting in abnormal urinary enzyme 
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excretion (Ishii et al, 2001) may all be involved. Evidence suggests that the increased ß- 
NAG enzymuria increases in diabetic state (Whiting et al, 1979; Price, 1992; UKPDS, 
1993) occurs prior to increased glomerular permeability as the two parameters measure 
different areas of renal integrity i. e. proximal tubular insult and glomerular permeability, 
respectively (Martin et al, 1990). This suggestion is further supported by the observation 
that renal tubular insult may precedes increased glomerular permeability and ß-NAG 
enzymeuria is an early indicator of renal insult (Whiting and Price, 2001) in the 
progression of early diabetic nephropathy and incipient tubulopathy (Holdt-Lelunann et 
al, 2000). 
Skrha and Hilgertova, (1999) recently demonstrated that subjects with diabetes and 
enhanced oxidative stress had higher serum NAG activities before the development of 
rnicroalbuminuria. A significant positive correlation between serum NAG activities and 
plasma MDA concentrations was observed in this study suggesting that oxidative stress 
may precipitate tissue damage and the autophagic response to this damage will result in 
lysososmal proliferation and increased NAG enzyme release. A decreased NAG activity 
observed after treatment with vitamin E (a-tocopherol) may further support the role of 
free radical mediated oxidative stress in the tissue insult that resulted in the increased 
NAG enzymuria (Skrha and Hilgertova, 1999). The results of the present study, which 
clearly demonstrated that direct association between increased urine, NAG activities, and 
TBARS (as described in Chapter 4) in both the established diabetic group 
(microalbuminuric) and recently diagnosed diabetic group (normoalbuminuric) subjects 
is consistent with this suggestion. This evident suggests that oxidative damage and renal 
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tubular insult may be associated with the onset of microalbuminuria. Furthermore, in an 
experimental animal model, those animals that exhibited albuminuria, had significantly 
higher levels of lipid peroxides in plasma, urine and renal proximal tubules, suggesting 
that increased oxidative stress in the diabetic kidney and lipid peroxidation is an 
important biological consequence of the free radical mediated oxidative process (Yaqoob 
et al, 1994; Koya et al, 1997; Koya et al, 2003). 
The toxicity of products of lipid peroxidation in a cell is reduced in part by GSH-Px and 
in part by other intracellular phase II defensive systems, for example, these involving 
glutathione-S-tranferases (GSTs); although, both enzymes are necessary for the 
detoxification of the products of lipid peroxidation. While GSTs are cytosolic enzymes 
the alpha isoenzyme (aGST) is present only in renal proximal tubular cells, whereas the 
pi (tGST) isoenzyme is confined to renal distal tubular cells as shown by 
immunohistochemical studies (Harrison et al, 1989; Sundberg et al, 1994; Branten et al, 
2000). Furthermore, both aGST and nGST activities were increased in the 
microalbuminuric group subjects compared to both normoalbuminuric and control group 
subjects (Figure 5.2.10, Figure 5.2.11). This suggests that while increased aGST levels 
were associated with proximal tubular insult and brush border damage (Branten et al, 
2000) the increased iGST levels were consistent distal tubular insult. The increased 
activities were also associated with glomerular permeability, manifested by increased 
microalbuminuria. A similar study performed by Branten et al, (2000) also demonstrated 
a direct association between 7EGST levels and increased serum creatinine and proteinuria 
and also suggested that a distal tubular insult was associated with glomerular 
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permeability. Furthermore, Fujita et al, (2001) demonstrated that aGST was increased in 
the proximal tubules, before the manifestation of the typical diabetic histopathological 
changes in the glomeruli of diabetic animals suggesting that increased expression of GST 
has the potential to be one of the earliest physiological adaptations to hyperglycaemia or 
early renal insult. Consequently, the identification of those changes, particularly in the 
early stages of diabetes, may well contribute to the elucidation of the basic mechanisms 
of diabetic nephropathy and permit a better understanding of the underlying 
pathophysiology (Fujita et al, 2001). 
Free radical mediated oxidative stress triggered by hyperglycaemia is thought to be a 
significant determinant of such renal tubular changes. The observed increased activities 
of GSTs may well be a protective response of renal tubular cells to the oxidative damage 
or other toxic effects of glucose. Furthermore, these toxic effects of glucose may 
ultimately contribute insult to both proximal and distal renal tubular system (Fujita et al, 
2001). However, the underlying mechanism that lead to an association of GST with 
increased glucose-induced lipid peroxidation and enhanced oxidative stress in diabetes in 
general and diabetic nephropathy in particular still need to be clearly defined. Other 
evidence also suggest that the formation of lipid peroxides could be a major triggering 
factor for apoptosis and enhanced oxidative stress in diabetic kidney could therefore 
induce apoptosis, which would also contribute to the development of diabetic 
nephropathy (Zhang et al, 1997; Kannan and Jain, 2000). 
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CHAPTER SIX 
GENERAL DISCUSSION 
0 
6. General discussion 
One of the main aims of the present studies was to investigate if the generation of free 
radicals and lipid peroxides, associated dyslipidaemia and renal insult was temporally 
related to the presence of hyperglycaemia. Consequently, length of disease duration 
rather than the type of diabetes present, was a major consideration in selecting study 
populations. However, this study design has the limitation that both diabetic study groups 
contained a mixture of Type 1 and Type 2 diabetic subjects. This limitation is due to the 
heterogeneous nature of the type 2 diabetic state. 
The present study has clearly demonstrated that persistent hyperglycaemia was the major 
determinant that linked altered glucose and lipid metabolism with the generation of free 
radicals, resulting in increased lipid peroxidation and depletion of antioxidant inhibitory 
and scavenger mechanisms and thereby enhanced oxidative stress. An' association 
between persistent hyperglycaemia-induced enhanced free radical mediated oxidative 
tress and profound early renal functional, and biochemical changes predating early 
diabetic nephropathy was also observed. In particular, the present studies have also 
demonstrated altered glomerular function in the presence of both proximal and 
surprisingly, distal renal tubular insult. 
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6.1 Altered glucose, lipid metabolism and generation of free radicals 
Previous clinical and experimental studies (Mauer et al, 1975; Weil et al, 1975; DCCT, 
1993; UKPDS, 1998; Stratton et al, 2000) have clearly demonstrated that hyperglycaemia 
and consequent poor glycaemic control is the main metabolic determinant associated with 
irreversible kidney damage in diabetes. The present study has confirmed and extended 
these earlier observations and a strong association between persistent hyperglycaemia and 
altered metabolic parameters such as glycated haemoglobin, fructosamine and 
lipoproteins in a cohort of diabetic subjects was also noted. Consequently, observations 
from the present study are consistent with the suggestion that both poor glycaemic and 
metabolic control may contribute to the progression and the development of diabetic 
nephropathy. Conversely, improved glycaemic control effectively delays the onset and 
retards the progression of diabetic nephropathy (UKPDS, 1998). Consequently, these 
observations provide impressive clinical evidence that hyperglycaemia per se is the major 
pathogenic factor in the development and onset of diabetic complications in general and 
diabetic nephropathy in particular. 
Amongst the irreversible changes that occur as a direct result of persistent 
hyperglycaemia are the formation of AGEs following protein glycation (Bucala et al, 
1993; Brownlee, 1995; Vlassara, 1995; Schmidt et al, 1995; Vlassara, 1996, Singh et al, 
2001). In the diabetic state the importance of these processes is manifest in two essential 
factors namely the changes in protein structure and function as a result of glycation and 
the use of glycated protein levels as a indicator of chronic/long term glycaemic control. A 
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classical example of non-enzymatic glycation is the formation of glycated haemoglobin, 
or, more precisely, MAI, as measured in the present study. 
In the established diabetic group increased fasting plasma glucose and fructosamine 
concentrations were directly associated with elevated HbAIc. Furthermore, chronic or 
persistent hyperglycaemia in diabetes has been well established to accelerate synthesis 
and tissue deposition of AGEs, an abnormality contributing to the pathogenesis of co- 
morbid complications. (West, 2000). A number of AGEs such as 1V`-[caboxymethyl]- 
lysine (CML), pyralline and pentosidine have been identified in the renal tissue of 
diabetics with or without ESRD, with AGEs accumulation increasing with the severity of 
diabetic nephropathy (Sugiyama et al, 1996). 
The elevated fructosamine and glycated haemoglobin levels associated with increased 
lipid peroxidation and reduced antioxidants and associated defence mechanisms noted in 
the established diabetic group implicates AGEs as a source of free radicals leading to 
enhanced oxidative stress and subsequent renal insult as suggested in Fig 1.3.7.2 in the 
introduction. However, although AGEs were not measured in the present studies due to 
resource and time limitations, their quantitation would have allowed a more detailed 
approach to demonstrating their role, as one end product of free radical activity in the 
pathogenesis of diabetic nephropathy. Furthermore, the generation of AGEs products, 
linked to the molecular mechanisms underlying the pathogenesis of renal dysfunction via 
ligation of AGEs receptors in renal tissue and the activation of the DAG-PKC pathway 
(Hunt et al, 1988; Inoguchi et al, 1992), may be just one pathway involved in the 
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multifactoral process precipitating changes in both GFR and renal tubular function. This 
may, of course ultimately also result in as increased susceptibility to free radical mediated 
oxidative stress and vascular dysfunction, which may be important in the early 
developmental stages of diabetic complications (Lee and Chung, 1999; Nakamura et al, 
2000). 
Many studies have demonstrated a direct link between hyperglycaemia and increased 
total cholesterol, triglycerides, LDL, and decreased HDL concentrations as a 
consequence of diabetic dyslipidaemia (Carvajal et al, 1983; Abbate and Brunzell, 1990; 
Tolins et al, 1992; Taskinen, 1987; Taskinen, 1996; Betteridge, 1997). The present study 
also clearly demonstrated that increased fasting glucose concentrations, fructosamine and 
HbAI, levels were observed in the presence of increased total cholesterol, triglycerides, 
LDL, and decreased HDL concentrations in established diabetes. These observations are 
consistent with those of Wanner et al, (2001) that suggested a direct association between 
poor glycaemic and metabolic control and diabetic dyslipidaemia. Furthermore, in 
subjects with diabetic nephropathy, hyperlipidaemia has been identified as a major risk 
factor for the rapid decline of GFR and increased mortality. 
Recently, high triglycerides and low HDL cholesterol concentrations have been identified 
as strong predictors of a more rapid progression of microalbuminuria in type 2 diabetic 
subjects with well controlled blood pressure (Wanner et al, 2001). However, when 
glycaemic control is poor, total serum cholesterol concentrations in diabetes can be 
significantly enhanced due to the additional accumulation of LDL (Taskinen et al, 1996), 
results similar to those observed in the established diabetic group investigated in the 
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present study. Furthermore, diabetic subjects with good or reasonable glycaemic control 
still tended to demonstrate LDL concentrations within the laboratory reference range. 
Kramer-Guth et al, 1996; Kramer-Guth et al, 1997, an observation similar to that 
observed in the recently diagnosed diabetic group in the present study. Overall, the 
results of the present study in which persistent hyperglycaemia was associated with 
increased protein glycation and dyslipidaemia suggests a central role for the latter, not 
only in diabetic atherogenesis but also in the pathogenesis diabetic nephropathy (Bucala 
et al, 1993; Vlassara, 1995, Galle et al, 1999). 
6.2. Increased lipid peroxidation, depletion of antioxidants and enhanced oxidative 
stress 
Previous clinical and experimental studies have demonstrated enhanced lipid peroxidaion 
in subjects with diabetes (Sato et al, 1979; Armstrong and Al-Awadi, 1991; Armstrong et 
al, 1992; Akkus et al, 1996; Santini et al, 1997, Hartnett et al, 2000). The direct 
association observed between increased fasting glucose concentrations and TBARS 
excretion in both diabetic groups in general, but the established diabetic group in 
particular, is consistent with hyperglycaemia-induced enhanced lipid peroxidation in 
diabetics, results consistent with those of earlier clinical and experimental studies. 
However, although in the present studies a trend towards increased lipid peroxidation 
associated with increased total cholesterol, triglycerides, LDL, and decreased HDL 
concentrations was observed in the established diabetic group, this did not achieve 
168 
statistical significance. Although the reason for this is not clear it may be that the process 
of peroxidation does not depend on lipoproteins levels and the increased total amount of 
circulating lipid plays an additional and exacerbating role in the enhancing this process in 
the presence of persistent hyperglycaemia as suggested by both Griesmacher et al, (1994) 
and Mooradian, (1991). Furthermore, although it is now well established that AGEs, 
lipid-advanced glycation and lipid oxidation processes generate free radicals and initiate 
lipid peroxidation in diabetic subjects with inadequate glycaemic and metabolic control 
(Bucala et al, 1993, Halliwell and Gutteridge, 1998) the control mechanisms remain 
unclear. 
Many studies have previously demonstrated significant depletion of antioxidants such as 
reduced plasma total antioxidant status (Sundharam et al, 1996; Maxwell et al, 1997), 
plasma vitamin E (Salonen et al, 1995, Reavan et al, 1995), both erythrocyte and plasma 
glutathione peroxidase (Mukherjee et al, 1998; Aaseth and Stoa-Birketvedit, 2000; 
Varvarovska et al, 2003) activities, and plasma selenium content (Schienger et al, 1988, 
Faure et al, 1993; Bennefont-Rousselot et al, 1997) in the diabetic state. Results from the 
present study also clearly demonstrated significantly decreased plasma total antioxidant 
status, plasma vitamin E content, both erythrocyte and plasma glutathione peroxidase 
activities, and plasma selenium content but only in the established diabetic group. 
Furthermore, significant correlations between MAI, and TBARS (r2 = 0.894, P<0.001), 
HbAIc and vitamin E (r2 = 0.367, P <0.001), and TBARS and vitamin E levels (r2 = 
0.896, P <0.0001) were also noted in the present studies. This suggests that HbA1c and 
glycaemic control are linked to both the rate of lipid peroxidation and depletion of 
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extracellular antioxidant scavengers and the presence of enhanced oxidative stress in the 
established diabetic group, consistent with the suggestion of Jain et al, (2000). The study 
of Armstrong et al, (1992) has suggested that reduced free radical production as a result 
of improved metabolic control would lead to reduced consumption of chain-braking 
antioxidants and that could eventually therefore, contribute to the improved antioxidant 
status and reduced lipid peroxidation, again adding weight to this suggestion. Further 
evidence supporting the presence of enhanced oxidative stress in the diabetic state has 
also been provided by animal studies (Ha and Kim, 1999) and by vitamin E dietary 
supplementation (Koya et al, 1997; Ha and Kim, 1999, Koya et a! 2003). Furthermore, 
vitamin E supplementation studies have recently revealed that increased cellular 
glutathione levels, decrease HbAIc levels and MDA concentrations were associated with 
a reduced incidence of vascular disease in poorly control diabetics (Jain et al, 2000). 
Glutathione peroxidases play a central role in the defence mechanisms dealing with lipid 
hydroperoxides, utilising glutathione and NADPH in the process to yield hydroxyl 
compounds, and hence in preventing the development of oxidative stress. In the present 
study plasma and erythrocyte glutathione peroxidase activities were decreased in the 
recently diagnosed diabetic group and further decreased in the established diabetics. 
Plasma glutathione peroxidase has been shown to originate from the renal proximal 
tubular cells and the parietal cells of the Bowman's capsule and is released into the blood 
via the efferent and peritubular capillaries. The proximal tubules are also the site of 
synthesis of selenoproteins which could explain in part the relationship between plasma 
glutathione peroxidase activity and plasma selenium concentrations, a similar observation 
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to that of Bennefont-Rousselot et al, (1997). In this regard, the observations of Brigellius- 
Flohe, (1999) could also be particularly relevant in that his studies demonstrated that a 
transient selenium deficiency, precipitating a rapid impairment of plasma glutathione 
peroxidase activity, was associated with a high index of both micro and macroangiopathy 
in diabetic subjects but without evidence of overt nephropathy being noted. 
In normal conditions, cellular defence mechanisms are sufficient to counteract the effects 
of free radicals but in the diabetic state they may be overwhelmed because of increased 
oxidative stress. The present study has clearly demonstrated that lipid peroxidation is 
increased in the presence of persistent hyperglycaemia which, along with the 
observations of reduced counteracting defence mechanisms, is consistent with the 
presence of profound oxidative stress being present in the diabetic state. This in turn is 
associated with diabetic complications in general and diabetic nephropathy in particular 
characterised by structural, functional and biochemical changes in diabetic kidney 
(Douillet et al, 1999). 
6.3 Renal glomerular and tubular changes in the diabetic state 
The difficulties that lie in the early diagnosis of diabetic nephropathy lie predominantly 
in the natural history of the disease. Significant structural changes, particularly thickening 
of glomerular basement membrane and mesangial expansion, occur only after several 
years of diabetes (Mogensen et al, 1984). Indeed, the early stages of the disease 
development are clinically silent and detected at present only by measurements of 
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microalbuminuria (Mogensen et al, 1984). Furthermore, serum creatinine measurements 
used as an indication of GFR are at best insensitive and only become elevated once less 
than 50% of nephrons remain functional. The glomerulus also demonstrates both a charge 
and size selectivity during filtration the former due to the so called glomerular polyanion 
consisting predominantly of heparin sulphate, sialic acid and other proteoglycans 
(Mayers et al, 1982). GFR begins to decline as the glomerular filtration barrier loses its 
charge and/or size selectivity resulting in an increasing magnitude of proteinuria and 
renal dysfunction. Consequently, the results of the present study which show reduced 
cystatin C levels, a new biomarker for the measurement of GFR (Jung and Jung, 1994; 
Newman et al, 1995; Piwowar et al, 1999; Stabuc et al, 2000; Page et al, 2000) in the 
presence of `normal' serum creatinine concentrations may provide a more sensitive 
indication of glomerular function in the diabetic state. In addition, the present study has 
also clearly demonstrated that increased microalbuminuria was significantly associated 
with elevated serum sialic acid concentrations in the established diabetic group subjects. 
Consequently, circulating cystatin C and sialic acid concentrations and quantitation of 
microalbuminuria may provide a more effective biochemical assessment of glomerular 
function in the diabetic state than serum creatinine and microalbuminuria alone as a 
predictor for incipient diabetic nephropathy. 
In the diabetic state, while glomerular disease is characterized by increased albumin 
excretion, manifestation of tubulo-interstitial damage is much more difficult to identify 
until GFR is reduced by at least 50%. Consequently, a wide range of new biochemical 
markers reflecting both early renal damage and site-specificity within the kidney has been 
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developed. These include specific low molecular proteins such as al-microglobulin and 
ß2-microglobulin, urinary enzymes such as ß-NAG, AAP and glutathione S transferases 
(for a review see Whiting and Price, 2001). 
The present study demonstrated a significant association between microalbuminuria and 
low molecular weight proteinuria (LMWP, al-microglobulin and ß2-microglobulin) in 
the established diabetic group subjects. Both increased glomerular permeability and 
proximal tubular absorptive dysfunction or the inability of the proximal renal tubule to 
reabsorb excess small molecular weigh proteins could explain this observation. The 
observation that the recently diagnosed diabetic group demonstrated reference range 
values for both LMWP and microalbuminuria could suggest either insufficient diabetes 
related renal insult was present or the mechanisms underlying tubular reabsorption of 
filtered proteins are less sensitive and primarily not involved in the development of 
incipient diabetic nephropathy. 
However, increased AAP and ß-NAG-enzymuria were significantly increased in both 
diabetic groups suggesting that hyperglycaemia, both early and persistent, is associated 
with both brush border and proximal tubular cell insult. This observation is similar to 
those of other studies (Whiting et al, 1980; Whiting et al, 1983a, b; Kordonouri et al, 
1998). Consequently, AAP and NAG-enzymuria, a sensitive indicator of proximal 
tubular insult, are of use in the recognition of those diabetic subjects predisposed to 
diabetic nephropathy, although a direct effect of hyperglycaemia, linked to polyol 
pathway activity, on lysosomal function cannot be excluded (Ishii et al, 2001). 
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In the present study, both the excretion of a-GST and that of a-GST were also increased 
in both recent onset and established diabetic subjects. As these particular enzymes are 
primarily located in the proximal and both distal tubules and collecting ducts, 
respectively (Harrison et al, 1989) this suggests insult at both these intrarenal sites. 
Moreover, a trend towards higher activities of both isoenzymes was observed in the 
established diabetic subjects with early diabetic nephropathy and their use as an adjunct 
for recognition of early renal insult in diabetic subjects deserves further attention. 
6.4 The presence of oxidative stress in the diabetic state 
There is now appreciable evidence that an oxidative injury occurs in the diabetic state 
which is in itself an important factor in the development of associated early renal insult 
and subsequent dysfunction (Kakkar et al, 1997; Arima and Ito, 2003). For example, 
microalbuminuria, a marker of glomerular insult, higher levels of lipid peroxides and 
decreased antioxidants in renal proximal tubules have all been causally related, 
supporting the concept of a hyperglycaemia-induced increased oxidative stress in diabetic 
nephropathy (Asayama et al, 1993; Ha and Kim, 1995; Sundaram et al, 1996; Kakkar et 
al, 1997; Ha and Kim, 1999; Koya et al, 2003). 
The present study clearly demonstrated that recently diagnosed diabetic subjects 
demonstrated `normalbuminuria' while established diabetic subjects were 
`microalbuminuric, ' consistent with the hypothesis that persistent hyperglycaemia is 
associated with early diabetic nephropathy. Furthermore, in the present study increased 
174 
levels of lipid peroxidation and decreased antioxidants/defence mechanisms were noted 
in the established diabetic group, again suggesting a link between persistent 
hyperglycaemia, poor metabolic control including dyslipidaemia, oxidative stress and an 
increased risk of developing microalbuminuria. Several other studies have also suggested 
that oxidative stress, as a result of poor glycaemic control and subsequent tubular and 
glomerular insult proceeding in parallel with endothelial cell damage may precede 
cellular damage and hence the development of diabetic nephropathy (Yaqoob et al, 1994; 
Skrha and Hilgertova, 1999). Early tubular insult characterised by NAG enzymuria 
(Whiting et al, 1979; UKPDS, 1993; Wetigasser et al, 1999) which occurs prior to 
microalbuminuria have also been described. The present study has clearly demonstrated 
that increased NAG enzymuria and TBARS excretion, in the absence of abnormal levels 
of microalbuminuria, were observed in recently diagnosed diabetic subjects, again 
supporting the concept that oxidative damage and renal tubular insult may accompany or 
even precede the onset/presence of microalbuminuria (Yaqoob et al, 1994). 
Furthermore, in both diabetic group, the presence of enhanced oxidative stress, associated 
with increased lipid peroxidation and depletion of antioxidants was associated with 
elevation of both aGST and iGST enzymuria. This is an important observation as 
pathological levels of microalbuminuria were not present in the recently diagnosed 
diabetic group and GST estimation could provide further evidence identifying those 
individuals at risk of developing diabetic renal dysfunction. Furthermore, as GSTs are 
important cellular components of the defence mechanisms responsible for the metabolism 
of lipid peroxides and the products of oxidative stress, any reduction in their cellular 
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concentration could further enhance any oxidative stress present. The results of the 
present study do inevitably suggest an involvement of GST in the pathogenesis of 
oxidative stress as a result of persistent hyperglycaemia and enhanced lipid peroxidation 
in the renal tubules. However, these suggestions would require further experimental 
validation. 
One speculative possible explanation for the increased GST enzymuria present in both 
diabetic groups could be that the increased enzymuria reflects an increase in cellular 
activities of this antioxidant defence mechanism as a compensatory consequence of 
increased lipid peroxidation. However, this again would also require experimental 
validation as does the association of GSTs with increased lipid peroxidation, enhanced 
oxidative stress and the role of apoptosis in diabetic nephropathy as suggested recently by 
several research groups (Zhang et al, 1997; Kannan and Jain, 2000). 
6.5 Conclusions 
Although the exact pathophysiological processes underlying diabetic nephropathy remain 
unclear, evidence is now accumulating linking free radical formation and oxidative stress 
to the cascade of events leading to diabetic renal. The present and several other studies 
have shown that persistent hyperglycaemia associated with poor metabolic control, 
particularly dyslipidaemia, is the major determinant in both the initiation and 
development of early diabetic nephropathy (DCCT, 1993; DCCT, 1995; UKPDS, 1998). 
Not surprisingly, persistent hyperglycaemia is temporally related to other biochemical 
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mechanisms suggested to play a role in early diabetic nephropathy, for example glucose 
autoxidation, non-enzymatic protein glycation, polyol pathway and altered lipoprotein 
metabolism resulting ultimately in the generation of free radicals. The present studies 
have indeed demonstrated an association between glycaemic control and glycation 
products, dyslipidaemia and the generation of free radicals. In addition, these studies 
have also demonstrated reduced both total antioxidant status and antioxidant defence 
mechanisms associated with renal glomerular and tubular dysfunction and consistent with 
enhanced oxidative stress being present in the diabetic state. 
In addition the present studies have investigated sensitive biomarkers including 
circulating cystatin C, microalbuminuria and sialic acid concentrations, indicators 
glomerular function and/or permeability, LMWP and enzymuria, including NAG, AAP 
and both aGST and irGST. The results obtained clearly demonstrate the potential for 
measurements of cystatin C, sialic acid and enzymuria, particularly ctGST and rtGST, to 
provide a significant and effective means for identifying those diabetic subjects at risk of 
developing early renal changes, particularly before the development of microalbuminuria. 
The results obtained here are particularly gratifying considering the apparent insensitivity 
of some of the standard measures regularly and routinely used currently in diabetic 
clinics, for example serum/plasma creatinine concentrations and some methods for 
quantifying microalbuminuria, the earliest indicator of incipient nephropathy in diabetics 
(Viberti, 1982; Mogensen, 1984; Okada et al, 1996). However, this would involve 
assessing diabetic patients more regularly in the clinic than at present and there is an 
obvious resource implication. 
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While the mechanisms involved in the development of diabetic nephropathy remain 
difficult to demonstrate in the clinical situation, especially considering the natural history 
of the disease process, the studies presented here have indicated that the measurement of 
sensitive biomarkers can indicate perhaps either the presence of, or an increased 
magnitude of, some of the implicated processes. For example, enzymuria can be linked to 
site specific insult within the renal tubular system in a similar fashion as plasma sialic 
acid can indicate loss of glomerular polyanion, total antioxidant status a reflection of the 
potential of oxidative stress, microalbumuria an increase in glomerular permeability and 
cystatin C, changes in GFR reflecting either hyper or hypofiltration at the glomerulus. 
Furthermore, while this study has demonstrated that renal functional changes could be 
associated with increased lipid peroxidation, oxidative stress and reduced antioxidants, it 
also provides a laboratory basis for assessing corrective therapy for the above, for 
example Vitamin E and selenium dietary supplementation to maximise protection against 
oxidative damage. Consequently, and similar to the findings of Koya et al, (2003) this 
study has concluded that free radical mediated oxidative stress may play an important 
role in the development and progression of diabetic nephropathy and antioxidant 
treatment would be potential corrective therapeutic possibility. 
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6.6 Future work 
The present study clearly demonstrated that free radical mediated oxidative stress plays a 
crucial role in the pathogenesis of diabetic nephropathy. The biomarkers for free radical 
damage are hampered by several factors. The measurement of free radical activity is 
difficult due to several factors including lack of specificity and sensitivity, difficulty in 
the definition of commonly accepted normal reference intervals, in part because several 
methods can be used for the same oxidative parameters and finally, effective control 
materials for antioxidants and oxidative stress parameters are not commercially available. 
Consequently, precise analytical methods for oxidative stress biomarkers with improved 
sensitivity and specificity need to be introduced for application in the routine clinical 
laboratory that will allow improved interpretation of laboratory results to be achieved. 
Although measurement of AGEs and N-c-(carboxymethyl) lysine (CML) are technically 
difficult, suitable routine analytical methods have still to be developed. 
Dietary supplementation with antioxidants, such as vitamin E and reduced glutathione, 
may be advantageously used in subjects with diabetes. Antioxidants might reduce protein 
glycosylation, inhibit glucose autoxidation and the formation of AGEs, while at the same 
time, operate as scavengers for free radicals, generated by both glucose autoxidation and 
glycated proteins (Ceriello and Giugliano, 2000). However, long-term intervention 
studies are now needed to evaluate the efficacy of this new therapeutic approach in the 
prevention and treatment of diabetic nephropathy. This would also allow further insight 
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into the relationship between hyperglycaemia, protein glycation, AGEs, total antioxidant 
status and lipid peroxidation events. 
Although the natural history of diabetic nephropathy is well known and new sensitive 
non-invasive biomarkers have been developed for the early detection of renal insult, the 
early detection of diabetic kidney damage has been neglected particularly the 
contribution that tubular function makes to overall renal function (Whiting and Price, 
2001). Consequently, longitudinal large prospective studies are needed now in order to 
further evaluate the predictive value of both proximal and distal tubular insult in the 
development of diabetic nephropathy. 
The role of free radicals and a relationship between both renal function and structure 
would be further examined by the use of animal models of diabetes (Streptozotocin 
induced diabetes or the use of BB-Wister rats). At various time points following either 
the recognition/induction of diabetes, PT cells would be isolated and the generation of 
free radicals assessed. Renal histology and function as well as estimation of glycaemia 
and protein glycation would also be estimated allowing any temporal relationship 
between lipid peroxidation, renal function and histological changes to be established. In 
addition, renal mitochondria could be prepared from either human or animal kidney and 
oxidative metabolism investigated in the presence of high glucose concentrations. This 
could include estimates of free radical formation, ATP/ADP and NADH/NAD ratios. 
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